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Non-technical summary of key points in this submission 
 
According to the Authority’s Draft Assessment Report (section 5.4.2.1), “LY038 corn must be 
shown to be as safe as other varieties of corn currently available if it is to be approved by 
FSANZ”. Only if the people of New Zealand and Australia can completely substitute LY038, 
or its descendant hybrids, for conventional corn, and only if they can prepare and eat it the 
same way and with exactly the same possible consequences as consuming conventional corn, 
has the Authority met its burden to responsibly recommend that the Food Code be amended. 
 
FSANZ does not have the evidence to declare that LY038 is as safe as other corn when 
consumed in the same manner. There is strong evidence to suggest that LY038 will produce a 
spectrum of food hazards significantly different from cooked or processed conventional corn 
because LY038 has extremely high concentrations of the amino acid lysine and its derivatives 
saccharopine, α-aminoadipic acid, pipecolic acid and cadaverine. The precise nature of these 
hazards cannot be adequately predicted from analysis of raw or cooked conventional corn, or 
raw LY038 corn. 
 
1. Scientific studies on LY038 do not prove it to be as safe as conventional corn 
 
FSANZ spokesperson Lydia Buchtmann was reported as saying to the West Australian on 10 
April 2006 that “FSANZ used product data from GM companies and compared it with data 
about conventionally grown food of the same type in deciding to approve products”, a process 
that would be consistent with international standards of review. That standard was not 
demonstrated in the Draft Assessment Report on A549. In particular, the control did not meet 
this test in the following respects: 
 
a. The molecular and compositional studies seeking to establish equivalence between 
LY038 and conventional counterparts remains outside of Codex Alimentarius 
guidelines1 and FSANZ policy. LY038 was compared to LY038(-), a sibling of the 
modified corn line and itself a product of gene technology. In the Authority’s own 
words, “[t]he Applicant has provided information comparing LY038 corn to a closely 
related control corn crop, LY038(-), both grown in the same location” (DAR p. 11). 
LY038(-) is not a conventional food. 
 
b. The high level of lysine in LY038 corn is dismissed as a dietary risk to humans by 
saying that “when compared to lysine from other dietary sources this is not a large 
amount of lysine” (DAR, p. 31 and p. 65). The comparison in this case was to eggs, 
red meat, chicken, fish, lentils, rolled oats and broccoli, none of which are 
conventional foods of the same type as corn. 
 
c. High levels of the lysine catabolite saccharopine were dismissed as a food hazard by 
                                                 
1 When referring to the Codex Alimentarius Commission (CAC), we make specific reference to the standards 
CAC/GL 44-2003 and CAC/GL 45-2003 found at http://www.codexalimentarius.net/web/standard_list.do?lang=en. 
Access date 26 April 2006. 
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saying that “[t]he levels of saccharopine found in LY038 corn grain (499 – 818 μg/g 
dwt, mean 650 μg/g) are substantially higher than those found in broccoli or 
cauliflower, but similar to the level in button mushrooms” (DAR, p. 48). Button 
mushrooms are not a conventional food of the same type as corn. 
 
d. High levels of the lysine catabolite α-aminoadipic acid, which has a known neurotoxic 
activity (Rozan et al., 2001), were dismissed as a human food hazard because 
‘[c]ompared to the levels found in other common plant foods, [e.g. lentils, mushrooms, 
cauliflower, green beans and broccoli] this level is not a cause for concern” (DAR, p. 
48). These plants are not a conventional food of the same type as corn. 
 
The foods used as a comparison to LY038 differ from corn in the varieties of ways they are 
prepared, the types of processed foods in which they are found, and in the quantities in which 
they are consumed. Kiwis and Aussies eat corn chips, but probably do not eat mushroom chips. 
 
2. LY038 has a substantially different potential to create food hazards during cooking 
 
LY038 has high concentrations of compounds that are known to produce food hazards when 
heated with the sugars found in corn. The modification results in highly elevated concentrations 
of lysine (total), free lysine (not in protein), saccharopine, α-aminoadipic acid, cadaverine and 
pipecolic acid, all of which may be converted into advanced glycoxidation endproducts (AGEs) 
during cooking and processing. 
 
AGEs are strongly implicated in causing a variety of dietary-related diseases including diabetes 
and Alzheimer’s and their sequela (Goldberg et al., 2004, Peppa et al., 2003a, Peppa et al., 
2003b, Vlassara et al., 2002), as well as cancer  (Heijst et al., 2005). AGE content in food 
increases with cooking and food processing temperatures and pressures (Elliott, in press, 
Goldberg et al., 2004). 
 
Compound Concentration in LY038 Potential Hazard 
Lysine 50% higher AGEs 
Free Lysine 50 times higher AGEs 
Saccharopine 110 times higher AGEs 
α-aminoadipic acid at least 10 times higher AGEs, neurotoxic 
Cadaverine unknown but expected to be higher 
AGEs, accentuates reactions to 
histamine, evidence of further 
toxic properties 
Pipecolic acid ≥100% higher* AGEs, chronic hepatic encephalopathy 
*Applicant only reports L-pipecolic acid levels. Because D-pipecolic acid can be created from L-
pipecolic acid by conversion of either pipecolic acid or lysine to the D-isoform during cooking or in the 
gut by bacteria, the Authority has likely underestimated pipecolic acid exposure levels derived from 
high lysine corn or produced by gut bacteria receiving higher levels of dietary lysine. 
 
In their reply to our original submission, the Authority has confirmed that it believes a higher 
than normal standard of review may be warranted for high-lysine corn. “In cases where the 
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composition of food has been significantly changed, as is the case with high-lysine corn, 
feeding studies with suitable livestock species may be useful to confirm the wholesomeness of 
the food” [emphasis ours]. Only feeding studies, using whole plant material in food that has 
been cooked and processed in ways that humans would consume it, can provide the proper 
basis for a safety review. No such studies were provided for public review in A549, and from 
the DAR we have no reason to suspect that such studies were ever provided to the Authority. 
We are particularly concerned that the Authority sight, or provide the people of Australia and 
New Zealand with, reliable data demonstrating that processing and cooking temperatures 
normal to products that could contain this corn are as safe as products that do contain 
conventional corn. 
 
3. Hybrids with LY038 could create significant additional food hazards 
 
The Applicant has assured the Authority that corn derived from LY038 and hybrids will have 
total lysine in the range of 3500 to 5300 ppm, and free lysine in the range of 1000 to 2500 ppm. 
However, it is known that research hybrids with parents similar or identical to LY038 could 
have much higher levels of lysine and free lysine. Free lysine and lysine catabolites were higher 
in crosses with other GM varieties of corn (Monsanto study published under Huang et al., 
2005). The Applicant already possesses hybrid lines of corn with total lysine levels reaching 
6160 ppm and free lysine levels reaching 2908 ppm, but apparently did not include that fact in 
the application. 
 
The Authority has argued that it also cannot restrict its amendment of the Food Code such that 
future hybrids of LY038 are not automatically approved. This is of concern because LY038 
could be bred, on purpose or by accident, with other varieties developed by conventional 
breeding that might generate substantially increased lysine, free lysine and lysine catabolite 
levels. If the Authority’s recommendation is approved, then it will be authorizing these 
uncharacterized hybrid varieties to enter the human food supply without further safety review. 
As we have repeatedly argued in this and a previous submission, the Authority would be 
making an extrapolation of safety that goes well beyond the scope of the existing scientific 
data. 
 
Automatic approval of hybrids formed between an approved GM event and a conventional 
variety, or between two separately approved GM events, leaves the Authority in the potential 
position of mechanically approving a hybrid high lysine variety with significantly higher levels 
of lysine. The Applicant has already reported the existence of additional high lysine varieties 
produced using gene technology. Those varieties achieve high lysine levels through a different 
biochemical mechanism that works synergistically with the modification reported in LY038 
(Huang et al., 2005). The synergistic effect reveals that, in “stacked” varieties (hybrids with 
both modifications) the levels of free lysine and lysine derivatives are higher than would be 
expected from an analysis of the modifications kept separate in different varieties. The 
Authority should indicate what levels of lysine and lysine catabolites it would consider to be 
potentially dangerous. If the Authority cannot restrict approval to the line described in A549, or 
provide reason to believe that future hybrids used in human food will not achieve dangerous 
levels of lysine and lysine catabolities, then it should not approve the LY038 event. 
 
8 
Should the Authority recommend a change in the Australia New Zealand Food Code to allow 
LY038 and its derivatives, it does so in the knowledge that total free lysine and lysine 
catabolite levels could reach significantly higher levels in LY038 hybrid corn varieties that do 
not require a safety assessment. 
 
4. Recombinant protein has no history of safe use 
 
The Authority should have undertaken work aimed at establishing that cDHDPS has a history 
of safe use by humans as food. However, the Authority has not reviewed data using whole plant 
derived material (grains) in feeding studies that demonstrate that the primary recombinant 
protein in LY038, cDHDPS, and its in planta produced derivatives, can be consumed safely by 
humans after normal cooking. Moreover, structural comparisons between cDHDPS 
(recombinant protein) with the natural corn DHDPS (mDHDPS) demonstrate non-equivalence 
(Blickling et al., 1997). Therefore, the safety of cDHDPS in cooked human food cannot be 
extrapolated from the historical presence of mDHDPS in cooked human food. In addition, there 
is no evidence that humans have been exposed to cDHDPS from natural sources at anywhere 
near the concentrations that they will be exposed to cDHDPS through eating LY038 corn. We 
estimate daily human exposure to cDHDPS from natural sources to be between 30 billion-4 
trillion times less than exposure through LY038 corn (Table 6). 
 
5. LY038 has been tested as an animal feed, not a human food 
 
LY038 is the first genetically modified crop plant substantially different in its nutritional 
profile to be considered for approval as a human food. In this way, A549 is an application that 
differs from all previous applications for amendment of the Food Code. The novelty of this 
product requires, in our opinion, adherence without exception to the highest standard of review 
and international consensus standards for review, such as described by the international bodies 
the Codex Alimentarius Commission (CAC), the UN Food and Agriculture Organisation (UN 
FAO), and the World Health Organisation (WHO). 
 
Despite its statement to the contrary (DAR section 5.4.2.1, p. 13), we believe that the evidence 
reviewed by FSANZ falls short of the evidence necessary to assure it is as safe as conventional 
corn. This is no surprise because the evidence provided was produced to assess LY038 only for 
use as animal feed. The key difference between the use of corn as an animal feed and a human 
food is cooking and processing, and the Authority has made no attempt to assess food hazards 
resulting from cooking or processing of LY038. 
 
Frequent reference by FSANZ to the Applicant’s “intent”, and to future market forces, to limit 
incorporation of LY038 into human food implies an added safety margin that is both 
inappropriate (because amendment to the Food Code does not bind the Applicant to keep 
LY038 out of the human food supply, restrict the foods that LY038 is used in, or to minimize 
co-mingling with varieties that are used in human food) and is no reason for allowing its tests 
as an animal product to substitute for proper human food safety tests. Examples of such 
references in the DAR are reproduced in the table below. 
 
“Furthermore, little LY038 will be entering the food supply, mostly in the form of 
processed products (e.g. corn syrup) that contain negligible amounts of protein” 
DAR p. 11 
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“Although LY038 will be grown as a high value animal feed, a small percentage of 
this corn may enter the food supply” 
DAR p. 20 
“because LY038 corn is not intended for food, human consumption is expected to 
be extremely low” 
DAR p. 23 
“Further, it is expected that the amount of LY038 grain entering the food supply 
will be small” 
DAR p. 31 
“It is less likely that food industry would pay premium price for high-lysine corn 
and therefore likely that the levels of high-lysine corn entering the food supply 
would be small” 
DAR p. 72 
 
6. The Authority has accepted a standard of evidence of safety that is below what it could 
request under international guidelines 
 
International bodies have set higher standards for the description and testing of genetically 
modified food organisms, such as LY038, that are significantly different from their 
conventional counterparts. According to CAC, the Authority could ask for: 
 
a. feeding studies using LY038 grains cooked and processed in ways that humans 
prepare corn for food to identify food hazards that derive from, for example, unusually 
high concentrations of AGEs. “The potential effects of food processing, including 
home preparation, on foods derived from recombinant-DNA plants should also be 
considered.” 
 
b. feeding studies using cooked and processed LY038 grains to determine the potential 
for cDHDPS to form toxic aggregates or sugar-protein derived allergens (another AGE 
product). “The absolute exposure to the newly expressed protein [cDHDPS] and the 
effects of relevant food processing will contribute toward an overall conclusion about 
the potential for human health risk.” 
 
c. a compositional analysis using a comparator that was “the near isogenic parental line”, 
and only if this were not feasible should the Authority consider another line that was 
“as close as possible”. In this particular case, the Authority does not have to accept the 
use of LY038(-) as a control because the non-GM parental line, H99, is 65.6% 
identical to LY038. We have seen no evidence to prove that LY038(-), the GM sibling 
line, is above 50% related, the average relatedness of siblings. 
 
Despite compelling scientific evidence that food hazards will form when corn derived from 
LY038 is cooked, and that the absolute exposure to cDHDPS will be astronomically higher 
than from natural sources, the Authority has not required studies that would be necessary to 
detect the presence of hazards specific to the use of LY038 as a human food. The Authority 
should explain why it believes that it is satisfactory to allow high lysine corn into the food 
supply following a safety review whose standards, in important respects, is frequently below 
what is allowed and recommended by international intergovernmental food safety agencies 
when this is acknowledged to be an important precedent. 
10 
7. A recommendation to amend the Food Code does not follow from a case-by-case 
assessment 
 
The Authority has expressed its commitment to case-by-case assessment. “The safety of GM 
foods cannot be assessed as a single class because the safety concerns depend on the type of 
food and the nature of the genetic modification. For this reason, safety assessments are 
performed on the foods derived from individual types of GM plants or animals”2. The Draft 
Assessment does not, however, adhere to its case-by-case assessment policy because the 
Authority is drawing general safety conclusions from experience with different types of 
modified corn. For example, the Authority’s statement that— 
“[t]o date, all approved GM plants with modified agronomic production traits have been shown to 
be compositionally equivalent to their conventional counterparts. Feeding studies with feeds 
derived from the approved GM plants have shown equivalent animal performance to that 
observed with the non-GM feed. Thus the evidence to date is that for GM varieties shown to be 
compositionally equivalent to conventional varieties, feeding studies with target livestock species 
will add little to a safety assessment and generally are not warranted” (DAR p. 49). 
is not specific to LY038, its use in human food, or the potential hazards that have been 
identified for LY038. Such use of evidence is outside the case-by-case assessment framework. 
 
In contrast, our submission is composed of an in depth examination of the scientific studies 
submitted to the Authority by the Applicant. This examination is supported by an analysis of 
up-to-date, peer-reviewed, scientific literature. This literature is specific to hazard identification 
or evaluation, consistent with CAC and OECD3 recommendations. 
 
The Authority (FSANZ) has committed itself to making assessments “based on risk analysis 
using the best available scientific evidence”4. Our submission is based on the best available 
scientific evidence. It has been updated with relevant references as recent as early 2006. Thus, 
we believe that to be consistent in the ‘case-by-case’ approach to assessment, and to be 
consistent with international recommendations for hazard identification, the Authority must 
refrain from substituting unsupported speculation—such as “expected to be”, “not expected”, 
“considered to be” or “not considered to be”—for hard scientific data, and either dismiss, or 
justify its use of, data that are not specifically relevant to High-Lysine Maize LY038, in reply to 
our specific analysis of LY038. 
 
8. Conclusions 
 
We believe that too much legitimate scientific uncertainty exists after consideration of the 
scientific studies submitted in support of A549 for the Authority to assert that LY038 and any 
hybrids derived from it are as safe as food derived from conventional corn. There is no case 
                                                 
2 ANZFA Occasional Paper Series No. 1 GM foods and the consumer (2000). 
3 When referring to the OECD, we make specific reference to the Consensus Document on Compositional 
Considerations for New Varieties of Maize (Zea Mays): Key Food and Feed Nutrients, Anti-Nutrients and 
Secondary Plant Metabolites (ENV/JM/MONO(2002)25) from OECD found at 
http://www.oecd.org/document/9/0,2340,en_2649_34385_1812041_1_1_1_1,00.html (access date 2 May 2006). 
4 FSANZ (2004). Initial Assessment Report: Application A549 Food Derived from High Lysine Corn LY038, p. 8-
9. 
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made for a benefit to Australians or New Zealanders to have LY038 in their food. There is 
considerable evidence of probable harm in comparison to conventional corn. 
 
In our view, the Authority is making a recommendation that is also inconsistent with Codex 
Alimentarius. At the very least, the Authority should commission the following: 
 a compositional study using H99 as the control in five sites over at least two years 
because H99 is the closest relative of LY038 and is the non-GM parental; 
 a compositional study describing the compounds formed during heating and processing of 
LY038 corn material as it would be in human foods—using the parental varieties as 
controls; 
 an animal feeding study using whole food derived from LY038 corn heated and 
processed as per normal use in human food—using the parental varieties as controls; and 
 human exposure studies (should the previous two studies not reveal clear hazards) that 
measure the effects of using whole food prepared from LY038 corn, pipecolic acid levels 
contributed from gut bacteria, and the potential for an allergic response to LY038 
following inhalation of LY038 flour. 
 
The Authority, if it ultimately recommends an amendment to the Food Code, should restrict 
that approval to the specific line evaluated in A549, and ensure that the approval cannot be 
extended to hybrids. The authority should also impose an actively managed post-marketing 
monitoring programme. 
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Overview 
  
This submission from the Centre for Integrated Research in Biosafety (INBI) is meant to 
support Food Standards Australia/New Zealand’s preparation of a Final Assessment on 
application A549.5 INBI is dedicated to development for the public good of all responsible 
biotechnologies. We are an assemblage of well-recognized researchers with independent 
credentials in the area of biotechnology and its social impact. 
  
A549 is an application to amend the Australia New Zealand Food Standards Code to allow 
foods derived from corn line LY038 to be sold in Australia and New Zealand. “Corn line 
LY038 has been genetically modified to have higher than usual levels of the amino acid 
lysine,” particularly in the corn grain.6 LY038 was modified by the gene cordapA, sourced 
from the bacterium Corynebacterium glutamicum, inserted into the corn genome using genetic 
engineering techniques. The gene “encodes the enzyme dihydrodipicolinate synthase 
(DHDPS). This enzyme is involved in lysine biosynthesis. The bacterial DHDPS enzyme, 
unlike the plant DHDPS enzyme, is not sensitive to lysine feedback inhibition, so lysine 
biosynthesis will continue in the presence of high levels of free lysine.”7  
  
Our submission is to form part of the consultation process of the FSANZ Draft Assessment 
Report and provisional recommendation that the Food Code be amended to include LY038. 
This submission follows from our February 2005 submission at the previous stage of 
consultation (made under our previous name, the New Zealand Institute of Gene Ecology), 
following the release of the Initial Assessment Report (IAR). We begin with introductory 
material describing who we are and why we are involved. The major content of our submission 
is organized into four main parts. In Part One, we address Attachment 4 of the Draft 
Assessment Report (DAR) prepared by FSANZ, which is the response to our February 2005 
submission (NZIGE submission). In this section, we set out the deficiencies in the FSANZ 
response and make recommendations for rectifying those deficiencies. 
                                                 
5 Our previous submission was under the name the New Zealand Institute of Gene Ecology. 
6 FSANZ (2004). Initial Assessment Report: Application A549 Food Derived from High-lysine Corn LY038, p. 6. 
7 Ibid, p. 9.  
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In Part Two, we review the scientific documents submitted by the Applicant in support of 
A549. We judged this material by two criteria: 1. Was the science at the best possible standard? 
and 2. Does the science add up to a package that is sufficient to assure the citizens of Australia 
and New Zealand that they may safely consume food derived from corn line LY038? In most 
cases we recommend how, why and when the Authority should seek further information before 
it advises the Ministerial Council that food derived from LY038 and derivatives is as safe as 
food derived from conventional counterparts. 
  
In Part Three, we comment upon the Impact Analysis and the conclusions derived from it. We 
assess the costs and benefits listed and propose further costs and benefits of the options under 
consideration. 
 
In Part Four, we note several issues related to FSANZ’s consultation process that require 
clarification, including the treatment of our submission to the A549 Initial Assessment Report. 
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Introduction 
 
I.1 This submission is the opinion of the submitter on Application A549 – high-lysine 
corn LY038 ‘MAVERA HVC with Lysine’. 
 
I.2 The submitter is the Centre for Integrated Research in Biosafety (INBI), a research 
organization (www.inbi.canterbury.ac.nz). INBI has no commercial interest in the 
product at the focus of this application, no direct or indirect connections with the 
Applicant, and has no connections to parties that seek to compete with the Applicant 
by developing a similar novel food. Our submission is informed by our extensive 
experience in the research areas discussed below. If there were to be a public hearing 
on the application, we would be pleased to present our view.  
 
I.3 Our submission relates to “the scientific aspects of this Application, in particular, 
information relevant to the safety assessment of food from corn line LY038” (DAR p. 
6). It also addresses the consistency of the DAR with “the objectives of FSANZ as set 
out in section 10 of the FSANZ Act” and provides “details of potential costs and 
benefits of the proposed change to the Code” (DAR p. 3).  
 
I.4 We have done our best to evaluate the scientific documents supplied by the Applicant 
in support of the application. 
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Part One: Evaluation of Attachment 4, DAR 
 
“At Initial Assessment, the New Zealand Institute of Gene Ecology (NZIGE) reviewed all the 
data submitted to FSANZ by Monsanto in support of this application and compiled a detailed 
submission, outlining a number of areas where it believes there are deficiencies in the safety 
data.”8 In fact, INBI reviewed all publicly available data submitted to FSANZ by Monsanto. 
FSANZ makes reference to several studies, including a rat study, two bioinformatics studies 
and a compositional study, that were not made available to us during the last round of 
consultation. 
 
In its response to the recommendations made by INBI, we believe that FSANZ has overlooked 
the extensive discussions underlying the recommendations. In many places, the FSANZ focus 
on the recommendation has missed important areas of scientific uncertainty. Here we will 
address the response made to the original submission, indicating in brackets the index numbers 
corresponding to the text from the original submission that explains the recommendation. The 
following sections are ordered as per the FSANZ response to the recommendations in our 
original submission (25 February 2005). 
 
FSANZ response to recommendation 1: Characterisation of novel protein, intended 
and unintended effects 
 
“Although general profiling techniques such as proteome analysis can be valuable research tools, a 
major challenge is in determining whether observed differences between two plants are 
distinguishable from natural variation, and if so, their relevance to food safety. For such techniques 
to be of use for the purpose of regulation they must be validated and the baseline range of natural 
variation clearly established (ILSI, 2004).” 
 
FSANZ has evaluated the molecular analysis of the inserted DNA in the genome of LY038 corn, 
which shows that only one copy of the gene encoding cDHDPS is present. No other novel proteins 
are produced in LY038. A full characterisation of this protein was done as part of the safety 
assessment of LY038 and is described in Section 4 of Attachment 2 of the Draft Safety Assessment 
Report. The data provided was comprehensive and included N-terminal sequencing, molecular 
weight determination, immunoreactivity, glycosylation analysis, peptide mass fingerprinting and 
matrix assisted laser desorption ionisation time of flight (MALDI-TOF) mass spectrometry. Further 
information such as suggested in this recommendation would not add to characterisation of cDHDPS 
and therefore has not been requested by FSANZ.” 
 
INBI: (1) Profiling techniques can be used in two different ways, only one of which is 
addressed in this response. (2) Our recommendation was not just for untargeted profiling, but 
for specific data on the full range of cDHDPS isomers produced in transgenic plants. (3) The 
extensive characterizations described above could not provide insight into isomers that the 
Applicant failed to identify in the first place. 
 
(1) First, as indicated, an unintended effect may be revealed through a statistically significant 
change in the concentration of a harmful metabolite, for example, protein, class of RNA or 
                                                 
8 DAR, p. 63. 
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other molecule. To establish statistical significance may require the Applicant to generate good 
baseline data and the Industry to invest in proper validation techniques. It is not the public’s 
responsibility to ensure that these verifications are completed for the Applicant. 
 
Second, as revealed in the full quote from ILSI, profiling techniques can be used to identify 
unintended changes that may be harmful to consumers even in the absence of data that 
indicates that gross changes are statistically significant. “Predictable and unpredictable 
unintended effects may or may not prove to have relevance in terms of product safety, but must 
be taken into account when assessing risk” (Cellini et al., 2004). Codex Alimentarius says 
“[m]olecular biological and biochemical techniques can also be used to analyse potential 
changes at the level of gene transcription and message translation that could lead to unintended 
effects” (p. 10). Even the Applicant has concluded that “this method [2D gel electrophoresis] 
could be used to interrogate proteome alterations such as a novel protein, fusion protein, or any 
other change that affects molecular mass, isoelectric point, and/or quantity of a protein” 
(Monsanto study published under Ruebelt et al., 2006a). The Applicant has published 
demonstrations of the application using transgenic Arabidopsis plants: “This study 
demonstrated that 2DE [2D gel electrophoresis] can be utilized to reliably analyze the seed 
proteome of transgenic A. thaliana” (emphasis ours) (Ruebelt et al., 2006b). 
 
While the profiling techniques may not be of the sophistication necessary to rule in or out harm 
by themselves (Ruebelt et al., 2006b), the Applicant should be responsible for pursuing 
unintended effects by whatever techniques are available to a point that would reasonably satisfy 
a regulator using international standards for safety assessment that the change was not 
meaningful. 
 
For example, the gross change in protein concentrations between healthy bovine and those 
suffering from Mad Cow’s Disease may not be statistically significantly different, but the 
change in the protein profile of bovine suffering from the disease would still be a matter of 
importance for assessing the beef as safe for humans to eat. Profiling techniques are capable of 
being used in this way (Riemer et al., 2004). Any differences detected can then be investigated. 
So while profiling does not produce final evidence of harm, failure to detect differences is an 
indicator of safety. 
 
(2) The Applicant’s case for safety requires that in planta produced cDHDPS is equivalent to 
the material that the Applicant isolated from other, surrogate, sources (e.g. Escherichia coli) 
because many of the Applicant’s subsequent analyses use protein isolated only from surrogate 
sources. We believe that FSANZ has an obligation to the public of Australia and New Zealand 
to verify scientifically that in planta produced cDHDPS is equivalent in all ways. 
 
(3) The two methods that the Applicant used to isolate cDHDPS from transgenic plants were 
both potentially compromised by post-translational modifications unique to the production of 
the protein in plants (5.3.15). 
“[I]t is important to note that there are fundamental differences between the identification 
of a protein and the analysis of its post-translational modifications. Minimal sequence 
information will suffice to ensure unambiguous protein identification but practically full 
sequence coverage must be obtained in order not to miss the (few) modified amino acids” 
(Küster et al., 2001). 
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The only scientifically sound way to confirm that there are no unique isomers of in planta 
produced cDHDPS is to use comparative 2D gel electrophoresis and MS. 
 
This fact was made most dramatically by authors of studies applying different techniques to 
catalogue the glycoforms of the human Prpc protein (the benign form of the human prion 
protein). A recent study found that many isomers, some with significant N-terminal truncations 
that they argue are not simple autolysis products (as the Applicant has argued for some rogue 
bands that appear on Western blots in this application), would not be detected by 1D 
approaches used in the studies provided to the Authority. “It is probable that, without resorting 
to 2-D map analysis, as in the present case, only a few spots of PrP might have been identified, 
but it is highly doubtful that such mono-dimensional techniques, even when coupled to the 
most sofisticated (sic) MS instrumentation, would have revealed the amazing structural 
complexity of PrP proteins from human tissues, where >60 different spots (vs. 3-4 by SDS 
PAGE) could be visualized” (Castagna et al., 2002). 
 
The Applicant’s use of purified protein followed by SDS PAGE and MALDI-TOF to verify the 
identity of the protein is not equivalent to a conclusion that all potential isoforms of the protein 
produced in planta were detected. The combination of techniques used verify protein identity, 
but are not verified as used as a pathway to a comprehensive isoform discovery (Küster et al., 
2001). The key data equating the E. coli and in planta-produced recombinant cDHDPS (Figure 
30, p. 50, of application) has several flaws for drawing the conclusion of identity. 
 The antiserum used in the Western blot lacks sufficient description. Post-translational 
modifications vary by species, tissue and time of development, and important epitopes 
can be masked by post translational modifications (Küster et al., 2001). Thus, the 
Authority cannot know that the antisera includes antibodies that would detect minority 
glycoforms, or other isoforms, unless it can verify that the goat anti-cDHDPS antisera 
was raised to protein isolated from the plant. 
 The protein loaded onto the SDS gel was purified using a combination of anion exchange 
and hydrophobic interaction chromatography, both of which can be affected by post 
translational modifications (and thus bias against detecting some post translational 
modifications) (Küster et al., 2001). Thus the Authority cannot know that all minority 
isoforms were retained in the protein fractions loaded onto the gel. 
 The analysis from which the Authority is working does not exclude either co-migration of 
isoforms with the detected form, or other bands on the gel but below the detection level. 
“1 pmol of a glycoprotein on a gel will represent a composite of many glycoforms present 
only in the low fmol range” (Küster et al., 2001). The Authority should know and report 
the detection level of this particular Western. 
 SDS PAGE does not detect modifications that contribute less than 1 kDa to molecular 
weight. Many types of modifications involve molecules less than 1 kDa. 
 
We also note that there are difficulties in interpreting 2D gels (Küster et al., 2001), but the 
difficulties are in distinguishing between kinds of post translational modifications rather than a 
bias against detecting variant isoforms. “Although this global view on protein glycosylation 
does not allow the detailed description of all aspects of glycoform heterogeneity, it is a good 
first round analysis in order to assess the overall complexity of the sample and thereby assists 
in deciding whether or not to investigate glycan structure in more detail” (Küster et al., 2001). 
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Thus, 2D gels are an essential complement to the Western analysis provided. 
 
While FSANZ may be choosing to conclude that all novel proteins not described by the 
Applicant are not required to be, it is not scientifically accurate for FSANZ to conclude from 
the data provided by the Applicant that “[n]o other novel proteins are produced in LY038.” 
Further, we are not able to determine how FSANZ can know that the outcome of scientific 
experiments looking for unanticipated changes “would not add to characterisation of cDHDPS” 
when those experiments have never been done. A sound scientific assertion of safety that 
FSANZ draws from the Applicant’s data requires, in our opinion, properly conducted profiling 
experiments that will detect unintended changes followed by whatever techniques the 
Applicant can use to evaluate those changes. 
 
Please see Part Two, “Characterisation of the novel protein”, for further discussion and 
recommendations.  
 
FSANZ response to recommendation 2: Toxicity, carcinogenicity and whole food 
feeding studies 
 
“It is unclear whether this recommendation refers to feeding studies with the purified protein or with 
the whole food. Long term feeding studies in animals are of limited value for determining the safety 
of whole foods, including GM food. The safety assessment of a GM food relies largely on a 
comparison with its conventional counterpart. This is discussed further under recommendation 12. 
 
The biochemical components identified in LY038 corn are the normal constituents of conventional 
corn with the exception of the cDHDPS protein. This protein is structurally and functionally related 
to an endogenous DHDPS protein. As with any whole food, incorporation of LY038 corn into the 
diet of animals at high levels and over long periods of time is likely to cause physiological and/or 
biochemical changes due to nutrient imbalances, rather than any specific toxicity. In terms of the 
contribution of diet to cancer risk, over the long term a balanced diet of nutritious foods is probably 
more important to health that the level of intake of any one food. 
 
There is no scientific justification for FSANZ to request lifetime carcinogenicity studies with LY038 
corn.” 
 
INBI: (1) Feeding studies are valuable studies to reveal unanticipated harms. (2) It is both 
wrong and misleading to imply that in planta-produced cDHDPS is structurally equivalent to 
the plant form of DHDPS just because they share an ancient evolutionary relationship (1.1.3). 
(3) Products unique to LY038 or at unique concentrations in LY038 that are produced during 
cooking (2.1) may lead to cancer. In the absence of a complete profile of novel forms of 
proteins (see above), RNA and metabolites in LY038, there is no scientific justification to 
assert that lifetime carcinogenicity studies and aggregation studies would not be valuable. See 
Part Two of this submission, “Characterisation of novel protein”, for additional analysis. 
 
(1) FSANZ assertions of safety should be demonstrably consistent with the results of animal 
feeding studies using whole cooked and processed food. 
 
(2) The bacterial and plant versions of DHDPS enzymes have an entirely different quaternary 
structure due to a profound rearrangement of the dimers forming the tetramer (Blickling et al., 
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1997). 
 
(3) We would not expect potentially dangerous aggregates to be detected in either the broiler 
feeding study or the acute mouse toxicity study, because exposure to some aggregated proteins 
in the amyloid form can take decades to produce an effect. Moreover, those studies did not use 
cooked or processed corn. As we have argued, the high levels of lysine, free lysine and lysine 
catabolites makes LY038 corn a potential source of high AGE content in food. “CML-modified 
proteins [lysine AGE endproducts] may be involved in the biology of tumors through the 
activation of transcription factor NF-κ, the up regulation of vascular endothelial growth factor 
(VEGF), vascular cell adhesion molecule 1 (VCAM-1), tissue factor (which could explain the 
CML positivity of capillaries), and the induction of intracellular reactive oxygen species. In 
addition, the presence of CML could lead to enhanced cancer progression by inducing DNA 
damage” (Heijst et al., 2005). Thus, long term carcinogenicity studies are warranted.  
 
See the next response for more information on AGEs. 
 
FSANZ response to recommendation 3: Food Processing, Maillard reaction 
 
“This recommendation is based on the concern that any increase in lysine in food may lead to 
adverse effects, for example, by altering the Maillard reaction products when LY038 corn is 
cooked…However, Maillard reaction products produced during the processing or cooking of LY038 
grain should not differ from those produced from conventional corn. With the exception of lysine, 
the amino acid profile of LY038 grain is comparable to conventional corn. 
 
It is well accepted that any normally healthy compound, when consumed in sufficiently large 
quantities, may cause health problems, however the levels of lysine in LY038 corn do not warrant 
the level of concern displayed by the NZIGE. Lysine is an essential amino acid that cannot be 
produced by humans and therefore must be obtained from the diet. Corn is not traditionally a good 
source of lysine and even though LY038 contains significantly increased lysine, this is not 
significant in relation to other dietary sources of lysine. The levels of lysine in some commonly 
consumed foods are given in the following table [not reproduced here]. 
 
It can be seen that LY038 grain has approximately 160 mg / 100 gm more lysine than the control 
corn grain, however when compared to lysine from other dietary sources this is not a large amount of 
lysine and does not represent a human health concern.” 
 
INBI: (1) AGEs may differ between LY038 and conventional corn after processing or cooking 
because—as FSANZ, the Applicant and we all agree on—the lysine concentration and other 
Maillard reactants are significantly higher and at unprecedented concentrations (especially free 
lysine) in a novel context in this transgenic plant. (2) It is neither true nor in our view 
responsible to suggest that there is historical evidence to dismiss the production of undesirable 
AGEs or anti-nutrients that would be specific to lysine at these concentrations in corn with its 
unique types and concentrations of carbohydrates, in the context of the products that corn is 
most often cooked with, and in the way that corn may be prepared (2.1.2). On the contrary, 
there is historical evidence of anti-nutrients formed by the Maillard reaction in corn. (3) LY038 
must be found to be as safe as conventional corn, not conventional red meat, fish, cheese, 
chicken, eggs, broccoli, lentils and rolled oats as suggested by FSANZ when drawing 
comparisons between total lysine in these foods and LY038 corn and inferring the importance 
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of dietary free lysine derived from cooked LY038 products. LY038 is not substantially 
equivalent to these foods, conventional or otherwise. (4) FSANZ cannot, in our view, meet its 
objective of the “protection of public health and safety” and “the provision of adequate 
information relating to food to enable consumers to make informed choices”9, and be consistent 
with Codex Alimentarius, while allowing a change in the Food Code that would permit the 
substitution of low AGE content (conventional) vegetables with genetically modified crop 
plants that could produce higher AGE content foods, considering the importance of AGE-
related diseases to Western society. 
 
Please see the “Food Processing” section in Part Two for details and recommendations. 
 
FSANZ response to recommendation 4: Characterisation of novel protein, aggregation 
 
“This concern has been raised by the NZIGE because amyloid fibrils are involved in a variety of 
medical conditions such as Alzheimer’s and Parkinson’s diseases. However, these fibril aggregates 
are produced from endogenous proteins that have sustained mutations or have been misfolded, rather 
than from the consumption of particular proteins. 
 
The ability to form fibrils is not limited to those proteins involved in amyloidoses, it appears that any 
polypeptide can be induced to form fibrils under appropriate conditions in vitro (Chiti et al., 2000; 
Ellis and Pinheiro, 2002; Bucciantini et al., 2002). There is also some evidence that protein 
aggregates are inherently cytotoxic (Bucciantini et al., 2002). Therefore testing cDHDPS to 
determine if it forms cytotoxic fibrils would not provide useful information for a safety assessment 
of LY038 corn. 
 
The cDHDPS protein is no more likely to form amyloid fibrils than any of the naturally occurring 
proteins in LY038. Even in the event that cDHDPS aggregates form in planta, a series of improbable 
events would have to occur in order for cDHDPS fibrils to display cytotoxicity in human cells. 
FSANZ is of the opinion that the studies submitted by the applicant demonstrate the safety of LY038 
corn and do not believe that results of such a study as suggested in this recommendation would add 
to the overall body of information.” 
 
INBI: (1) Amyloid fibrils are produced from endogenous proteins, but it is incorrect and 
misleading to say that they are not spread through the consumption of particular proteins. (2) It 
is impossible without testing to conclude that cDHDPS, in corn cells and through processing of 
foods with corn content, is “no more likely to form amyloid fibrils than any of the naturally 
occurring proteins in LY038”. (3) The Authority should explain why it believes that the 
connection between cDHDPS aggregates and cytotoxicity relies on a series of improbable 
events, considering that there is published evidence of the cytotoxicity of protein aggregates. 
 
(1) Some aggregates do transfer through food and are infectious. Variant CJD (vCJD) disease 
in the UK is caused by the consumption of beef derived from diseased animals. Aggregates 
formed by similar proteins, those that cause CWD (the cervid version of mad cow disease) are 
stable in soil for at least two years and can be transmitted between animals through contact, 
through grazing near rotting carcasses of diseased animals or through feces (Miller et al., 
                                                 
9Ibid, pp. 8-9. 
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2004). These examples directly demonstrate the ability of xeno-aggregates to transfer their 
effects to endogenous proteins in humans and other mammals.  
 
(2) Our argument is not that cDHDPS aggregates will create prions in human consumers or 
cause prion-associated diseases in human consumers. Our argument is simply that protein 
aggregates of many forms, including amyloid fibrils, can be shown in laboratory experiments to 
be cytotoxic. cDHDPS is not a normal constituent of human food (see Table 6), and certainly 
not at the concentrations that LY038 and its derivatives may make it. cDHDPS is not the same 
protein as the endogenous DHDPS and cDHDPS does not normally reside under physiological 
conditions of the plant chloroplast. Thus, its tendency to form aggregates of potential 
cytotoxicity cannot be determined by argument or reliance on GRAS. 
 
(3) In our original submission, we provided the Authority with a list of references describing 
the current scientific view of how proteins form aggregates and how this process was a function 
of milieu conditions. We also provided the Authority with references (e.g. Bucciantini et al., 
2002) demonstrating that proteins derived from natural sources generally regarded as safe can 
be cytotoxic if allowed to re-fold under different conditions. It is now the burden of the 
Authority to provide the people of Australia and New Zealand with evidence for their statement 
that a “series of improbable events would have to occur in order for cDHDPS fibrils to display 
cytotoxicity in human cells.” 
 
We are aware that Monsanto provided the “improbable events” rationale to the Authority and at 
the Authority’s request (as it has for most of the FSANZ responses in Attachment 4, DAR). 
The original Monsanto advice provided to the Authority reads as follows, with INBI comments 
in brackets: 
 
“In the event the cDHDPS were to form amyloidal fibrils or aggregates in planta, these fibrils 
or aggregates would have to exit the chloroplast intact and gain access to the cytoplasm of a 
susceptible cell.” [It is necessary for the Authority or the Applicant to provide evidence 
that chloroplast proteins are completely destroyed by digestion within the plant or human 
consumer. We are not aware of such evidence. On the contrary, we are aware of evidence 
demonstrating that many proteins survive digestion. We are also aware that proteins 
transmitted through food do gain access to the cytoplasm of a large range of human cells. 
This has been demonstrated by prions (Soto, 2004), and was the reason we discussed 
prions in our original submission.] “Once in the cytoplasm of a susceptible cell, the fibril 
would then have to either exert cytotoxicity directly, or act as the nucleus for the 
aggregation/fibril formation of an endogenous protein(s). In the unlikely event that cDHDPS 
forms in planta aggregates…” [We believe that it is necessary and possible to remove this 
issue of uncertainty by measuring the propensity of in planta-produced cDHDPS to form 
aggregates and relate that propensity to the conditions of the chloroplast. There is no 
scientific reason to assume that aggregation is unlikely.] “…a series of improbable, if not 
physically impossible events would have to occur in order for cDHDPS fibrils to display 
cytotoxicity” (Monsanto reply to FSANZ). 
 
Please see Part Two “Characterisation of novel protein, aggregation” for further discussion and 
recommendations. 
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FSANZ response to recommendation 5: Molecular characterisation, untranslated 
RNA 
 
“The rationale behind this recommendation is presented in the NZIGE submission in Section 1.3. 
This section presents a summary of the biological properties of RNA that is generally accurate. 
However, the scientific evidence does not support the theory that RNA molecules in food can be 
transmitted to mammalian cells and exert effects on endogenous genes. 
 
RNA is rapidly degraded even in intact cells. Following harvest, processing, cooking and digestion, 
it is unlikely that intact RNA would remain. Even if it did, it is very unlikely that it would enter 
human cells and be able to exert effects on endogenous genes. 
 
What little is known about transcription levels of genes across entire plant genomes indicates that 
gene transcription may vary considerably even between closely related plants (Bruce et al., 2001; 
Guo et al., 2003; Umezawa et al., 2004). This high level of differential expression is thought to be 
due to a number of factors including environmental conditions and genotype. For this reason, 
analysis of changes in the transcriptome, while interesting, would not indicate whether these changes 
are within the range of natural variation nor would it provide any further information on the safety of 
the food.” 
 
INBI: (1) The Authority has avoided the recommendation and replied with no scientific 
evidence to support their assertion that dsRNA of the type involved in phenomena such as 
RNAi, PTGS, etc. are so unstable as to not have biological relevance. (2) In fact, evidence to 
the contrary is rapidly accumulating. (3) In addition to the extensive discussion in our original 
submission (1.3), and its list of references, we have these comments. 
 
(1) The Authority is requested to note that dsRNA are stable enough in mammalian cells to be 
routinely used as gene regulators. Up to one third of human genes are regulated by dsRNA 
(Lewis et al., 2005). It is transmitted through food in other animals, where it survives 
degradation in bacteria producing the molecule and digestion in the animal gut. The medical 
literature is already exploring the use of exogenously developed dsRNA as therapeutics 
(Stevenson, 2004). Delivery mechanism in mammals include through food (Brisibe et al., 2003) 
and injection (e.g. Lewis et al., 2002). Injection of dsRNA into the tail of a mouse affects gene 
expression in broadly distributed organs, thus demonstrating its stability and transmissibility 
inside mammals (e.g. Check, 2004, Zamore and Aronin, 2003). 
 
(2) As of May 2006, it has been demonstrated the dsRNA constructs produced in E. coli can 
effect gene silencing (RNAi) in the gut cells of mice (Xiang et al., in press). Mice were fed E. 
coli expressing dsRNA directed against genes in the intestinal cells. In this study, the bacteria 
were nonpathogenic but engineered to invade human cells. What the study demonstrates is that 
dsRNA is stable in E. coli, stable in the human stomach under some conditions, survives the 
intestine and is biologically active in intestinal cells. The dsRNA was transmitted to the animal 
through oral ingestion, as if it were food. The Authority should note that this is what we 
indicated was possible when we wrote our first submission over a year ago. Although this 
demonstration was not the same as feeding naked dsRNA, the Authority should also be aware 
that the dsRNA in LY038 would be protected by the plant cell or cellular debris, or the surface 
of bacteria, and therefore could very likely survive the stomach. This field of research is so new 
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that such strong statements of confidence as the Authority has made are inappropriate and lack 
credibility. 
 
(3) Transcriptional variability in plants is irrelevant to this issue. Variability of transcription is 
not the cause of novel species of dsRNA; transcription of novel DNA sequences is. It is 
transcription of novel DNA sequences that were, and may have been, created through insertion 
of the I-DNA into a traditional food source: corn. What is relevant is whether, as a direct or 
unanticipated consequence of the modification of corn, a type of dsRNA may emerge that has 
biological consequences in humans. 
 
The techniques we suggested for discovering novel dsRNAs may not be the only options 
available to the Applicant. They are, as discussed above, a first step in identifying unanticipated 
RNA species. If the technique recommended is not used, then the Authority should still sight 
evidence that all novel RNA species have been identified, characterized and tested for food 
safety. 
 
Please see Part Two, “Characterization of the genetic modification” for further discussion and 
recommendations. 
 
FSANZ response to recommendation 6: Glb1 promoter 
 
“This recommendation has been made due to concerns of the NZIGE that the intact Glb1 promoter 
sequence and the cordapA gene to which it is attached may be taken up by human cells following 
ingestion and cause the over-expression of cDHDPS in human cells or deregulate expression of 
endogenous genes. 
 
The Glb1 promoter comes from corn and therefore has been consumed safely by humans for 
thousands of years. No safety concerns have been identified with the consumption of DNA from GM 
plants. A typical diet contains DNA from many sources – bacteria, plants, and animals. It is highly 
unlikely the Glb1 promoter from corn poses any greater risk than any other piece of DNA in the 
human diet. As only one copy of this promoter has been inserted into LY038, this will not 
appreciably increase the amount of this element ingested as it is estimated that the entire novel DNA 
insert in LY038 represents only 0.0002% of the corn genome.” 
 
INBI: We are satisfied with this response so long as the Authority can verify that the “Glb1 
promoter” is unaltered at the DNA sequence level. 
 
INBI recommendation: 
R.1 The Authority should report the DNA sequence of the Glb1 promoter in event LY038. 
Since the Applicant claims that it is the endogenous corn promoter, the actual 
sequence should not be a commercial secret. 
 
FSANZ response to recommendation 7: Compositional analyses, NMR 
 
“The major nutrients and anti-nutrients present in corn have been identified by the OECD (OECD, 
2002). These components were analysed in LY038 corn and non-transgenic control corn. In addition 
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to those components identified by the OECD, specific lysine related metabolites were analysed and 
compared between conventional and LY038 corn grain. 
 
In addition to targeted compositional analyses mentioned above, profiling methods (such as 
metabolomic analysis) may be able to provide insight into metabolic pathways in the plant (ILSI, 
2004). However, as has been observed in relation to compositional analyses, the large range of 
natural variation that occurs between plants can mean that a statistically significant difference 
between the test and control plants for any given nutrient may not necessarily be biologically 
significant. This is also a major challenge with the use of profiling techniques and therefore these 
techniques need to be validated and the range of natural variation clearly established before they can 
be used for the purpose of safety assessment (ILSI, 2004). 
 
Currently the internationally accepted practise for evaluation of new GM plants relies on a variety of 
data and information, including compositional analyses, to identify any unexpected changes in the 
plant, which are then subject to further scrutiny to determine their biological relevance and potential 
impact on food safety. FSANZ considers these data and information, when considered in total, 
provide assurance that the food is unlikely to have an adverse effect on human health.” 
 
INBI: (1) Our recommendation resulted from a published demonstration of the effectiveness of 
this technique for profiling. The full ILSI paper referred to is not available to us. Our 
recommendation is repeated unless the ILSI specifically addressed, and criticized, this 
technique for profiling. (2) The Authority should elaborate on the variety of analyses used to 
identify unexpected changes, since in every other response to our submission it has attempted 
to justify the absence of methods for identifying unknown RNAs and proteins. 
 
Please see Part Two, “Compositional analysis”, for discussion and recommendations. 
 
FSANZ response to recommendation 8: Allergenicity studies, pepsin resistance 
 
“The Applicant conducted an in vitro digestibility study on the novel protein present in LY038 corn, 
cDHDPS, using a standardised protocol that has been shown to distinguish known allergens from 
proteins known not to be allergenic (Thomas et al., 2004). This protocol is not intended to be an 
exact replica of conditions in vivo, but rather is used to compare the test protein to known allergens 
under the same conditions. 
 
The NZIGE object to the use of this protocol because the ratio of pepsin to protein is higher than 
would occur naturally in the human stomach and gastrointestinal tract. 10U of pepsin were used for 
every μg of test protein (2.64:1 ratio based on weight). Although in vivo protein levels will almost 
always exceed those of pepsin (Taylor, 2003), a standardized pepsin resistance assay is needed. For 
this reason the Applicant has used a protocol that has been shown to distinguish in vitro known 
allergens from non-allergens. 
 
The recommendations of the WHO/FAO paper (2001) does not specify pepsin activity, but 
recommends an amount of pepsin based on weight. However, in reactions of this kind, enzyme 
activity is more relevant to the outcome than enzyme weight and for this reason, the protocol used by 
Thomas et al. (2004) is considered by FSANZ to be appropriate for assessing relative digestibility.” 
 
INBI: We are aware of the Thomas et al. paper and cited it in our original submission (7.1.10). 
This response does not address our concerns. The weakness of the FAO/WHO protocol is that 
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it does not control for variability in pepsin activities between studies. But an advantage of the 
FAO/WHO protocol is that it creates a more realistic ratio of pepsin to protein (Taylor, 2003) 
in the relevant environment, the stomach (conditions that are not standardized for AU of 
pepsin). It also requires the use of standard control proteins which were absent in the 
experiments submitted by the Applicant (7.1.12). There is no scientific justification for the 
Applicant to pursue one test over the other, especially considering the FAO/WHO standard is 
the international consensus and the Thomas et al. standard is only the Industry preference. 
Therefore, the analysis should be done to both standards.  
 
Please see Part Two, “Toxicity and allergenicity, pepsin resistance” for discussion and 
recommendations. 
 
FSANZ response to recommendation 9: Amino acid levels 
 
“The reason the NZIGE has made this recommendation is elaborated on page 42 of the NZIGE 
submission. They are concerned by some apparent compositional differences (in amino acid levels) 
between the conventional corn lines used as controls in this study and the 99% tolerance interval 
from the conventional corn lines used as controls in study MSL-19172 (compositional analysis). 
Table 1 on page 42 of the NZIGE submission compares these values, however the data in the studies 
(MSL-18883 and MSL-19172) uses different units and therefore cannot be directly compared in this 
way. 
 
Once the amino acid values in question are expressed using the same units (% total amino acids) they 
fall within the 99% tolerance interval as shown in the table below” [not reproduced here]. 
 
INBI: We are satisfied with this response addressing confusion of the units in Table 1 of our 
submission. However, it is still unclear why the commercial corn lines used in MSL-18883 
were not used in MSL-19172 (Compositional analysis). Surely the most complete analysis 
would have used varieties common to both studies. In MSL-18883, LY038 had higher levels in 
all of the 18 measured amino acids among the four commercial varieties used as references. In 
fact, the total amount of amino acids for LY038 was 115.17 mg/g compared to an average of 
77.8 mg/g for the four commercial varieties. 
 
We will elaborate on other concerns in Part Two, “Compositional analysis”. 
 
FSANZ response to recommendation 10: Nutritional impact, feeding studies 
 
“The study referred to in this recommendation is the broiler chicken feeding study. The NZIGE 
recommends dismissing this study due to confusion over the levels of amino acid in the control lines 
compared to those used in the compositional analyses. As discussed in Recommendation 9, these 
apparent compositional differences were due to differences in the units used. 
 
Study MSL-18883 is a comparison of different corn diets, including LY038 corn and conventional 
corn (either supplemented with lysine or not), in supporting the growth and performance of broiler 
chickens. This study was submitted by the Applicant to demonstrate the wholesomeness of LY038 
corn. The rapidly growing broiler is considered to be sensitive to changes in nutrient quality in diets, 
and therefore is often used as a model to assess normal growth and well-being and the 
wholesomeness of corn. 
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Normally, FSANZ does not require animal feeding studies to be submitted because when GM 
varieties have been shown to be compositionally equivalent to conventional varieties, feeding studies 
using target livestock species will add little to a safety assessment. In these circumstances the extent 
of the compositional data, molecular characterisation and toxicity / allergenicity data is considered 
sufficient to establish the nutritional adequacy and safety of the food. In cases where the 
composition of food has been significantly changed, as is the case with high-lysine corn, feeding 
studies with suitable livestock species may be useful to confirm the wholesomeness of the food 
[emphasis ours]. 
 
It is important to note that comparative feedings studies, like the one submitted for high-lysine corn, 
are not safety or toxicity studies and are only conducted with the purpose of demonstrating 
nutritional adequacy. Nevertheless, providing the study has been well conducted, the absence of 
adverse effects can provide additional assurances of safety. FSANZ has no valid reason to dismiss 
this particular study.” 
 
INBI: (1) The Authority is mistaken in its understanding of our reasons for concluding that the 
broiler study was too flawed to be considered valid for assessment of human food safety. (2) 
New Zealand and Australia are adherents of case-by-case assessment. Thus, generalities about 
past studies using different material do not substitute for properly conducted studies using 
whole food derived from LY038. (3) Given that high-lysine corn is a case of substantial 
nutritional change, and since FSANZ have chosen to defend the broiler study, we repeat our 
recommendations. 
 
We were in part concerned about the amino acid levels. However, this was not the only reason 
we found the broiler study less than satisfactory (7.2.4-7.2.7). Broilers fed LY038 and 
derivative corn had significantly lower adjusted weight gain in the first 21 days than groups fed 
conventional corn supplemented with similar amounts of lysine (p=0.008; t-test). This result 
suggests that there may be an unexpected and unexplained negative factor acting on broilers fed 
GM lysine-producing corn that prevented them from reaching the same growth rates as broilers 
fed conventional corn. The Authority has not addressed this observation. 
 
We also were troubled by the apparent contamination of LY038 seed stock by MON810, a 
different transgenic line. Individual PCR analysis found that up to 20.5% of LY038 seed 
carried the MON810 event, or that up to 20.5% of the seed was MON810. This was also 
confirmed using an immunological detection method. The Applicant goes on to say that “the 
presence of the MON810 trait was considered as an ‘inert ingredient’ that would not impact the 
objectives and interpretation of this study” (MSL-18883, p. 23 of 165). In our view, the 
presence of substantial quantities of MON810 invalidates claims about LY038 because it has 
substantially diluted any concentration-dependent effects of the high-lysine line. The Authority 
has not addressed this observation. 
 
Please see Part Two “Nutritional impact, broiler studies” for recommendations. 
 
FSANZ response to recommendation 11: Toxicity studies, animal models 
 
“As mentioned in the response to recommendation 10, FSANZ does not routinely require animal 
feeding studies to support the safety of a GM food. There are limitations in the extent to which such 
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comparative feeding studies can be used to detect adverse effects because there are constraints on the 
amount of test material (in this case, high-lysine corn) that can be incorporated into an animal’s diet 
without creating nutritional imbalances. These studies are really only designed to demonstrate that 
the new GM food supports typical growth and wellbeing in the test animal. As a consequence, 
detailed blood analyses are rarely done. 
 
These analyses have been requested by the NZIGE on the basis of a study in rabbits fed diets 
supplemented with various amino acids (Giroux et al., 1999). This study showed that diets high in 
lysine in combination with high levels of other amino acids led to increased serum cholesterol and 
phospholipids in the liver. Rabbits were fed diets containing 32.9 g lysine/kg diet, a very large 
amount of lysine compared to the levels found in LY038 corn (0.48% on a dry weight basis, or 4.8 
g/kg dry weight). As the level of lysine in the supplemented diets given to the rabbits was very much 
higher than the levels found in high-lysine corn, this study is not considered relevant to the safety of 
high-lysine corn. In addition to this, corn is not a significant source of lysine in the human diet and 
even LY038 corn would not contribute significantly to lysine in the diet compared to other sources 
of dietary lysine.  
 
There is no basis for the rationale that consumption of lysine from LY038 corn may have an effect 
on serum cholesterol.” 
 
INBI: (1) The Authority also said in their response to recommendation 10 that a valid feeding 
study was warranted in the case of high-lysine corn because it was substantially nutritionally 
different from conventional corn. (2) The Giroux et al. study was provided to the Authority to 
assist them in identifying a protocol for testing adverse affects. The Giroux et al. study did not 
preclude effects at lower concentrations of lysine than used, so this in itself is no reason to not 
do a comparable study with high-lysine corn. (3) The Authority has not addressed why they 
accept a level of reporting below that recommended by Renwick (Renwick, 2004). (4) The 
Authority has not addressed why they do not require a pig study of the type we recommend, 
especially considering that this would be far more suitable as model for humans than are 
chickens. 
 
FSANZ response to recommendation 12: Toxicity studies, whole food feeding studies 
 
“Long-term animal toxicity studies are not generally appropriate for the testing of whole foods. Such 
studies are commonly used in the safety assessment of discrete chemical compounds including 
pesticides, pharmaceuticals, industrial chemicals and food additives. In these cases, the test 
substance is well characterised, of known purity, of no nutritional value, and human exposure is 
generally low. It is therefore possible to feed such compounds to laboratory animals at a range of 
doses (using amounts greatly above expected human exposure levels) in order to identify any 
potential adverse effects. Establishing a dose response relationship is a pivotal step in toxicological 
testing. By determining the level of exposure at which no adverse effects occur, a safe level of 
exposure for humans can be established which includes appropriate safety factors. 
 
In contrast, traditional toxicological testing is not intended to be applied to the assessment of whole 
foods. Foods are complex mixtures of constituents and have wide variations in composition and 
nutritional value. Due to its bulk, a food can only be fed to laboratory animals at low multiples of the 
amounts that might be present in the human diet and it is therefore not possible to conduct normal 
dose-response experiments in the same way that these experiments are conducted for medicines and 
chemicals. In addition, a key factor in these experiments is the need to maintain the nutritional value 
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and balance of the diet. A diet that consists entirely of a single food can cause adverse effects on 
nutritional status, potentially masking any other smaller effect of a component or components of the 
food being tested in the animals. 
 
The observations from single food studies can therefore be confounded by a range of adverse effects 
not directly related to the food being tested. 
 
Thus, a more focussed approached is required when the safety of a whole food is being considered. 
This approach is based on the principal that the safety of GM foods can be assessed by comparison 
to a conventional counterpart having a history of safe use, taking into account both intended and 
unintended effects. Rather than trying to identify every hazard associated with a particular food, the 
intention is to identify new or altered hazards relative to the conventional counterpart. 
 
A component of this approach is to focus on the potential toxicity of any new proteins that have been 
introduced into the food through genetic modification. Because proteins are discrete chemical 
entities they can be fed to animals in large amounts, therefore it is possible to conduct animal 
toxicity studies to determine their safety. Acute toxicity testing has shown that the novel protein in 
LY038 corn, cDHDPS, is not toxic at high doses in rats. 
 
However, a 3-month rat feeding study using LY038 corn was conducted by the Applicant and 
supplied to FSANZ. This study demonstrated no test substance adverse effects in rats fed up to 33% 
LY038 corn in their diets.” 
 
INBI: (1) Tests of the lengths that we recommend have been recommended by others in the 
peer-reviewed literature. (2) Animal feeding studies should not be dismissed because of the 
possibility that they could yield false positive results, especially considering that the alternative 
is to institutionalize potentially false negative indications of safety. (3) Our concerns are not 
just toxicological. (4) However, confirmation of the 3-month rat feeding study referred to 
above is welcome. 
 
Please see Part Two, “Toxicity and allergenicity” for discussion and recommendations. 
 
FSANZ response to recommendation 13: human tests 
 
“The safety assessment for a GM commodity compares the molecular, toxicological and nutritional 
and compositional properties of the food to the non-GM form. The assessment focuses on the new 
gene product(s), including the intentional and unintentional effects of the genetic modification, and 
examines any compositional changes, including whether the genetic modification has altered the 
potential allergenicity and toxicity of the food. The assessment is therefore a comparative analysis 
using the commonly consumed conventional food as a benchmark for safety. 
 
This comparative analysis is regarded by organisations such as the World Health Organisation 
(WHO)/Food and Agriculture Organisation (FAO), the Organisation for Economic Cooperation and 
Development (OECD) and the Codex Alimentarius Commission as the most practical approach for 
assessing the safety of a GM food. FSANZ regularly reviews procedures for assessment to ensure 
that recent scientific and regulatory developments are reflected in the process. At the international 
level, FSANZ is actively involved in the development of a framework for the assessment of GM 
foods within the Codex Alimentarius Commission. 
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Although the NZIGE does not specify the human tests that they would accept, human studies are not 
considered an appropriate or necessary part of the safety assessment process for GM foods.” 
 
INBI: (1) We agree that FSANZ should benchmark with international food safety 
recommendations, but notes that FSANZ has accepted lower standards from submitted studies 
than recommended by these same bodies at several stages in assessing the safety of A549. (2) 
While we accept that FSANZ may choose not to require human testing, Codex Alimentarius 
does allow for more intensive pre-market testing for possible human-specific hazard 
identification beyond that provided by the Applicant. 
 
(1) For example, FSANZ has accepted a study on cDHDPS digestion that is outside of UN 
FAO/WTO protocols. It has ignored Codex Alimentarius recommendations for testing using 
cooked and processed LY038 corn, and their recommendations that all novel proteins be 
isolated (refer to Part Two, “Characterisation of the genetic modification” and the 12 new open 
reading frames around the insert). In each case, the Authority has, in our view, relaxed 
adherence to international standards for safety testing when that better suited the Applicant’s 
submitted work, and imposed international standards whenever that was a lower standard than 
we recommended. 
 
(2) According to CAC/GL 44-2003 (p. 19 paragraph 48) “[F]oods derived from recombinant-
DNA plants that have undergone modification to intentionally alter nutritional quality or 
functionality [emphasis ours] should be subjected to additional nutritional assessment to assess 
the consequences of the changes and whether the nutrient intakes are likely to be altered by the 
introduction of such foods into the food supply.” Since LY038 is this type of modification, 
higher standards of review are justified. 
 
FSANZ response to recommendation 14: Post market monitoring 
 
“GM food products are not permitted on the market if any question associated with negative health 
effects is left unanswered during the pre-market safety assessment. For this reason post-market 
monitoring is not considered necessary or useful as there is no potential adverse health outcome to 
monitor. 
 
Further, in Australia and New Zealand, as in most other countries, the responsibility for postmarket 
surveillance is covered by an ongoing duty of care on the part of the developer. The developer is 
expected to monitor for existing and emerging risks that may be associated with its product and 
notify regulatory authorities whenever new information is uncovered.” 
 
INBI: (1) The post-market monitoring of GM nutritionally enhanced foods is currently a 
subject of serious discussion in international food regulation, and FSANZ’s regulation of 
LY038 should reflect this. (2) The Applicant’s post-market monitoring plan has not been 
released for public comment. 
 
(1) Codex Alimentarius states in CAC/GL 44-2003 that post-market monitoring may be 
appropriate “in specific circumstances”. However, the necessity of post-market monitoring is 
not clear-cut internationally, especially for cases of nutritionally enhanced plants, such as 
LY038. 
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We highlight paragraph 31 of the Report of the Fifth Session of the Codex Ad Hoc 
Intergovernmental Task Force on Foods Derived from Biotechnology (ALINORM 06/29/34), 
which shows that post-market monitoring is a key consideration, particularly for nutritionally 
enhanced plants such as LY038: 
 
“The Delegation of the European Community, supported by some other delegations and observers, 
stated that considerations on post marketing monitoring systems should be an essential element of 
the work on this item because consumptions of nutritionally enhanced plants may cause significant 
changes in dietary intake patterns, in accordance with paragraph 20 of the Principle for the Risk 
Analysis of Foods Derived from Modern Biotechnology (CAC/GL 44-2003).” 
 
With regard to continuing discussion at the international level, we support more stringent 
oversight of post-market monitoring as the direction of Codex Alimentarius becomes clear. 
 
(2) Bearing in mind the Applicant’s responsibility to undertake post-market surveillance, we 
assume that FSANZ has requested details from the Applicant on its post-market surveillance 
plans, to ensure that they exist and are of a suitable standard. We ask that this information be 
released. If these details have not yet been submitted to FSANZ, we recommend that they are 
requested now and are evaluated before a recommendation is made to the Ministerial Council. 
 
Please see Part Two, “Reasons for post-market monitoring” for recommendations. 
 
FSANZ response to recommendation 15: Food/feed 
 
“FSANZ is evaluating the safety for human consumption of food from LY038 corn. FSANZ does 
not have jurisdiction in relation to animal feed.” 
 
INBI: Recommendation 15 stated that FSANZ “should clarify its proper jurisdiction with 
regard to this Application;  in particular, it should clarify whether and how it is equipped to 
analyse the impact of the availability or non-availability of LY038 animal feed.” 
 
The answer did not properly address the issue we raised. FSANZ is indeed only mandated to 
assess food safety, and is funded and resourced with this in mind. However, in its Impact 
Analysis it included a statement related to the availability of LY038 animal feed for industry. 
This statement does not concern an impact of LY038 as a food ingredient. It refers to the 
import of LY038 as a separate product, and for a separate purpose, than the one being evaluated 
by FSANZ.  
 
FSANZ’s objectives and guidelines require it to take into account “the promotion of fair trading 
in food” and “the desirability of an efficient and internationally competitive food industry” 
[emphases added]. Nothing in FSANZ’s objectives or guidelines asks it to consider 
implications for the animal feed industry. 
 
For this reason, we are concerned that FSANZ does not have the ability, as a food safety body, 
to investigate the impact of animal feed availability or non-availability. As animal feed is 
outside FSANZ’s mandate, we do not see how it can measure this impact. If the impact cannot 
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be measured, it cannot be considered to support either Option 1 or Option 2. 
 
FSANZ response to recommendation 16: Impact analysis 
 
“FSANZ has conducted a comprehensive safety assessment on LY038 corn (Attachment 2 to the 
Draft Assessment Report), as it does on every new GM food and has not allowed the intention of the 
Applicant to segregate LY038 from the food supply to influence the rigour of the assessment.” 
 
INBI: FSANZ also stated in the DAR that it “is assessing LY038 corn as if it were intended to 
be consumed by humans. The safety assessment conducted on LY038 is as rigorous and 
thorough as for any GM food product, and assumes that if approved, corn from line LY038 
could be routinely entering the food supply and not present just as an occasional inadvertent 
ingredient” (p. 13). 
 
If the intention to segregate were disregarded, why were there references made to inadvertent 
contamination, or the likelihood of only small amounts of LY038 entering the human food 
supply, in the Safety Assessment or the Impact Analysis? 
 
It is not clear why, if the intention to segregate were disregarded, FSANZ has continued to 
make reference to inadvertent contamination, or the likelihood of only small amounts of LY038 
entering the human food supply, in the DAR. For example: “it is possible that a small 
percentage of LY038 grain will inadvertently be co-mingled with conventional corn and enter 
the human food supply” (p.8); “little LY038 will be entering the food supply” (p.11); “the 
amount of LY038 corn entering the food supply is likely to be low so the cost to consumers 
wishing to avoid GM food by a potential restriction of choice of products, or increased prices 
for non-GM food is likely to be low” (p.16); “because LY038 corn is not intended for food, 
human consumption is expected to be extremely low” (p. 31). 
 
These references suggest that FSANZ has continued to evaluate LY038 in relation to the 
Applicant’s current, declared intention rather than in relation to the potential impact of the 
approval. The statement that LY038 is being assessed “as if it were intended to be consumed by 
humans” is not substantiated by the nature of the investigations FSANZ has undertaken. We 
repeat: an approval will allow the legal import of LY038 as food, in whatever form or quantity 
the Applicant or Industry decide is appropriate in the future.  
 
Please see Part Three, “Impact analysis” for discussion and recommendations. 
 
FSANZ response to recommendation 17: Impact analysis 
 
“A ‘split approval’ process with different standards for products destined for animal feed to those 
destined for the human food chain has led to problems internationally when products unapproved for 
human consumption inadvertently entered the food supply. To prevent this occurring, FSANZ and 
the Office of the Gene Technology Regulator (OGTR) have a Memorandum of Understanding 
(MoU) that no ‘split approvals’ will be made. As the OGTR is responsible for the assessment and 
regulation of GM feeds, the MoU sets out an agreement that where a GM food product such as corn 
has not undergone safety assessment by FSANZ, the OGTR would not approve its use as animal feed 
until such time that it is shown to be safe for human consumption, through assessment by FSANZ. 
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For this reason, FSANZ has agreed to assess the safety of this product for human consumption prior 
to it being used in animal feed. FSANZ has written the Regulatory Impact Statement to reflect this.” 
 
INBI: While we understand this regulatory arrangement, we seek further clarification on this 
issue because FSANZ has only mentioned the Australian regulatory system. FSANZ is a 
transnational regulatory body. The OGTR is an Australian body only, and nothing in this 
description pertains to the New Zealand regulatory system. 
 
FSANZ response to recommendation 18: Impact analysis 
 
“FSANZ has an obligation to assess this GM food application and determine whether it would be 
appropriate to amend the Code to approve the use of food derived from corn line LY038 under 
Standard 1.5.2. In developing or varying a food standard, FSANZ is required by its legislation to 
meet three primary objectives, which are set out in section 10 of the FSANZ Act. These objectives 
are also set out in Section 3 of the Draft Assessment Report on Application A549. Neither these 
three objectives nor the additional five points to which FSANZ must have regard specify that cost to 
government is a valid reason to reject an application. Furthermore, if FSANZ did not take this 
opportunity to assess high-lysine corn for its safety for human consumption and it were later detected 
in the food supply, the cost to government may be significant. 
 
FSANZ believes that the cost to consumers who wish to avoid GM products will not be significant 
even if this application were approved. Producers of high-lysine corn will aim to sell their product at 
a premium price as animal feed due to the high levels of lysine. It is less likely that food industry 
would pay premium price for high-lysine corn and therefore likely that the levels of high-lysine corn 
entering the food supply would be small. Further, food containing high-lysine corn is likely to be 
required to be labelled as GM and nutritionally different to conventional corn, allowing consumers to 
avoid this if they so chose.” 
 
INBI: (1) We question the Authority’s reasoning in stating that it need not consider cost to 
government in its assessment. (2) In determining consumer impacts, FSANZ makes 
assumptions about the marketing of LY038 that overlook some significant possibilities, both 
deliberate and inadvertent, for its entry into the food supply. 
 
(1) The Authority’s argument that nothing in its objectives or guidelines “specify that cost to 
government is a valid reason to reject an application” implies that it does not need to 
investigate this issue. 
 
However, this appears to be contradicted in the Authority’s own summary of its own regulatory 
impact assessment: “Following a cost and benefit analysis of the potential impact of each of the 
options on the affected parties (consumers, the food industry and government [emphasis ours]), 
Option 2 is the preferred option as it potentially offers benefits to all sectors with little 
associated cost” (p.7). It is also contradicted within the FSANZ response to recommendation 18 
itself, when it states: “if FSANZ did not take this opportunity to assess high-lysine corn for its 
safety for human consumption and it were later detected in the food supply, the cost to 
government may be significant” [emphasis ours]. FSANZ has a statutory requirement to 
consider the cost to government in its decision-making (FSANZ Act 13.2(c)), an impression 
strengthened by the fact that its Impact Analysis continues to refer to Government as an 
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Affected Party, and to government revenue and resource impacts as Impacts. Finally, it is not 
consistent with the Authority’s approach to other proposed changes to the food code; for 
example, in the DAR for P293 it explicitly notes that “impact on enforcement costs for 
government” was one of the factors considered when determining its preferred regulatory 
option.  
 
This Impact Statement referred to an impact on government monitoring resources for the 
implementation of labelling requirements. A quality regime of food safety and labelling relies 
on government funding and oversight. Without an assessment of the cost to government of 
monitoring and labelling, the oversight required to ensure “the provision of adequate 
information relating to food to enable consumers to make informed choices” (objective two), 
“the desirability of an efficient and internationally competitive food industry” (guideline three) 
and “the promotion of fair trading in food” (guideline four) cannot be guaranteed. 
 
As previously stated, the need for a careful appraisal of monitoring and labelling costs comes 
from the fact that they are immediate and certain, rather than speculative, impacts of the 
proposed amendment to the food code. The implications should therefore be carefully detailed, 
showing the extent to which the introduction of LY038 might impact already stressed resources 
with unique monitoring requirements to be applied to the full range of products that may be 
affected. The list is extensive, and it is reasonable to expect a significant impact on monitoring 
resources. Similarly, the costs of labelling will certainly impact upon the food industry.  
 
Monitoring costs, both to industry and to government, are more than just possibilities. In order 
for this issue to be carefully considered, it is reasonable to ask for supporting information from 
FSANZ. Without such information, it is difficult to see how the Impact Analysis can be 
properly assessed. 
 
(2) This statement rests on the Applicant’s declared current intention to import LY038 only as 
animal feed. However, the proposed amendment to the Code will approve LY038 for human 
consumption. We reaffirm our position that any decision that is premised on a mere intention, 
which will not be secured by the regulation itself, is not appropriate or acceptable regulatory 
practice.  
 
In Part Three, “Evaluation of the Impact Analysis, DAR, Option 2” we note several pathways 
through which it is reasonable to expect that LY038, if approved, will enter the food supply 
and, in doing so, will impose significant costs on consumers and food producers wishing to 
avoid LY038.  
 
FSANZ response to recommendation 19: Special restriction on LY038 hybrids 
 
“Food from a hybrid plant line does not warrant a separate pre-market safety assessment if food from 
the parental GM plant lines have already been approved. FSANZ considers the food safety risks 
posed by the conventional breeding of GM plants are no different from those arising from the 
conventional breeding of non-GM plants. It is widely recognised that unintended changes may occur 
during conventional breeding, however the products of conventional breeding have a long history of 
safe use and are not regulated by FSANZ.” 
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INBI: We have provided ample evidence in the case of LY038 to justify a restriction in Column 
2 of the Table to limit this approval. However, if the Authority prefers, it could consider 
imposing a restriction with an expiry clause with conditions of review. 
 
We will return to this topic in Part Two, “Reasons for special restrictions on any approval of 
LY038 in human food”. 
 
FSANZ response to recommendation 20: Cartagena Protocol 
 
“New Zealand has ratified the Cartagena Protocol on Biosafety, a multinational agreement to 
regulate the international trade of living modified organisms. The protocol is intended to help ensure 
that countries are themselves able to make decisions on import of living modified organisms to 
ensure their biodiversity is protected. Its main provisions relate to living modified organisms for 
intentional introduction into the environment (i.e. seeds for planting crops), although it has less 
extensive provisions relating to live modified organisms for food, feed and processing. If food 
derived from LY038 corn were to be approved by FSANZ, permission by other agencies in New 
Zealand (the Environmental Risk Management Authority) and Australia (the Office of the Gene 
Technology Regulator) would still be required before viable corn grain could be imported into either 
country. 
 
It is anticipated that if LY038 grain enters the food supply in Australia and New Zealand, it will be 
via processed imported food products.” 
 
INBI: We are satisfied with this response. 
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Part Two: Evaluation of the DAR 
This section is a direct evaluation of the scientific documents submitted by the Applicant in 
support of A549, and FSANZ interpretations of the data. Additional detail may be found in the 
February 2005 NZIGE submission. 
Characterisation of the genetic modification 
 
Our recommendations are based on the evaluation of the study MSL-19109: “Amended Report 
for MSL-17770 “Molecular Analyses of Lysine Maize LY038” written by Mittanck, D.W., 
Rice, J.F., Palmer, G.M. and Reiser, S.E. (Monsanto Company 2004); and MSL-19871 
“Molecular analysis of the LY038, LY038(-) Control and Inbred Maize Lines Contributing to 
the Genetic Background of LY038 and LY038(-)” written by Groat, JR, Wolff, BJ, Scanlon, 
NK and Masucci, JD (Monsanto Company 2005). 
 
In the studies examined for the IAR, we raised the issue that the Southern blots used to 
conclude that 
“These results demonstrated that Lysine maize LY038 does not contain the cre cassette nor any 
associated partial or intact genetic elements” (p. 20) and “Results from these Southern blot analyses 
described below support the conclusion that the nptII cassette and any associated partial or intact 
genetic elements are absent in Lysine maize LY038 as no hybridisation signals were observed” (p. 
19 Application, 24 October 2004) 
were flawed because the comparisons were to another GM plant, thus what the Applicant 
referred to as nonspecific hybridization could not be distinguished from weak binding between 
probes and target sequences that were partial or re-arranged in both corn lines. The Authority 
has asked the Applicant to justify why it did not use a non-GMO control, preferably a parental 
line, in its molecular analyses10. The Authority rightly required the Applicant to address this 
issue. The Applicant replied with study MSL-19871 (dated 14 October 2005). Here we review 
that study. 
 
Discrepancy in breeding histories 
 
The origin of LY038(-) in the breeding schemes provided by the Applicant (e.g. figure 4 of 
MSL-19871 and figure 23 of the original application) remains confusing. In response to USDA 
questioning, the Applicant said that “Seed from a single ear on a single F1 plant were used to 
plant the F2 generation. The seeds on the F3 ears harvested from the F2 generation plants were 
planted in a separate row for each of the F3 ears. In the resulting F3 generation of plants, LY038 
was selected from one of the aforementioned advanced ears, and the near isogenic control, 
LY038(-), was selected from another of the aforementioned advanced ears, based on its 
phenotypic similarity to LY038, and the absence of the LY038 trait based on event-specific 
PCR analysis” (p. 124)11. According to this, LY038 and LY038(-) were segregated at the F3 
                                                 
10 Letter to Monsanto from Dr. Peter Abbott, FSANZ; dated 17 March 2005. 
11 USDA/APHIS Environmental Assessment in response to Monsanto Petition 04-229-01P Seeking a 
Determination of Nonregulated Status for Lysine Maize line LY038. 
http://www.aphis.usda.gov/brs/aphisdocs2/04_22901p_com.pdf. Access date 30 May 2006. 
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generation shown in figure 4 of MSL-19871), 2 crosses after the Cre-recombinase line was 
crossed to the progenitor line. 
 
The Applicant replied to a similar question from the Authority12 with the text they claimed they 
had also provided to the US FDA, but which is significantly different from what they told the 
USDA. “LY038 and LY038(-) progenitor plants were identified by selecting plants positive 
and negative for the linked cordapA and nptII genes based on nptII assay of intact plants before 
crossing with Cre recombinase-expressing plants in the F1’ generation”13. The Authority 
should note that in this version of the breeding history, progenitors of LY038 and LY038(-) 
were already segregated before crossing to the Cre-recombinase line, about 3 generations 
earlier than reported to USDA (Figure 1). 
 
We do not see how both of these histories can be correct. The significance of this observation is 
that the two sibling lines (LY038 and the negative segregant) would have bred separately for 
more generations in the FSANZ rendition than in the USDA rendition of the history, further 
reducing the already highly unlikely probability that LY038 and LY038(-) are more closely 
related to one another than either is to H99. (See also section “Compositional analysis”, below, 
for additional discussion on this point.) 
 
Figure 1: Breeding histories of LY038 and LY038(-). 
 
We could find no explanation of the Applicant’s response to FSANZ about the choice of 
controls. We can only assume that the Authority has chosen to exercise a standard that is lower 
than it could under CAC. The uncertainty that arises from the breeding histories undermines the 
strength of the conclusions derived in the molecular and the compositional studies, because they 
                                                 
12 Email from Bronwyn Dixon (FSANZ) to Beth Bertuch (Monsanto), 11 March 2005. 
13 Email from Beth Bertuch (Monsanto) to Bronwyn Dixon (FSANZ), 11 March 2005. 
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rely on LY038(-) being the most closely related line. 
 
R.2 The Authority should report the true breeding history for both LY038 and LY038(-) 
that includes the precise point at which the two lines segregate. From this history, the 
Authority should evaluate whether there is certain evidence that LY038 is more 
closely related to LY038(-) than to H99. 
 
Sensitivity of Methods and Controls 
 
Both the molecular characterization data from the original application (NZIGE submission 
sections 4-4.3.10) and in the supplemental study MSL-19871 fail to provide a description of 
probe sensitivity and investigator-determined stringency of washes. Such information is 
essential for drawing conclusions about the presence of insertions that are not full length or of 
identical structure (with regard to the probe DNA sequence). Partial fragments of I-DNA or 
genomic DNA interspersed into I-DNA have been detected as fragments as small as 15 bp in 
the peer-reviewed international literature (Makarevitch et al., 2003, Svitashev et al., 2002) 
(NZIGE submission section 4.3.5-4.3.7). The Authority should note that the residual loxP 
sequence would be about 34 bp. 
 
Consistent with CAC/GL 44-2003, “[t]he data and information, based on sound science, 
obtained using appropriate methods and analysed using appropriate statistical techniques, 
should be of a quality and, as appropriate, of quantity that would withstand scientific peer 
review.” The Authority should hold the science of its assessment to this standard. 
 
Study MSL-19871 updates the previous studies by including the parental stocks from which 
LY038 was derived. Consistent with the Applicant’s claim, they can produce images of 
autoradiographs with identical patterns of “background” bands. There are two possible 
explanations for this. First, the background bands are actually limited to those composed of 
DNA sequences with fortuitous similarity to the probe (the Applicant’s and the Authority’s 
chosen explanation). Second, the Applicant has chosen a stringency of washes that removes 
probes bound weakly to small inserts composed of DNA corresponding to only part of the full 
length recombinant DNA used in transformation. This can be clarified by the Applicant 
revealing the sensitivity of their methods and positively identifying the sequence of all 
background bands detected at a sensitivity that would detect inserts significantly smaller than 
full length. 
 
In figure 6 of MSL-19871, probe 2 was used to identify the cordapA gene inserted into LY038, 
verify that it was absent in LY038(-), and confirm that miscellaneous bands that hybridize in 
both LY038 and LY038(-) are explained by the genomic background of the two varieties. We 
have some concerns about this data. The inconsistencies are not easily explained by normal 
variation in the procedure. For example, we can see a weakly hybridizing band in lane 4 at 
about the 6.1kb mark (Figure 2). This lane has Inbred A genomic DNA. The hybridization 
signal is much less intense than in any other lane with a DNA fragment of the same size. This 
alone is not troubling, but, when coupled with the result in lane 11, it is. In lane 11, two bands 
are visible, each producing a signal that is far more intense than the single band in lane 4. How 
is this possible? How did the Applicant find more than twice the amount (and perhaps more 
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like 4 times the amount) of hybridizing DNA just by using different restriction enzymes? 
 
Although not as clear cut, we have similar concerns about the pattern of hybridization 
intensities between lanes 8, with bands at about the 7.1kb and 0.7kb marks, and lane 15, with a 
band at about the 6kb mark. These lanes have Inbred B genomic DNA. The hybridization 
signal is much less intense than in any other lane, and the band is a different size than in the all 
other genomic samples. The hybridization signal of the apparent 6kb band in lane 15 is now as 
intense as any other band on the Southern. Moreover, it is a different size than in lane 8. All the 
other genomes produced two bands using this combination of enzymes, making Inbred B 
dissimilar in two ways from all the other genomes. The change in size may be expected since a 
combination of two different restriction enzymes was used, but the intensity should not change. 
Why did the Applicant not see equivalently intense hybridization in lane 8? 
Figure 2: Stylized cartoon of figure 6 from MSL-19871. 
 
Too many easy errors in set up (e.g. loading the lanes with the wrong sample, sourcing DNA 
from mixed seeds) could have caused the results shown. If the results are not explained by 
simple errors in set up, then it suggests that they are dramatically affected by choice of probes 
and wash stringencies. Coupled with the extensive flaws in the other Southern blots submitted 
in MSL-19871 (see below), these unexplained anomalies leave us with little confidence in the 
data. 
 
R.3 The Authority is requested to have the anomalous result in figure 6 of MSL-19871 
explained, or have the analysis re-done, before accepting this as evidence of either a 
single insertion in LY038 or the absence of insertions in LY038(-). 
 
In figures 5, 7 and 9 the Applicant claims that the observed diffuse hybridization near the top of 
the gel cannot be resolved as individual bands because of their high molecular weight. However, 
resolution of high molecular weight fragments can be achieved using pulse field electrophoresis, 
low concentrations of agarose, low running voltages and with the use of other restriction 
enzymes. Such techniques should be used to bring certainty to the interpretation of this Southern 
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because, as can be seen in, for example, figure 7, lane 3, at ~50kb there is evidence of another 
band that is unique to LY038. 
 
The quality of figure 8 is of particular concern. In lanes 1-3 (LY038(-) and LY038) we observed 
faint, diffuse hybridization at ~35kb that is not seen for any of the conventional five inbred 
lines. In the previous molecular characterization study (MSL-19109), the blot was hybridized 
with probes that spanned the entire sequence of the PV-ZM003 plasmid (Figure 14, MSL-
19109). No or only light background hybridization was observed. In this blot, a unique band was 
produced for LY038 DNA digested with Spe I (at ~3.8kb) and another unique band was 
produced with the digestion using Xho I and Xba I (at ~3.5kb). These results were explained as 
hybridization of the R-act1 promoter probe with the cordapA cassette containing the R-act1 
intron. None of these bands were visible in Figure 8, creating concern in the reproducibility of 
the experiment, the suitability of the long probes and of the stringency of the washes used by the 
Applicant.  
 
In both figures 8 and 9 the plasmid PV-ZM003 produced a single band that was larger than the 
expected plasmid fragment. This was explained by a possible difference in salt concentrations 
between the test substance DNA sample and the molecular weight marker. Although this 
explanation is plausible, it is challenged by the fact that none of these observations were made 
with plasmid PV-ZMPQ76 (Figure 5, 6 and 7) even though they were used with the same test 
substance, LY038(-). 
 
Ambiguity about the amplification products in lane 3 of figure 22 of the original application 
remains. Lane 3 is DNA amplified using a primer specific to the I-DNA rAct1 intron. Up to 5 
bands were generated from LY038(-). Under questioning from the USDA14, the Applicant 
explained that the “Polymerase chain reaction with LY038(-) control DNA produced faint 
products; however, none of these products was the expected 4.1 kb in size.” However, close 
inspection of the gel image reveals a band that does co-migrate with a band in the LY038 lane 
at approximately 4.1kb.  
 
The Authority should be wary of the use of PCR to confirm the absence of other inserts. The 
anchor primer is to chromosomal DNA, and thus there is no guarantee from this analysis that 
inserts in other regions of the genome will be amplified efficiently if at all. Thus, there is no 
reason to dismiss the obvious implication of the amplification using LY038(-) DNA based on an 
expectation of the size of the amplified DNA. If the insert (partial or whole) were not precisely 
in the same place in both genomes, then the amplified products would not be the same size. This 
analysis only shows that an identified insert has an organization in the plant genome that is 
roughly similar to the organization it had in the original plasmid. 
 
INBI recommendations: 
R.4 Consistent with CAC/GL 45-2003, “the sensitivity of all analytical methods should be 
documented.” Therefore, the Authority should report the minimum size of target DNA 
that all probes could detect at a minimum stringency of 0.5 copies per genome. 
                                                 
14 USDA/APHIS Environmental Assessment in response to Monsanto Petition 04-229-01P Seeking a 
Determination of Nonregulated Status for Lysine Maize line LY038. 
http://www.aphis.usda.gov/brs/aphisdocs2/04_22901p_com.pdf. Access date 30 May 2006. 
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R.5 We recommend that the Authority require a range of analytical methods that includes 
a combination of FISH, fiber-FISH and Southern analysis. 
R.6 The issue of background hybridization could be fully proved by sequencing the light 
bands visible in the Southern blots. The Authority should therefore base their final 
conclusion on the results of sequencing. 
R.7 The Authority should clarify whether additional insertions are present in LY038 by 
requiring additional studies on the high molecular weight fragments in MSL-19871. 
 
Antibiotic Resistance: Removal by Cre Lox recombinase  
 
Additional evidence is also required to verify the Applicant’s claim that “[t]he excised nptII 
gene cassette (circular extragenomic DNA), which did not contain an origin of replication, was 
subsequently lost, most likely through cell division” (Monsanto Australia Limited 2004, p. 7). 
It is not always true that the DNA between loxP sites is lost. In a similar strategy to A549, 
transgenes in wheat were removed by crosses with a Cre-recombinase donor (Srivastava and 
Ow, 2003). The excised and retained DNA was only detected using PCR, not Southern blotting. 
While these transgenes did not have recognized replication sequences, there is the possibility 
that excised circles replicated (Srivastava and Ow, 2003). Depending on the efficiency of 
replication, nptII DNA might persist at less than an average of 1 copy per genome across the 
cells of the transgenic plant. The authors only pressed their Southern analysis to approximately 
0.5 copies per genome rather than, say, 0.01 copies per genome (or one gene per 100 cells) 
(NZIGE submission 4.3.8).  
 
INBI recommendation: 
R.8 The Authority should explain how it has confidence that the experimental procedures 
used by the Applicant would have detected an insert the size of the loxP site in an 
unknown location at 0.5 copies per genome. 
 
Finally, the Authority should be aware that processing of loxP sites does not entirely reverse 
the effects of the original insertion nor leave the site with the same risk spectrum as before the 
insertion of loxP sequences. Processing leaves an intact loxP sequence in the chromosome. 
This sequence may make the chromosome vulnerable to double strand breaks should, by 
chance, LY038 produce hybrids with a cre containing line [or the cre recombinase gene or 
activity ever again transfer to LY038 (e.g. by horizontal gene transfer or hybridization)]. In a 
study of tobacco plants, single loxP sites on different chromosomes mediated recombination 
between the chromosomes precisely at loxP in the presence of the cre recombinase (Qin et al., 
1994). Thus, the Authority should be confident that all loxP sites in LY038 have been 
identified and eliminated. 
 
INBI recommendation: 
R.9 The Authority should verify that the residual loxP site in LY038 is not processed by 
the cre recombinase.  
 
Untranslated RNA 
 
See also “FSANZ response to recommendation 5”, above. 
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The potential to inadvertently create novel RNA regulatory molecules, often in the form of 
dsRNA, is too high by chance to ignore. They can be created by insertion of the transgene into 
a previously transcribed region (and not all transcripts emanate from ORFs), by aborted 
transcripts of the new transgene, read-through of terminator sequences, through fortuitous 
sequence similarity with an endogenous transcript, and by activation of a pseudogene. (For 
examples of such phenomena, see (Rang et al., 2005) and (Hirotsune et al., 2003)) (1.3). 
 
Since our last submission, the Applicant has now revealed that there are 12 new open reading 
frames around the insertion (DAR, p. 27). “The flanking corn genomic DNA was also 
sequenced. 1781 bp and 667 bp were sequenced at the 5’ and 3’ ends of the insert, respectively. 
Analysis of the sequence spanning the junction regions indicated that in the 6 reading frames at 
each junction…” As we previously argued, there is likely to be another open reading frame 
created by read-through of the nos terminator used by the Applicant (Rang et al., 2005), 
bringing the total to at least 13 known or likely new open reading frames. 
 
New evidence indicates that dietary sources of dsRNA that have the potential to silence human 
genes can in certain circumstances be transmitted through food. dsRNA constructs produced in 
E. coli can effect gene silencing (RNAi) in the gut cells of mice (Xiang et al., in press). Mice 
were fed E. coli expressing dsRNA directed against genes in the intestinal cells. In this study, 
the bacteria were nonpathogenic but engineered to invade human cells. Although this 
demonstration was not the same as feeding naked dsRNA, the Authority should also be aware 
that the dsRNA in LY038 would be protected by the plant cell or cellular debris, or the surface 
of bacteria, and therefore could very likely survive the stomach. 
 
According to CAC/GL 44-2003 (p. 14, paragraph 32), “Information should be provided on any 
expressed substances in the recombinant-DNA plant; this should include: the gene product(s) 
(e.g. a protein or an untranslated RNA); the gene product(s)’ function…”. Regardless of 
whether the variant RNAs arise from a cryptic splice site within nos, through other processing 
pathways, or from newly created open reading frames, all novel RNA species in LY038 must 
be reported and tested for a proper safety assessment. 
 
INBI recommendations: 
R.10 The Authority should provide evidence that all novel RNA species have been 
identified, characterized and tested for food safety. 
R.11 We recommend that the Authority require a complete microarray description of the 
LY038 transcriptome, compared to the unmodified control, for proper hazard 
identification.  
R.12 The Authority should require the Applicant to report on results of microarray analyses 
using the mouse genome and RNA extracts from the intestinal cells of mice fed 
LY038. 
 
The Applicant goes on to say that “As mentioned in Section 3.3, only one novel open reading 
frame starting with a methionine codon and of significant size (>100 amino acids) was 
identified. However, bioinformatics analysis of this and the other 11 putative open reading 
frames was performed using the ALLPEPTIDES, TOXIN5 and AD4 (the allergen database) 
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databases. Analysis was also done on the putative polypeptides encoded by reading frames two 
to six of the cDHDPS protein coding sequence of the insert. No biologically relevant structural 
similarities to allergens, toxins or pharmacologically active proteins were observed for any of 
the putative polypeptides” (DAR, p. 37). 
 
The Applicant has imposed criteria on its bioinformatic characterization that are not universal. 
For example, not all proteins begin with the AUG codon. Futhermore, FSANZ has the option, 
under Codex Alimentarius, to request biological data. According to CAC/GL 44-2003 (p. 14, 
paragraph 32), 
“Information should be provided on any expressed substances in the recombinant-DNA plant; this 
should include: the gene product(s)’ function…” and (p. 22 Section 2) “As there is no single test that 
can predict the likely human IgE response to oral exposure, the first step to characterize newly 
expressed proteins should be the comparison of the amino acid sequence and certain 
physicochemical characteristics of the newly expressed protein with those of established allergens in 
a weight of evidence approach. This will require the isolation of any newly expressed proteins from 
the recombinant-DNA plant, or the synthesis or production of the substance from an alternative 
source, in which case the material should be shown to be structurally, functionally and biochemically 
equivalent to that produced in the recombinant-DNA plant. Particular attention should be given to 
the choice of the expression host, since post-translational modifications allowed by different hosts 
(i.e.: eukaryotic vs. prokaryotic systems) may have an impact on the allergenic potential of the 
protein” (emphasis ours). 
The Applicant has produced no biological demonstration that the additional putative peptides 
are biologically irrelevant. This uncertainty could largely be addressed through the conduct of a 
proper animal feeding study using material from whole plants cooked and processed as in 
human food preparation. Moreover, there is now considerable evidence that small peptides 
(<100) can have many important biological roles but these proteins are systematically under-
reported in the literature (Kastenmayer et al., 2006). 
“Knowledge of sORF (small open reading frame; <100 amino acids) function is limited compared 
to that of larger genes, although small proteins include members of important classes such as 
mating pheromones, proteins involved in energy metabolism, proteolipids, chaperonins, stress 
proteins, transporters, transcriptional regulators, nucleases, ribosomal proteins, thioredoxins, and 
metal ion chelators (for review, see Basrai et al. 1997). Computational discovery of sORFs is 
difficult because they are “buried” in an enormous pile of meaningless short ORFs that arise by 
chance. In addition, sORFs are not favorable targets for random mutagenesis. Similar challenges 
plague attempts to identify non-coding RNAs (ncRNAs), transcripts that function at the level of 
RNA rather than as templates for translation (for review, see Eddy 2001). Despite the challenges of 
sORF identification, reports since the publication of the S. cerevisiae genome indicate that sORFs 
are quite numerous in S. cerevisiae and many are evolutionarily conserved from distantly related 
fungi to humans” (Kastenmayer et al., 2006). 
 
INBI recommendation: 
R.13 While the Applicant continues to rely upon unvalidated methods (e.g. bioinformatics 
as described above) for hazard identification, the Authority should make the insertion 
and flanking sequences publicly available for evaluation by those who may then bring 
more relevant analyses to bear. 
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Food Processing 
 
According to CAC (p. 18 paragraph 47) “[t]he potential effects of food processing, including 
home preparation, on foods derived from recombinant-DNA plants should also be considered. 
For example, alterations could occur in the heat stability of an endogenous toxicant or the 
bioavailability of an important nutrient after processing. Information should therefore be 
provided describing the processing conditions used in the production of a food ingredient from 
the plant.” These criteria apply to LY038 because it has an enhanced potential to create toxic, 
harmful and anti-nutrient products via the Maillard reaction. It would be valid in a case-by-case 
assessment to require food processing studies for LY038. (See also Part One, “FSANZ 
response to recommendation 3”, above). 
 
AGEs are linked to cancer, allergens and adverse health effects 
 
Maillard reactions are non-enzymatic browning reactions which occur between amino acids 
and carbohydrates (particularly reducing sugars). Amadori products are created in the first 
stage of the reaction through condensation between a free amino group, usually of lysine, and a 
carbonyl group of a reducing sugar (Gerrard, 2006, Henle, 2005). “Depending on time and 
temperature during heating or storage, up to 70% of lysine initially present in proteins may 
react to the Amadori product” (Henle, 2005). These reactions are, in fact, a series of parallel 
reactions that are “influenced by each other as well as by milieu parameters” (Henle, 2005). 
 
Amadori products may undergo several degradation reactions in foods leading to the formation 
of 1,2-dicarbonyls (Henle, 2005). These species are highly reactive with proteins and lead to 
formation of late Maillard products. Therefore, the compositional elements from corn relevant 
to the safety assessment of Maillard reaction products are proteins, free amino acids 
(particularly lysine) and carbohydrates (particularly reducing sugars). 
 
In biological systems, “glycation” products including carbonyl derivatives and advanced 
glycoxidation endproducts (AGEs) are produced by corresponding Maillard reactions 
(Akagawa et al., 2005, Gerrard, 2006, Henle, 2005). Dietary AGEs are thought to contribute 
“to the pathologic sequelae seen in normal aging, diabetes, and kidney disease” (Goldberg et 
al., 2004), including wound healing retardation (Peppa et al., 2003a) in diabetics, and 
neurodegenerative diseases such as Alzheimer’s (Elliott, in press). Recently, a link between 
lysine AGEs and cancer was made (Heijst et al., 2005). Higher levels of AGEs are detected in 
Creuzfeldt-Jacob Disease (CJD) patients, but it is unknown whether they are a symptom, side-
effect or contributor to the disease (Freixes et al.). Glycation can alter the longevity of peptides 
in the intestine; this stabilization of proteins has implicated glycoxidation with diabetes related 
autoimmunity (Elliott, in press). There is also evidence that some AGEs may be beneficial 
(references in Henle, 2005). 
 
Glycation products have a low resorption rate (Henle, 2005), thus glycation of lysine and 
protein reduces the nutritional value of the food while increasing the stability of the protein 
and, concomitantly, the potential for glycation products to become allergens. The very latest 
research indicates that some allergens are attenuated or removed by heat or during processing, 
but other allergens become more potent as a result of heating and in the presence of 
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carbohydrates (Gruber et al., 2005). These can only be identified using food prepared in a 
fashion representative of how people will consume it. 
 
“In contrast to these so-called pollen-related allergens, roasting has been reported to increase the 
allergenicity of raw peanuts (10). For example, protein extracts of thermally treated peanuts have 
been shown to bind IgE antibodies from patients’ sera at up to 90-fold higher levels than extracts 
obtained from the corresponding nontreated peanuts (10). In addition, inhibitory ELISA experiments 
revealed a significant increase in the IgE binding activity of the purified major allergens Ara h 1 and 
Ara h 2 after thermal treatment in the presence of carbohydrates (Gruber et al., 2005)”. 
 
In this example, even the minor allergen Ara H 1/2 (peanut agglutinin) was converted into an 
IgE-binding product after incubation with sugar at elevated temperatures (Gruber et al., 2005). 
These results clearly indicate that the allergenicity of cDHDPS and other proteins in LY038 or 
its derivatives cannot be identified by past experience feeding animals uncooked and 
unprocessed sources of corn. 
 
There is overwhelming scientific reason (presented in the following paragraphs) to believe that 
LY038 composition is likely to yield Maillard reaction products, including anti-nutrients and 
AGEs, and that it will produce these compounds in higher quantities than conventional corn 
and many other foods with comparable total lysine. 
 
LY038 is substantially different in composition to conventional corn with respect to the 
potential to form food hazards.  
 
For food, milieu parameters effecting Maillard reactions will include the availability and 
concentration of reactants (both free amino acids and those in proteins, and reducing sugars 
present in carbohydrates) and exposure to elevated temperatures. These are the milieu elements 
relevant to the product being considered—LY038 and its derivatives—that have been modified 
to produce high endogenous levels of lysine, because one reactant (lysine) is at unprecedented 
concentrations in the milieu of reducing sugars characteristic of the corn grain. 
 
Our analysis of the Table provided on p. 65 of the DAR revealed four important points.  
1. The “control corn grain” for which a lysine level is reported (320 mg/100g) is not a 
valid control. CAC/GL 44-2003 (p. 2 paragraph 4) does not allow another GM crop to 
serve as a control, because neither crop has a history of safe use. 
2. LY038 corn has the potential to significantly alter AGE intake in the Australia/New 
Zealand diet. High lysine corn would provide amounts of free lysine comparable to 
animal sources of free lysine (in absolute amounts; Table 1 column 5). LY038 would 
thus eliminate corn as a source of calories and nutrients that would be expected to be 
low in AGE content and endanger recommendations to encourage consumers to eat 
more vegetables instead of meat. 
3. Generally speaking, it is not informative to compare absolute lysine levels when 
reviewing the potential effects of AGEs because those conventional foods with high-
lysine levels are extremely low in carbohydrates (Figure 3). Moreover, foods high in 
lysine content are usually extremely low in free lysine (Table 1). 
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4. The ratio of free lysine to total lysine is profoundly different between LY038 and all 
other foods we could find comparisons to (Table 1, column 4). The ratio is 31, 47, 19, 
28 and 70 times larger in LY038 than in LY038(-), sweet corn, lentils and various 
species of fish, respectively. 
 
Figure 3: Lysine and carbohydrate relationships in common foods and LY038 
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Table 1: Comparisons of free lysine in common foods and LY038 
Annual Free 
Lysine (g) 
Consumption15 Food 
Free 
Lysine 
(mg/100g) 
Total 
Lysine 
(mg/100g) 
Free/Total 
Lysine (%) Australia/New 
Zealand 
Free 
Lysine 
Reference 
Corn, 
LY038 
135 480 28 7.2/3.3  
LY038(-) 3 320 0.9 0.2/0.075  
Lentils 
(raw) 
cotyledon 
seedling 
 
13* 
30* 
1957  
0.6 
1.5 
 (Rozan et 
al., 2000) 
Fish16 
Mahi-mahi 
flounder  
bigeye tuna 
 
53 
17 
8 
 
N/A 
1731 
2147 
 
N/D 
1 
0.4 
 
11.7/14 
3.8/4.5 
1.8/2.1 
(Antoine 
et al., 
1999) 
*fresh weight 
 
LY038 cannot be compared to other varieties of corn or other foods because other varieties of 
corn and other foods have much lower levels of free lysine (Table 1). Vegetables normally are 
low in free amino acids, especially lysine (Mennella et al., 2006). There is approximately 52 
times the amount of free lysine in LY038 in comparison to the Applicant’s control17. The ratio 
of free lysine to total lysine is also significantly different in LY038 and the Applicant’s control; 
28% of lysine in LY038 is free lysine, vs. only 0.9% in LY038(-) (Table 1). Maillard reaction 
products and reaction rates can differ between free lysine and lysine in protein because the 
context of lysine in the peptide influences reactivity (Mennella et al., 2006). 
 
LY038 cannot be compared to non-corn foods because non-corn foods with higher lysine levels 
have much lower levels of carbohydrates. Conventional corn will likely have different 
concentrations and types of carbohydrates available to react with lysine than do red meat, eggs, 
cheese or fish, or any of the products in the table18 provided by FSANZ (Table 219). 
 
LY038 must be found to be as safe as conventional corn, not other conventional foods. The 
goal of the assessment is to determine whether people could source 100% of their normal 
intake of corn as LY038. The goal is not to compare the health trade-offs of eating LY038 corn 
and roast lamb. Because the Maillard reaction products we discuss are milieu-specific, the table 
                                                 
15 Based on annual per capita corn consumption of 2.5kg in New Zealand and 5.3kg in Australia. Source 
FAOSTAT 2006. 
16 Based on annual per capita fish consumption of 26.3kg in New Zealand and 22.1kg in Australia. Source 
FAOSTAT 2006. 
17 Comparison from Table 14 of MSL 19172. 
18 DAR p. 65 
19 Unless specified otherwise, source is USDA Nutrient Data Laboratory 
http://www.ars.usda.gov/main/site_main.htm?modecode=12354500. Access date 29 April 2006 
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of lysine content for different kinds of foods is immaterial to this risk assessment. 
 
Table 2: Carbohydrate and lysine content by food 
Food20 Lysine content 
(mg/100g) 
Carbohydrate 
content 
(mg/100g) 
Corn, LY038 48021 8180022 
Oats 701 66270 
Corn, sweet 137 19020 
Broccoli (raw) 135 6640 
Lentils (raw) 1957 6080 
Cheese (edam) 2660 1430 
Egg (raw, fresh) 914 770 
Chicken (Chicken, broilers or fryers, back, meat 
only, raw) 
1661 0 
Fish (Pacific cod, raw) 
Fish, flatfish (flounder and sole species), raw 
Fish, tuna, fresh, yellowfin, raw 
1644 
1731 
2147 
0 
0 
0 
Red meet (Beef, chuck, blade roast, separable 
lean and fat, trimmed to 1/2" fat, prime, raw) 
1359 0 
 
LY038 hazards will be seen only after cooking. 
 
It is justified on scientific grounds to expect the production of undesirable AGEs or anti-
nutrients in LY038 above and beyond that found in conventional corn after heating, processing 
or cooking. AGE content in food increases with cooking time and temperature (Elliott, in press, 
Goldberg et al., 2004, Henle, 2005). “The amount of AGEs present in all food categories 
[including vegetables] was related to cooking temperature, length of cooking time, and 
presence of moisture” (Goldberg et al., 2004). 
 
The use of infant formula has been associated with a rise in childhood autoimmune diseases. 
Infant formula (e.g. Enfamil) already contains corn (7.1.9) and corn-derived products and are 
already known to be 100-fold higher in AGE content than human or bovine milk (Goldberg et 
al., 2004). There can be no justification for increasing higher concentrations of glycation 
reactants in infant formula, as an amendment to the Food Code would allow. 
 
In our previous submission, we highlighted the relationship between free asparagine, sugar and 
heat in producing acrylamide by the Maillard reaction in cooked food. This relationship is 
increasingly well documented and attracting significant concern.23 In a seminal study of french 
fries made from 66 potato varieties that differed in sugar and free amino acid content, Becalski 
                                                 
20 Unless specified otherwise, source is USDA Nutrient Data Laboratory 
http://www.ars.usda.gov/main/site_main.htm?modecode=12354500. Access date 29 April 2006 
21 Source Table 11 of Appendix IV Monsanto Application, October 2004 
22 Source Table 14 of MSL 19172 
23 http://www.sciencenews.org/articles/20021214/food.asp. Access date 3 May 2006. 
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et al. (2004) found (Figure 4, redrawn from original) that “the formation of acrylamide is 
favored by an excess of sugars” in potatoes (Becalski et al., 2004). They conclude for this 
Maillard reaction that “our study shows the importance of controlling the precursors of 
acrylamide” for controlling the accumulation of acrylamide in food. There is no reason at 
present to suspect that lysine and sugar reactants that produce other potentially harmful AGEs 
would differ from these findings with acrylamide. 
 
According to Science magazine23, “[N]one of these data even start to indicate whether the 
concentrations of acrylamide now present in the human diet pose a risk to health at the amounts 
currently being consumed. Such an assessment will probably require rodent-feeding trials with 
a range of intakes representative of different population groups” [emphasis ours]. Why is the 
Authority content with an application that does not attempt to measure well documented 
potential harms using an appropriate animal feeding study? Asking for such data would be 
consistent with international food safety standards as set out by the CAC. 
 
Historical evidence of anti-nutrients 
 
There is historical evidence that lysine formed anti-nutrients by the Maillard reaction in corn 
(Panigrahi et al., 1996), which means that lysine in corn cannot be generally regarded as safe 
(GRAS) in this particular case. Broiler chicks fed corn with varying levels of stackburn were 
found to receive up to 14% less nutritive value than chicks fed control corn. Stackburn is the 
result of Maillard reactions occurring during corn storage. It occurs at temperatures much 
milder than those that may be used during processing and cooking for human foods. 
 
Figure 4: Acrylamide formation in cooked potatoes 
 
Lysine is the major reactant in the formation of Amadori products in stackburn corn, with up to 
half of the lysine converted (Panigrahi et al., 1996). Under these mild heating conditions with 
conventional corn—of inherently low lysine content—there was no evidence of short term 
toxicity from the Maillard products. There was, however, demonstration of a significant anti-
nutrition effect and a corresponding decline in metabolizable energy with increases in 
browning. 
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LYO38 has the potential to augment the AGE content of processed food and elevate the risk of 
AGE-related adverse effects 
 
LY038 has elevated levels of pipecolic acid and total lysine, and unprecedented levels of free 
lysine, saccharopine and α-aminoadipic acid (Table 3). All of these compounds and cadaverine 
can react with reducing sugars to form Maillard reaction products (AGEs) (e.g. Akagawa et al., 
2005). In addition, α-aminoadipic acid has a neurotoxic activity (Rozan et al., 2001), pipecolic 
acid may incite chronic hepatic encephalopathy, and cadaverine augments histamine toxicity. 
There is overwhelming reason to suspect that LY038 will produce an entirely unique spectrum 
of food hazards when cooked or processed. These hazards will be completely beyond what can 
be predicted from raw LY038 corn or raw or cooked conventional corn. 
 
While vegetable sources probably contribute the least amount of AGE content in the diet, 
LY038 and its derivatives have the potential to boost exposure from all foods that have a corn 
component, including many processed foods which are heated to high temperatures. 
“Processing of some ready-to-eat cereals, which includes heating at temperatures over 230°C, 
may explain the high AGE content of these products. Also, many cereals and snack-type foods 
undergo an extrusion process under high pressure to produce pellets of various shapes and 
densities. This treatment causes major chemical changes, thermal degradation, dehydration, 
depolarization, and recombination of fragments all of which can promote glycoxidation” 
(Goldberg et al., 2004). 
 
Table 3: Maillard reactants and factor increase in LY038 
Reactant LY038 (μg/g) Control (μg/g) Factor increase 
α-aminoadipic acid 56.59 <5 ≥10 
saccharopine 650.29 5.88 110 
free lysine 1351.13 25.99 52 
cadaverine <5 <5 unknown 
L-pipecolic acid 28.72 14.96 1.9 
 
We cannot see how it is in the interests of the people of New Zealand or Australia to augment 
the AGE content potential of processed foods or infant formula. There is no scientific 
justification for not testing the effects of this transgenic material under conditions that 
approximate the forms in which LY038 products will most often be consumed by people. 
 
INBI recommendations: 
R.14 The Authority should report not just total lysine content of foods, but free lysine 
content of foods and provide comparisons with conventional corn, especially H99. The 
Authority should also consider the ratio of carbohydrate to free lysine. 
R.15 The Authority should provide the people of Australia and New Zealand with reliable 
data demonstrating that processing and cooking temperatures normal to products that 
could contain this corn are as safe as products derived from conventional corn, 
particularly the parental varieties of LY038. 
R.16 The Authority should request an analysis of all novel AGE content or AGE 
concentrations, including Maillard reaction products and glycotoxins, that could arise 
from cooking, storage or processing of LY038 corn compared to parental varieties. 
51 
R.17 The Authority should justify its conclusion that lysine levels in a genetically modified 
variety of corn can be considered safe by comparison to lysine levels in unrelated food 
sources, such as red meat, chicken, eggs, cheese, broccoli, lentils and fish. 
R.18 The Authority should require that the Applicant supplement application A549 with a 
complete set of long-term, chronic, sub-chronic and acute toxicity feeding studies and 
allergenicity studies using cooked products derived from LY038, and compared to the 
parental varieties. 
R.19 The Applicant should conduct dietary AGE mouse feeding studies equivalent to those 
reported by Peppa et al. (Peppa et al., 2003b). 
R.20 The Authority should justify its claim with reference to recommendations of 
international food safety agencies that for LY038, with its significantly different 
nutritional profile, additional feeding studies are not required. 
 
Compositional Analysis/Comparative Analysis 
 
Our recommendations are based on the evaluation of the study MSL-19172 : “Compositional 
Analyses of Forage and Grain collected from Lysine Maize LY038 grown in the US Field 
Trials in 2002” written by Reynolds, T.L., Nemeth, M.A., Fuhrman, J.D., Trujillo, W.A. and 
Sorbet, R . (Monsanto company 2004). 
 
Choice of control maize and statistical relevance of results 
 
The Applicant must make comparisons to proper controls, what CAC calls ‘conventional 
counterparts’; “a related organism/variety, its components and/or products for which there is 
experience of establishing safety based on common use as food” (CAC/GL 45-2003, p. 1 
paragraph 8). “It is recognized that for the foreseeable future, foods derived from modern 
biotechnology will not be used as conventional counterparts” (CAC/GL 45-2003 p. 1 footnote 
5). Additionally, the OECD recommends that “measurement data from the new variety should 
ideally be compared to those obtained from the near isogenic non-GMO line grown under 
identical conditions” (ENV/JM/MONO(2002)25 p.18) 24. In FSANZ’s instructions to Applicants 
(Format25) (p. 6), the Authority advises that “normally, [the comparator] would be the near 
isogenic line or strain that was transformed to produce the GM line or strain (i.e the parental 
line). Where this is not possible, the comparator should be as close as possible to the GM line or 
strain.” 
 
In this case, the most suitable control was both the parent and “the near isogenic line or strain 
that was transformed to produce the GM line”, H99, because it was not a product of gene 
technology and it is more closely related to LY038 than is LY038(-). LY038 shares more than 
                                                 
24  When referring to ENV/JM/MONO(2002)25, we make specific reference to the Consensus Document on 
Compositional Considerations for New Varieties of Maize (Zea Mays): Key Food and Feed Nutrients, Anti-
Nutrients and Secondary Plant Metabolites from OECD found at 
http://www.oecd.org/document/9/0,2340,en_2649_34385_1812041_1_1_1_1,00.html Access date 2 May 2006. 
25 http://www.foodstandards.gov.au/_srcfiles/Application%20Format%20-%20GM%20June%2005.doc. Access 29 
May 2006. 
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65% of its genome with H99. LY038 and LY038(-) are siblings. Mendel’s law of independent 
assortment means that LY038 and LY038(-) are as likely to be 100% related as they are to be 
0% related. On average, siblings have 50% identity. What we can say with near certainty is that 
LY038(-) does not have at least one chromosome that LY038 has, the one with the cordapA 
insert. Depending on whether LY038 is homozygous or heterozygous, LY038(-) and LY038 
must differ by at least ~10% or 5%, respectively. 
 
There is nothing in the breeding histories to tell us that LY038 and LY038(-) were screened 
beyond the characterization that LY038(-) does not have the cordapA gene, so we cannot say 
how many chromosomes from H99, Inbred A, B, or C, that each sibling has from these parents 
they also hold in common. They may have more, depending on how many of the same 
chromosomes from the parentals each holds in common, and may in fact have no chromosomes 
in common. In the absence of data, the Authority can only assume that, on average, siblings will 
be 50% identical.  
 
That makes H99 the closest related corn. Moreover, it is also a non-GM parental, making it 
without question the suitable comparator line for the molecular characterization and the 
compositional analysis. Inbred D, which is not in the parentage of LY038 (Figure 2), is the 
closest relative of LY038(-). 
 
Instead, in the Authority’s own words, “[t]he Applicant has provided information comparing 
LY038 corn to a closely related control corn crop, LY038(-), both grown in the same location” 
(DAR p. 11). Why has the Authority accepted LY038(-) as a comparator in the molecular and 
compositional studies? The Authority’s recommendation appears to be based on data derived 
from a control strain that is outside Codex Alimentarius recommendations and FSANZ policy. 
 
Both parentage and environment contribute to the variance in phenotypes measured for the 
compositional analyses (Reynolds et al., 2005). In the Applicant’s words: “The large number of 
statistically significant differences in the levels of these analytes between seven commercial 
hybrids emphasizes the importance of genetic background and environment as determinants of 
the biochemical composition of maize grain” (Monsanto study published under Reynolds et al., 
2005). Geneticists have been aware of the influence of genotype on phenotype for about a 
century (Heinemann and Roughan, 2000), and thus put great weight on using isogenic series of 
organisms when trying to determine the effects of single genes or mutations. The isogenic 
series would normally be composed of the parental genotype and the recombinant derivatives. 
 
The Applicant has not used a non-GMO isogenic series to draw conclusions about the 
composition of LY038 and conventional corn. By not making measurements between the 
parental varieties of LY038 and LY038 in a series of five environments, the Applicant may 
inflate the variation and mask potential hazards. The Applicant has possession of the non-GMO 
parental lines (H99, Inbred A, B, C and possibly D). For these reasons, the Authority should 
expect the Applicant to provide the comparator data in the format specified by the Authority.  
 
The Applicant has also made one-off measurements (with internal replicates) of four different 
non-GMO varieties per site and compared the range of those measurements to LY038. 
Variability among measurements of constituents in the non-GMO varieties is proportional to 
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the diversity of their genotypes within each test site. The only comparison thus provided to the 
Authority was between LY038 and LY038(-) at a site and the average and variance of 18 
distantly related varieties grown at 5 different sites. 
 
From the data provided, it would also appear that the compositional measurements at each site 
were made within a single year. This is also outside the standards set by FSANZ in their advice 
to Applicants. The Authority advises that “trials should be over a sufficient number of years to 
allow adequate exposure to conditions met in nature” (Format p. 6). 
 
The Applicant changed both the environment and the composition of genotypes by planting four 
different non-GMO “reference” varieties at each of the different sites. The combined data then 
produces an overwhelming variance range because it is a composite of a few replications of 
each genotype, each genotype grown in only one environment, and five different environments. 
It is improbable, if not impossible, with this type of experimental design to recognize and 
eliminate outliers or produce useful baseline data for hazard identification. 
 
This is also contrary to the format specified by the Authority (Format, p. 6) where it says that  
“[t]he pooling of data from different sites is acceptable provided data from the separate sites is 
also submitted and separately evaluated”, which it was not in A549. In the statistical analysis, 
the range of observed values for the reference substances was always a combined value across 
all sites. There was no reference range reported by site. 
 
Natural variability is not a baseline for analysis, despite what the Applicant repeatedly claims 
(e.g. Reynolds et al., 2005). Hazard identification is the baseline for analysis. Thus, minimizing 
non-specific variability should be the goal of a risk assessment. This is most reasonably done 
using the proper non-GMO parental lines as controls. 
 
The Authority has asked the Applicant to justify why it did not use a non-GMO control in its 
compositional analyses, and why it did not use the parental varieties as controls in its 
compositional analyses26. We could find no explanation of the Applicant’s response to FSANZ. 
We can only assume that the Authority has chosen to exercise a standard that is lower than it 
could under CAC. No cogent rationale has been offered to the people of New Zealand and 
Australia by the Applicant or the Authority as to why the Authority should accept a lower 
standard than it could under international guidelines. 
 
INBI recommendations: 
R.21 The Authority should explain why it has accepted comparisons between LY038 and 
another product of gene technology with no history of safe use, LY038(-), rather than 
the CAC recommended standard of a comparison to conventional parental varieties. 
R.22 The Authority should explain why LY038(-) was used as a control instead of the more 
closely related conventional variety, and parent, H99. 
R.23 If the Authority accepts LY038(-) as a control, then it should explain how it verified 
the absence of small inserts in LY038(-) with experiments that would detect the 34 bp 
loxP sequence at 0.5 copies per genome. 
                                                 
26 Letter to Monsanto from Dr. Peter Abbott, FSANZ; dated 17 March 2005. 
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R.24 The Authority should provide a statistical analysis of the reference ranges per site. 
R.25 The Authority should base its recommendation to amend the Food Code based on a 
proper comparison between LY038 and its parental varieties H99, Inbred A, B, and C 
grown under identical conditions in at least five test sites repeated in at least two 
growing seasons. 
 
Choice of conventional counterparts and references 
 
Since the Applicant has provided compositional studies with flawed controls, notably the 
improper substitution of a GM corn variety [LY038(-)] for a conventional counterpart, we 
recommend that the Authority consider substituting formal OECD historical ranges for 
proximates (ENV/JM/MONO(2002)25 p.20), reproduced in Table 4. 
 
Our analysis of Table 4 revealed two important points.  
1. The value of protein content, TDF, ADF and NDF for LY038 is outside the OECD 
range. “If the characteristic level for a specific component, which is altered in a 
specialty type of maize, is outside the general range of values found in scientific 
literature, the comparison with the parent line will be decisive” 
(ENV/JM/MONO(2002)25 p.19). Therefore the Authority must ask the Applicant to 
provide data using the parental lines H99, Inbred A, B, and C. 
2. Some of the reference maize range values are significantly outside the OECD range. 
This observation again leads us to question how the Applicant came to choose specific 
lines for this study, and whether or not those reasons were consistent with a design to 
optimize the analysis of LY038 as a human food. 
 
Table 4: OECD Proximate Analysis 
 LY038 value Range from OECD 
Table 2 
Range of reference 
maize Table 5 from 
DAR 
Ash 1.44 ±0.033 1.1-3.9 1.05-1.75 
Carbohydrates 81.8 ±0.62 82.2-82.9 80.26-87.96 
Moisture  8.91 ±0.40 7-23 7.68-11.1 
Protein 12.90 ±0.56 6-12.7 7.61-14.69 
Total fat 3.86 ±0.20 3.1-5.8 2.03-4.53 
TDF 20.77 ±2.48 11.1 12.58-35.31 
ADF 6.57 ±0.42 3.0-4.3 4.29-9.56 
NDF 12.56 ±1.08 8.3-11.9 9.93-20.57 
Bold values are outside the OECD ranges. 
 
Application A549 is for use of high lysine corn in human food. As such, the conventional 
counterparts used as control should be varieties of maize with a history of safe use commonly 
used in the same way in human food. “The data for the non-modified comparator can be the 
natural ranges published in the literature for commercial varieties or those measured levels in 
parental or other edible varieties of the species” (ENV/JM/MONO(2002)25 p.11). 
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Two reference lines used by the Applicant are considered by the Canadian authorities to be 
novel food, and were approved for use only 8 years ago27. These varieties are Garst 8464 IT 
and Garst 8590 IT, in the Clearfield production system28. They are tolerant to imidazoline-
based herbicides.  
 
Five varieties were designated as “high extractable starch corn” (Syngenta N60-N229, Golden 
Harvest H255230, DKC 60-1531, N45-T532 and N72-J533). High starch corn is defined as being 
“lower in fiber than regular corn”34 and as a corn with normal levels of oil, usually lower 
protein and with extractable starch yields in the range of 67–72%35. High starch corn variety 
has been grown in the field only since 200136. N45-T5 and N72-J5 are Syngenta seed products 
branded NK® Brand Extra Edge™ that have been available only since the 2005 growing 
season37. What “experience of establishing safety” has the Authority to justify these reference 
varieties of corn “based on common use as food” (CAC/GL 44-2003, p. 2 paragraph 8)? 
 
INBI recommendations: 
R.26 If the Authority is satisfied with the existing compositional data, we then ask it to 
indicate how it determined the values provided by the Applicant were as scientifically 
sound as those used in international guidelines. 
R.27 The Authority should evaluate the use of other novel foods as comparators in safety 
assessments and determine how long a novel food must be used safely before it is 
considered having a “history of safe use.” 
 
Key nutrient and key toxicants comparison 
 
The Applicant has not evaluated all the components that are relevant to the use of LY038 as a 
human food. “If only agronomical traits are influenced by the genetic modification, derived 
products need not be analysed separately. In other cases, the additional analysis of derived 
products can be useful, depending on the nature and purpose of the modification (e.g. 
deliberately changing the oil composition). This can apply to the following products: maize oil, 
starch, grits, meal, and flour” (ENV/JM/MONO(2002)25 p.31). The proximate analysis in 
                                                 
27 http://www.hc-sc.gc.ca/fn-an/gmf-agm/appro/index_e.html  .Access date 2 May 2006 
28 http://www.garstseedco.com/GarstClient/PDF/Silage/8464IT.pdf and  
http://www.garstseedco.com/GarstClient/PDF/Silage/8590IT.pdf  .Access date 2 May 2006 
29 http://web.aces.uiuc.edu/value/on-farm/2002%20On-Farm%20VE%20Research %20Report.pdf. Access date 2 
May 2006 
30 http://web.aces.uiuc.edu/value/on-farm/2002%20On-Farm%20VE%20Research %20Report.pdf . Access date 2 
May 2006 
31http://www.monsanto.com/monsanto/us_ag/content/enhanced_value/pro_per/pro_per_corn/products.pdf Access 
date 2 May 2006 
32 http://www.nk-us.com/infosilo/seedguide/seedguide3.asp?slctdEdition=05&slctdState=IA&slctdStateName 
=Iowa&slctdCounty=19011&slctdCountyName=Benton&slctdCropType=2&slctdVariety=N45-T5 . Access Date 2 
May 2006 
33http://www.nk-us.com/infosilo/seedguide/seedguide3.asp?slctdEdition=05&slctdState=IA&slctdStateName 
=Iowa&slctdCounty=19013&slctdCountyName=Black%20Hawk&slctdCropType=2&slctdVariety=N72-J5. 
Access date 2 May 2006  
34 http://www.vegrains.org/english/varieties_highstarch.htm. Access date 2 May 2006 
35 http://www.vegrains.org/documents /2002veg_report/highstarch/hsmktdev. html  Access date 2 May 2006 
36 http://www.oardc.ohio-state.edu/hocorn/ip%20faq.htm . Access date 2 May 2006 
37 http://www.plantmanagementnetwork.org/pub/cm/news/2004/extraedge/ .Access date 2 May 2006 
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maize starch, grits and flour should be provided by the Applicant to prove the equivalence of 
those derived products for food use. 
 
INBI recommendation: 
R.28 The Authority should require the proximate analysis of maize starch, grits and flour 
derived from LY038. 
 
Saccharopine and α-aminoadipic acid  
LY038 has higher levels of the lysine catabolites saccharopine, α-aminoadipic acid and 
cadaverine. Saccharopine and α-aminoadipic acid levels in particular significantly change the 
hazard profile of LY038 in cooked and processed foods (as discussed in section 6.1.9 of 
NZIGE submission 2005). There is 100 times more saccharopine by weight in LY038 than in 
LY038(-) and at least 50 times more than in the reference controls. The increase in α-
aminoadipic acid could not be calculated because it was at levels too low in controls to detect, 
but averaged 56.69μg/g (39.65 – 82.34 μg/g) in LY038 (DAR, p. 47). So α-aminoadipic acid is 
at least 10 times higher in LY038 than in conventional corn, based on the Applicant’s reported 
limit of detection (5 ppm or 5 μg/g). While differences in the production of these catabolites 
may have been anticipated, they are not intended and must be the subject of further studies. 
 
The Authority has argued that “[t]hese analyses…demonstrate a history of exposure to these 
lysine catabolites from the consumption of commonly available foods.” However, these other 
foods do not have the same concentration of other metabolites as corn, are not eaten or 
prepared in precisely the same ways as corn, or eaten in the same quantities. For example, 
based on United States per capita maize consumption (0.52 g/kg BW/day), the mean 
consumption of saccharopine is estimated to be 290µg/kgBW/day. This is more than 15-times 
the mean consumption of saccharopine in food containing high levels of saccharopine (e.g. 
button mushroom at 19µg/kgBW/day). Again, LY038 must be able to substitute for cooked and 
processed conventional corn and not for button mushrooms, in the human diet. 
 
Saccharopine and α-aminoadipic acid, analogues of standard amino acids, are also probably 
substrates for Maillard reactions in cooked or processed material. The potential for AGE 
formation in corn with high saccharopine levels, for example, cannot be inferred from white 
button mushrooms because LY038 has approximately 20 times the carbohydrate found in 
mushrooms38 (81800 vs 4000mg/100g).  
 
Part of the justification for assuming that these catabolites are safe comes from a study of α-
aminoadipic acid in lentils (Rozan et al., 2001). Surprisingly, that same study reports that α-
aminoadipic acid has neurotoxic activity. The authors were concerned about the levels of this 
metabolite in lentils, not suggesting that other foods should be introduced with similarly high 
levels. The Authority should consider not just the absolute amounts in LY038, but the cumulative 
exposure should LY038 be introduced as the source of corn in a normal diet. 
 
Interestingly, in another study—published by the Applicant—detailing saccharopine and α-
                                                 
38 USDA Nutrient Data Laboratory http://www.ars.usda.gov/main/site_main.htm?modecode=12354500. Access 
date 9 May 2006. 
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aminoadipic acid levels, they report no significant increase in varieties of maize that have 
higher lysine levels achieved through a post-transcriptional inhibition of zein translation 
(Huang et al., 2005). Only when the maize accumulate higher levels of lysine through the use of 
recombinant cDHDPS do free lysine and the lysine catabolites increase. This can be seen in 
Table 5 (which is a combination of values from Tables 3 and 4 of the Applicant’s 2005 
publication (Huang et al., 2005)) comparing rows 1-3 with 4-6. Once free lysine is subtracted 
from the total lysine in high lysine plants, there is no significant difference in lysine levels 
(Table 5, column 4). Thus, the use of cDHDPS recombinant plants is a fundamentally different 
hazard than can be extrapolated from analysis of plants higher in total lysine or other foods 
higher in total lysine.  
 
Table 5: Free lysine and not total lysine is key indicator of risk 
Total1,2 Mechanism for 
higher lysine Lysine Free lysine Lysine-Free lysine saccharopine AAA3 
low zein (PQ15) 2930 64 2866 25 13 
low zein (PQ17) 3320 67 3253 13 9 
control 2575 43 2529 17 9 
cDHDPS 
(CordapA) 4290 1838 2452 459 81 
PQ15 x 
CordapA 6160 2908 3252 588 80 
PQ17 x 
CordapA 
5475 2498 2977 488 59 
1. ppm 
2. Numbers in bold are significantly higher than control (Table 4 of Huang et al., 2005) before 
adjusting for free lysine. Reasons for highlighting these are described in text 
3. α-aminoadipic acid 
 
INBI recommendations: 
R.29 The Authority should justify its conclusion that lysine catabolite levels in a genetically 
modified variety of corn can be considered safe by comparison to lysine levels in 
unrelated food sources. 
 
Cadaverine and pipecolic acid 
The Authority has not addressed the cadaverine and pipecolic acid levels in LY038. Pipecolic 
acid levels were approximately double in LY038 in comparison to LY038(-). Since cadaverine 
is formed by decarboxylation of lysine, the levels also may be significantly higher in LY038. In 
one section of the DAR, the Authority indicates that cadaverine levels are elevated in LY038 
relative to controls (p. 12), but in another section asserts that cadaverine levels could not be 
measured because they were below detection concentrations in both LY038 and the controls (p. 
39). This discrepancy should be addressed. 
 
The Authority also claims that: “FSANZ has not been able to identify any adverse nutritional 
impacts from increased intakes of these substances in the available scientific literature” (p. 12). 
According to the US FDA and Department of Human Services of the Victorian Government, 
Australia, cadaverine is a food hazard. It normally achieves biologically relevant concentrations 
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when bacteria, particularly those found on fish, “convert free amino acids to biogenic amines 
(e.g. histamine)” that can cause allergic reactions expressed as mild skin discomfort to nausea, 
vomiting and diarrhoea39. Cadaverine inhibits the enzymes “diamine oxidase (DAO) and 
histamine-N-methyl transferase (HMT) which convert histamine to harmless degradation 
products.” 40 
 
Cadaverine may also have other toxic activities. The Victorian Government concluded that 
while there have been “[n]o limits…set in the Australian Foods Standards Code for putrescine 
and cadaverine[, t]hese amines may also be toxic in addition to their DAO and HMT enzyme 
inhibiting effects which potentiate the toxicity of histamine. However, further research is 
required to determine the toxicity of all biogenic amines to set safe levels in food for human 
consumption” [emphasis ours]40. Cadaverine could be of particular concern to those taking 
monoamine oxidase inhibitors (antidepressants). The Authority would also recognize that 
cadaverine is a potential Maillard reactant as well. 
 
If cadaverine levels are expected to be higher in LY038, then the Authority should assess what 
levels in corn would be relevant to human health concerns, and ensure that LY038 and any 
hybrids formed with LY038 (particularly other high lysine varieties) do not achieve these 
levels. If the Authority cannot bind the Applicant to a quantitative ceiling level of cadaverine in 
all LY038 derivatives, then the Authority should not recommend an amendment to the Food 
Code. 
 
Pipecolic acid at high levels is found in patients with Zellweger syndrome, and it is “considered 
to be a neurotransmitter or neuromodulator” because it acts as γ-aminobutyric acid receptor 
agonist (Fujita et al., 2003). It also “could be involved in the pathogenesis of hepatic 
encephalopathy” (Fujita et al., 1999). Pipecolic acid is found in two enantiomers, the D- and L-
isoforms and both are found in mammals. D- and L-pipecolic acid are formed by enzymatic and 
non-enzymatic reactions from one another, and they are formed directly from L- and D-lysine. 
Dietary sources of L-pipecolic acid may provide a source of D-pipecolic acid in humans. 
“Some studies have reported that heat, alkali or the combination of both treatments [common to 
food processing] caused amino acid racemization in food proteins”, making cooking and 
processing a likely source of D-pipecolic acid in our food (Fujita et al., 2003). 
 
The Applicant has only provided the Authority with measurements of L-pipecolic acid. 
Moreover, the Applicant has not measured levels of L- and D-pipecolic acid in cooked and 
processed LY038 product. Thus, the Applicant has likely under-stated the concentration of 
pipecolic acid relevant to human health considerations. 
 
It is now clear that D-isomers produced by intestinal bacteria using either D- or L-enantiomers 
of either pipecolic acid or lysine can be taken up by gut cells. D-pipecolic acid in humans 
                                                 
39 http://www.cfsan.fda.gov/~dms/3fs3re12.html. http://www.health.vic.gov.au/foodsafety/research/toxins.htm.  
Access date 21 May 2006. 
40 www.foodsafety.vic.gov.au. Investigation of biogenic amines in fermented fish and fish products. Access date 21 
May 2006. 
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increases when they are on lysine rich diets and decreases if they are taking an antibiotic, 
further indicating that dietary lysine reaches gut bacteria and is fed back as pipecolic acid 
(Fujita et al., 1999). It would be impossible to measure the human health effects of elevated 
levels of pipecolic acid from a compositional study, or using animals with significantly 
dissimilar intestinal flora in a feeding study, or using raw corn. It is also necessary to assess the 
effects of high lysine and pipecolic acid with regard to those who suffer from chronic hepatic 
encephalopathy. 
 
INBI recommendations: 
R.30 The Authority should provide quantitative evidence of cadaverine levels in LY038, 
perhaps by requiring NMR combined with chemometrics and univariant statistics to 
achieve more sensitive detection. If it does not, then the Authority should require 
feeding studies using LY038 cooked and processed as normal for human food to 
assess the potential for cadaverine at elevated levels in corn to produce food hazards. 
R.31 The Authority should assess the sensitivity of those on monoamine oxidase inhibitors 
to measured levels of cadaverine in a diet composed of LY038 corn. 
R.32 The Authority should report total pipecolic acid levels in LY038 and not just L-
pipecolic acid levels. 
R.33 The Authority should assess the contribution the intestinal flora will make to pipecolic 
acid levels in consumers who eat corn with high levels of lysine, free lysine and 
pipecolic acid. 
R.34 The Authority should explain how it has considered the impact of pipecolic acid in 
high lysine corn on those suffering from chronic hepatic encephalopathy. 
 
Measurements of free and total amino acids 
The Applicant reports amino acid levels as a proportion of amino acids. This can mask 
important changes in the amounts of amino acids, especially in distributions between protein-
incorporated and free amino acids (Toro et al., 2003). 
 
INBI recommendation: 
R.35 The Applicant has reported absolute amounts (by weight) of the amino acids in its 
most recent study (MSL-18881) but the Authority has accepted the statistical analysis 
based on %AA. The Authority should present the statistical analysis based on absolute 
amounts by weight. 
 
Lysine synthesis and lysine catabolism (section 2.2.3-2.2.7 in NZIGE submission) 
 
Animals feeding on plants have adapted to particular levels of total and free lysine and any 
derivative metabolites. mDHDPS is feedback-inhibited by lysine, as are all known plant 
DHDPS enzymes (Azevedo and Lea, 2001). Why this is the case is not explained by the 
Applicant, but there is evidence that higher levels of lysine alter the metabolism of the plants 
and could be harmful (Azevedo and Lea, 2001). Lysine is a feedback inhibitor of aspartate 
kinase (AK), the first step in the common pathway leading to production of lysine off one 
branch, and isoleucine, threonine and methionine off the other (Azevedo and Lea, 2001). While 
there is evidence of multiple isozymes of AK, the lysine-responsive isozyme is the major 
activity in maize (Azevedo, 2002). Thus, plant biochemistry is responsive to lysine 
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concentration. De-regulating DHDPS could cause fluxes in the amount of β-aspartyl phosphate 
available for the second branch and vary the concentration of these essential amino acids, 
proteins or other metabolites, or select for compensatory mutations.  
 
The Applicant has recently published a paper revealing the analysis of protein distribution in 
varieties of corn hybridized with a parent of highly similar if not identical description to LY038 
(Huang et al., 2005). This description raises significant discrepancies with the application. 
 
The Applicant reported to the Authority that “[t]herefore, in Lysine maize LY038, the expected 
total lysine would range from 3500 to 5300 ppm” (p. 2). In Huang et al. (2005), hybrids were 
expressing up to 6160 ppm total lysine, an increase of up to 100% over the levels reported in 
the Applicant’s controls in A549. 
 
The Applicant reported to the Authority that “[l]evels of free lysine are expected to be in the 
range of 1000 to 2500 ppm in Lysine maize LY038 grain” (p. 2). In Huang et al. (2005), 
hybrids were expressing nearly 3000 ppm. 
 
Interestingly, the natural limitation to lysine accumulation in maize endosperm is lysine 
catabolism rather than limited production. The LOR-SDH lysine catabolic pathway first yields 
saccharopine by action of lysine 2-oxoglutarate reductase (LOR) and then aminoadipic 
semialdehyde and glutamate via saccharopine dehydrogenase (SDH). Maize mutants, and 
mutants of Phaseolus vulgaris that accumulate lysine in seed, also have low LOR-SDH activity 
(Azevedo, 2002, Toro et al., 2003). In Huang et al. (2005), the Applicant has found cDHDPS 
recombinant plants have the same LOR-SDH activities as plants that do not accumulate lysine. 
However, in mutants with high lysine due to changes in zein protein increases, the activity of 
this pathway is increased. Combined, the studies of Azevedo’s group and Huang et al. (2005) 
confirm that cDHDPS recombinants achieve their levels of lysine accumulation in part by 
compensatory changes in lysine catabolism (either decreased activity or failing to increase 
activity relative to conventional varieties), a factor that cannot be predicted in advance for 
novel hybrids. 
 
For whatever reason, cDHDPS has achieved a higher concentration of lysine, especially free 
lysine, in seed in line LY038 (MSL-19172). In conventional maize mutants with higher lysine 
yields, this has been due to an increase in protein incorporated lysine rather than free lysine 
(Toro et al., 2003). 
 
INBI recommendations: 
R.36 The Authority should provide evidence that hybrids with the LY038 event have the 
same absolute amounts of glutamate, free lysine, saccharopine and α-aminoadipic acid 
as LY038 to assure the Authority that LY038 has no physiological behaviours that are 
unique to its genetic background with regard to lysine catabolism in seed. 
R.37 The Authority should address the difference in expected ranges of total and free lysine 
(as reported in A549) and the higher values already known to exist in hybrids created 
by the Applicant by explaining how it has determined what absolute levels of these 
compounds in corn could be a cause for concern. 
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There are indicators that elevated levels of cadaverine in corn could have physiological 
consequences altering other nutrient levels or in the creation of potential food hazards. 
Cadaverine levels were found to follow heat stress in marigolds, indicating that cadaverine has 
a role in recovery from stress. Chronic high levels of cadaverine, therefore, are not the norm for 
plants. According to the authors of the study “the superproduction of cadaverine would result in 
SAM [S-adenosyl-L-methionine] deficiency and, consequently, in the suppression of 
spermidine and spermine syntheses. In addition, in some cadaverine-containing plants, an 
unconventional behavior of cadaverine relative to ethylene and putrescine-type polyamines was 
observed” and “[t]he data obtained support the suggestion that cadaverine serves as a stress 
signal at the whole-plant level” (Shevyakova et al., 2000). LY038 may have the physiology of 
perpetually stressed plants and not conventional corn. 
 
INBI recommendation: 
R.38 The Authority should provide evidence that LY038 and any hybrids with the LY038 
event have the same absolute amounts of SAM and spermidine, and report on feeding 
studies using LY038 corn prepared as per normal for human consumption to assure the 
Authority that LY038 has no physiological behaviours that are unique to its genetic 
background with regard to lysine catabolism in seed. 
 
Characterisation of novel protein 
 
Our recommendations are based on the evaluation of the studies MSL-18585 “Characterisation 
of the cDHDPS Protein Purified from Grain of Lysine Maize LY038 and Assessment of the 
Physicochemical and Functional Equivalence of the Plant-Produced cDHDPS Protein and the 
E. coli-produced cDHDPS Protein” written by Rice, E.A., Kapadia, S.A., Thoma, R.S. and 
Hileman, R.E. (Monsanto company 2003) and MSL-18365 “Characterisation of the E. coli-
Produced Corynebacterium glutamicum Dihydrodipicolinate Synthase (cDHDPS) Protein” 
written by Rice, E.A., Kapadia, S.A., Dalton, C.M., Brown, T.P., Thoma. R.S., Hileman, R.E. 
and Astwook, J.D. (Monsanto Company 2003). 
 
Ambiguities in protein identification 
 
The Authority has concluded that “SDS-PAGE and Western blotting techniques were used to 
demonstrate that the cDHDPS protein expressed in LY038 corn was of the expected size. N-
terminal sequencing and MALDI-TOF mass spectrometry further confirmed that the desired 
protein was expressed in LY038. Glycosylation analysis showed that cDHDPS is not 
glycosylated in LY038” (DAR, p. 21). However, this conclusion does not seem to be consistent 
with experimental fact. 
 
(1) In Table 3 of Appendix MSL-18585 the Applicant makes clear that proteins of 33, 34 and 
35kDa band are detected using SDS PAGE. The proteins of 35kDa are present at a relative 
abundance of less than 10%, the arbitrary cut off imposed by the Applicant (see “Methods, 
Specific Analyses to be Performed” p. 43 MSL-18585). 
 
(2) Only the 33kDa bands produced in E. coli and in-planta are subsequently used for N-
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terminal sequencing. Thus, the sequencing data does not prove the identity between the E. coli 
and in-planta produced recombinant cDHDPS, it only establishes that the 33kDa species 
produced by both E. coli and LY038 have the same N-terminal sequence. 
 
(3) Only the 33kDa band produced in E. coli is used in subsequent allergenicity and toxicity 
studies. 
 
INBI recommendation: 
R.39 The Authority should report on the characterization of the 35kDa bands found in 
preparations of cDHDPS produced in-planta. 
R.40 The 34 and 35kDa forms should be demonstrated to be free of all post translational 
modifications, not just the addition of sugars. 
R.41 The 34 and 35kDa forms should be used in allergenicity and toxicity studies. 
 
Unreported additional changes in cDHDPS seen in MALDI-TOF data 
 
There is evidence of an undeclared modification to in planta-produced cDHDPS. The amino 
acid sequence of cDHDPS available on SwissProt41 reports a leucine at position 266. The 
Applicant reports a serine at position 266 (269 of the recombinant protein because of the transit 
peptide). 
 
This is a significant difference because serine can be glycosylated. This modification could 
have been missed by the Applicant, even using in gel protein digestion, because the in planta-
produced protein fragments analyzed by MALDI-TOF did not include the region (264-267 
AASR) with residue 266 (Figure 5, reproduced from Figure 29, p. 49, of the application).  
 
We remind the Authority “that there are fundamental differences between the identification of a 
protein and the analysis of its post-translational modifications. Minimal sequence information 
will suffice to ensure unambiguous protein identification but practically full sequence coverage 
must be obtained in order not to miss the (few) modified amino acids” (Küster et al., 2001). 
 
Figure 5: Plant cDHDPS MALDI-TOF coverage 
 
As recommended in the Codex Alimentarius in CAC/GL 45-2003, information should be 
provided to demonstrate whether deliberate modifications made to the amino acid sequence of 
the expressed protein result in changes in its post-translational modification or affect sites 
critical for its structure or function. 
 
INBI recommendation: 
R.42 The Authority should be able to confirm the existence of molecular data to 
                                                 
41 http://ch.expasy.org/uniprot/P19808 . Access date 12 May 2006. 
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demonstrate that the modification made to the amino acid sequence, in this case amino 
acid 266, does not affect its post-translational modification or range of biochemical 
functions. 
 
Immunoreactivity studies and glycosylation (see sections 5.3.6.8 and 5.3.6.12, and 5.3.15-
5.3.17 in NZIGE submission) 
 
Recombinant cDHDPS must be found equivalent to the E. coli-produced recombinant cDHDPS 
because the Authority is presently allowing the Applicant to substitute E. coli-produced 
cDHDPS for in planta-produced cDHDPS in toxicity and allergenicity studies. The Applicant 
has only submitted studies on one type of post translational modification, called glycosylation, 
the enzymatic addition of sugars to certain amino acid residues. This is not sufficient to 
conclude identity even if the glycosylation studies were conducted to the necessary standard, 
which, in our view, they were not. 
 
Glycosylation can change the characteristics of a protein in such a way as to cause it not to be 
detected by methods that rely on the overall chemical properties of the protein or on 
antibiodies. Glycosylation and other post-translational modifications, or their absence, can 
create different antigenic epitopes from those present in otherwise identical polypeptides. Also, 
glycosylation can significantly change the molecular weight and charge profiles of proteins; 
both of these parameters are relevant to the Applicant’s isolation method. 
 
“[P]rotein glycosylation is generally species, tissue and cell type specific. Therefore, from a 
biological point of view, it is highly desirable to study the naturally expressed protein rather 
than a recombinant version” (Küster et al., 2001). 
 
The Applicant should have first developed a profile of proteins in LY038 grain and worked 
from that to an identification of all cDHDPS variants. Failing this, their result demonstrating an 
absence of glycosylation could be a false negative result due to exclusion of one or more minor 
forms (e.g., possibly the 35kDa form) that are glycosylated. Currently, the Authority is 
reaching its conclusions based on an SDS PAGE profile that does not have the sensitivity of 2D 
gel electrophoresis (see Part One “response to recommendation 1” for references and 
discussion). Moreover, the Authority has not reported the sensitivity of the method. 
 
Recently, the Applicant published an analysis of the proteome of six recombinant A. thaliana 
lines and their mutual parent (Monsanto study published under Ruebelt et al., 2006b). The six 
transgenic lines were chosen because they had only one insert each of the same transgene 
construct (but display different rates of expression in leaves). After 3 generations from the 
parent, the proteome varied very little between recombinant and parent in pairwise 
comparisons, with 97% of the parental protein spots matched in all six recombinant lines and 
between 93% and 98% of spots from recombinants matched to the parental. These match rates 
correspond to differences in only 10-30 spots on the 2D gel. 
 
What this study (Ruebelt et al., 2006b) demonstrated was that the: 
 Applicant can use profiling techniques for the identification of unintended effects; 
 variation between parent and recombinant should be small (~3%); 
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 number of unique spots is not too large to investigate. 
 
The study also demonstrates the absolute requirement to make comparisons between 
recombinant plants and their immediate non-modified parent, when using profiling to make 
hazard identification. The Authority should be requiring comparisons to the LY038 non-
modified parent.  
 
INBI recommendations: 
R.43 We recommend that the Authority require a complete proteomic analysis of LY038 
grain using 2D gel electrophoresis and MS and an account of all changes between 
LY038 and its non-modified parent. The Applicant has demonstrated in a recent series 
of publications that it has the technology to do such profiling (e.g. Monsanto studies 
Ruebelt et al., 2006a, Ruebelt et al., 2006b). Each change should be identified as either 
a variant of cDHDPS or an unintended change in the modified plant. All variant forms 
of cDHDPS should be characterized for glycosylation or other post-translational 
modifications (5.3.17). 
R.44 The Authority should know and report the detection level of the Western blots, and 
justify those detection levels if they are above the fmol range (Küster et al., 2001). 
R.45 The Authority should indicate how it has eliminated the possibility of post-translational 
modifications with molecules other than sugar. 
R.46 All previously un-notified changes in the protein profile of the plant compared to its 
non-modified parent should then be analysed for potential harmful affects on 
consumers. 
 
The goat anti-cDHDPS antiserum is described to a standard less than necessary for a proper 
evaluation of the use of this tool in identifying all isoforms of recombinant cDHDPS produced 
in planta. There remains the possibility that the Applicant failed to detect all forms of cDHDPS 
produced in planta.  
 
INBI recommendations: 
R.47 The Authority should verify and then report whether the antiserum used for protein 
isolation was raised against E. coli-produced cDHDPS, C. glutamicum DHDPS, or in 
planta-produced cDHDPS (5.3.6.9). If the antiserum was not raised against the latter, 
then the Authority must confirm that the antisera will detect all in planta-produced 
isoforms detected by 2D gel electrophoresis and MS. 
R.48 The Authority should confirm whether the antiserum was affinity purified and 
comment on how the purification might bias the reported results. 
R.49 The Authority should report how many exposures and how frequently goats were 
exposed to the antigen(s) and the antibody classes of the serum. 
R.50 The Authority should report whether the antiserum affinity purified. If yes, the 
Applicant may have lost any antibodies that would bind to antigens unique to in 
planta-produced cDHDPS.  
R.51 The Authority should address the possibility that other classes of antibodies could 
have masked epitopes from those classes used in the detection assay. 
R.52 The Authority should confirm that the antiserum was raised to in planta-produced 
protein(s) rather than raised against E. coli-produced cDHDPS or C. glutamicum-
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produced cDHDPS. 
R.53 The Authority should confirm that the goat anti-cDHDPS antiserum used is not 
affected by post-translational modification of cDHDPS, for example glycosylation, by 
demonstrating that the antisera will detect all in planta-produced isoforms detected by 
2D gel electrophoresis and MS. 
 
Aggregation propensity (NZIGE submission sections 1.2 and 7.1.24-7.1.27) 
 
The Authority has provided no scientific evidence that the newly expressed recombinant 
cDHDPS when present in corn and prepared as a human food will not form aggregates of 
potential concern. In contrast, we provided preliminary scientific evidence in our analysis of 
cDHDPS and mDHDPS that they have a different sequence landscape for aggregation 
potential. These results suggest that high quantities of cDHDPS in the human diet may increase 
exposure to new forms of protein with properties different from mDHDPS. The safety of these 
species in food is unknown. 
 
The Authority has provided no scientific evidence to exclude the transmission of cDHDPS-
derived aggregates to humans through food. In contrast, we provided a list of peer-reviewed 
scientific studies that indicate that proteins and hazardous aggregates of proteins survive 
digestion and are distributed throughout the human body. We therefore recommend that: 
 
INBI recommendations: 
R.54 The Authority should provide evidence that cDHDPS has no more propensity to form 
toxic aggregates when produced in planta than mDHDPS produced in planta. 
R.55 The Authority should provide evidence that proteins in the chloroplast of corn cells do 
not survive through digestion in humans, or cannot be taken up by gut cells. 
R.56 The Authority should provide evidence that all recombinant forms of cDHDPS are 
exclusively located in the chloroplast and not found in the ER, golgi or cytoplasm of 
plant cells at some concentration. If they are, then the Authority should provide 
reliable evidence that these forms do not survive through digestion in humans, or 
cannot be taken up by gut cells. 
R.57 The Authority should provide evidence that transgenic cDHDPS aggregates do not 
form in the plant chloroplast or during cooking/processing of the whole food derived 
from the modified plant. 
R.58 If aggregates are detected, they Authority should provide evidence for their safety 
using established tissue culture assays for cytotoxicity and animal feeding studies. 
 
Potential dietary exposure to novel protein (NZIGE submission sections 1.1 and 5.3.2) 
 
A history of safe use of the cDHDPS protein cannot be extrapolated from either: 
a. structural similarities between cDHDPS and mDHDPS, or 
b. consumption of cDHDPS from natural sources. 
 
The safe use of the plant enzyme does not extend to the recombinant bacterial enzyme because 
the cDHDPS differs structurally from the plant version. This difference in molecular 
architecture means that different faces of the protein are presented to the solution, with 
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different direct allergenic potential and different indirect allergenic potential through Maillard 
reaction products (Gruber et al., 2005). The key concern of this observation is that the epitopes 
of endogenous DHDPS (mDHDPS) and in planta-produced cDHDPS could be very different 
and the potential allergenicity of the transgene may be different from expected. 
 
The C. glutamicum enzyme (cDHDPS) shows high similarity to the E. coli enzyme, the 
structure of which has been solved (Mirwaldt et al., 1995). Similarly, the maize enzyme shows 
a high similarity to the only plant enzyme, that from Nicotiana sylvestris, for which the 
structure is known (Blickling et al., 1997). Both prokaryotic DHDPS and eukaryotic DHDPS 
are tetrameric and have a common fold in their tertiary structure. Natural DHDPS is a highly 
unusual enzyme, however, in that the bacterial and plant enzymes have an entirely different 
quaternary structure due to a profound rearrangement of the dimers forming the tetramer. 
 
INBI recommendation: 
R.59 The Authority should justify how it can assume the history of safe use of cDHDPS 
based on an extrapolation from the mDHDPS structure when there are profound 
differences in structure. 
 
There is also no evidence that we are aware of that humans have had a significant exposure to 
cDHDPS in their diets. C. glutamicum is a soil microorganism. We estimate that its maximum 
concentration in soil will not exceed 1000/g. The amount of DHDPS produced by bacteria is 
extremely small, between 24 and 250 monomers/bacterium.42 This corresponds to between 1 x 
10-12 and 1 x 10-11μg of DHDPS/cell. An expression level of 26μg/g in grain in LY038 (DAR, 
p. 33) is equivalent to the consumption of between 2 x 1012 and 2 x 1013 bacteria, the amount 
that would naturally be found in 2-20 million kg of soil. At average daily corn consumption 
rates of 0.52g/kgBW43, the US per capita consumption, the amount of cDHDPS consumed 
daily would be 12.5μg/kgBW, or a total of 1mg for males and 0.857mg for females each day.44 
For equivalent exposure, people would have to eat between 80-800 million (males) or 60-700 
million (females) kg of soil each day, or nearly as much as 10,000kg/second 24 hours a day 
seven days a week. 
 
At actual estimated maximum daily soil intakes of 207mg for children and 625mg for adults 
(Davis and Mirick, 2006), we estimate daily human exposure to cDHDPS from natural sources 
to be between 6 x 10-9 to 6 x 10-10μg (adults) and 2 x 10-9 to 2 x10-10μg (children), or about 30 
billion-4 trillion times less than exposure through LY038 corn (Table 6). We have also 
highlighted variances by country because per capita consumptions are averages and do not 
capture the range of possible exposures. Mexicans living in Australia or New Zealand may 
have exposure rates closer to their national averages. 
 
                                                 
42 Based on an over-expression system in E. coli 32. Laber, B., Gomis-Rüth, F. X., Romao, M. J. and Huber, R. 
(1992). Escherichia coli dihydropicolinate synthase. Biochem. J. 288, 691-695., DHDPS yield was 100mg/30g of 
cells. Assumptions were that over-expression is 10-100 times natural production, the weight of a bacterium is 
~10-14g and the mass of DHDPS is 32kDa. 
43 See NZIGE submission 25 February 2005 section 6.1.6.1. 
44 Based on average weights of 80.4kg for males and 68.7kg for females. Source Statistics New Zealand. 
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Table 6: cDHDPS exposure levels from natural sources and LY038 
Source (daily intake μg) 
Consumer C. 
glutamicum 
LY038 factor of increase exposure 
Adults (New Zealand) 45 6 x 10-9 164 3 x 1010 
Children (New Zealand) 2 x 10-9 164 8 x 1010 
Adults (Australia)46 6 x 10-9 348 6 x 1010 
Children (Australia) 2 x 10-9 348 2 x 1011 
Adults (US) 47 6 x 10-9 936 2 x 1011 
Children (US) 2 x 10-9 468 2 x 1011 
Adults (Mexico)48 6 x 10-9 8259 1 x 1012 
Children (Mexico) 2 x 10-9 8259 4 x 1012 
 
INBI recommendation: 
R.60 The Authority should justify how it can assume the history of safe use of cDHDPS 
based on historical human consumption of natural cDHDPS. 
 
The Authority persists in arguing that recombinant cDHDPS exposure will be much less than 
these amounts because LY038 will be a minor proportion of the corn supply, despite its 
statements that its evaluation comes from assuming LY038 would be consumed at the same 
levels as conventional corn when they say: 
 
“The highest level of expression of cDHDPS in the grain of LY038 based on the expression data 
above was 26 ng/g [sic, Table 4 on p. 33 of the DAR reports units as μg/g] dry weight. However, the 
actual exposure to this protein in the diet is expected to be much lower than this [emphasis 
ours]. LY038 corn is intended strictly for use as an animal feed for poultry and possibly pigs. As 
such, LY038 corn will be subjected to identity preservation methods to segregate this 
nutritionally enhanced animal feed from conventional commodity grain to ensure the recovery 
of the commercial value of this product [emphasis ours]. Even at peak market penetration, the 
Applicant expects that this crop will represent less that 7% of the field corn grown in the 
U.S.A. [emphasis ours] and because of the identity preservation methods that will be used to 
segregate this product from conventional grain, it is unlikely that more the 5% on average LY038 
would be inadvertently co-mingled with conventional corn and enter the human food supply 
[emphasis ours]. Much less than this would be expected to reach Australia or New Zealand, and 
much of this would be as processed products such as high fructose corn syrup that contains little or 
no protein” (DAR, p. 34). 
 
The Authority has no control over the Applicant’s intention nor is it capable of assessing the 
mix of future economic drivers that may erode incentives to minimize LY038 incursion into the 
human food supply. These arguments are not only superfluous to the assessment, but 
undermine the Authority’s claim to keep separate the issue of safety from expected exposure. 
                                                 
45 Based on New Zealand annual corn consumption of 2.5kg/person. Source FAOSTAT 2006. 
46 Based on Australian annual corn consumption of 5.3kg/person. Source FAOSTAT 2006. 
47 Based on 75kgBW (average of adult male and females), and half the adult average for children. US consumption 
of corn at 0.52g/kgBW/day. 
48 Based on Mexican annual corn consumption of 125.6kg/person. Source FAOSTAT 2006. 
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Once approved, the Authority has to be confident that LY038 can be consumed as the sole 
source of corn in the human diet and be as safe as conventional corn. 
 
INBI recommendation: 
R.61 Should the Authority recommend amendment of the Food Code to allow LY038, then 
it should impose quantitative restrictions on the levels of LY038 that may enter the 
human food supply to ensure that Applicant intentions are translated into responsible 
achievements should this material be approved for human food. 
 
Toxicity and Allergenicity studies 
 
Our recommendations are based on the evaluation of the studies MSL-18585 “Characterisation 
of the cDHDPS Protein Purified from Grain of Lysine Maize LY038 and Assessment of the 
Physicochemical and Functional Equivalence of the Plant-Produced cDHDPS Protein and the 
E. coli-produced cDHDPS Protein” written by Rice, E.A., Kapadia, S.A., Thoma, R.S. and 
Hileman, R.E. (Monsanto company 2003); MSL-18365 “Characterisation of the E. coli-
Produced Corynebacterium glutamicum Dihydrodipicolinate Synthase (cDHDPS) Protein” 
written by Rice, E.A., Kapadia, S.A., Dalton, C.M., Brown, T.P., Thoma. R.S., Hileman, R.E. 
and Astwook, J.D. (Monsanto Company 2003); MSL-18735 “An Acute Oral Toxicity Study in 
Mice with E. coli-produced cDHDPS Protein” written by Kaempfe, A.J. (Monsanto Company 
2003); MSL-18744 “Bioinformatics Analysis of the cDHDPS Protein Expressed in Lysine 
Maize Event LY038 and LY049 Utilising the AD4, TOXIN5 and ALLPEPTIDES Databases.” 
written by McCoy, R.L and Silvanovich, A. (Monsanto Company 2003) and MSL-18676 
“Assessment of the in vitro Digestibility of the cDHDPS Protein in Simulated Gastric Fluid” 
written by Rice, E.A., Kapadia, S.A. and Hileman, R.E. (Monsanto Company 2003). 
 
Toxicity of lysine and animal studies 
 
We recommend that the Authority require the Applicant to use the promising pig intestinal 
models for assessing amino acid toxicity (Baracos, 2004). These models show promise for 
assessing the “maximal gut capacity to deal with amino acid insults under different 
physiological conditions” (Baracos 2004). “The downregulation of intestinal protein 
degradation by amino acids contributes to controlling amino acid entry into free pools from 
proteolysis in the function of the dietary supply. Our models can be used to identify maximal 
response and the amino acids most potent in eliciting this change…This approach has 
application in studies to define the upward limits of the adaptive regulation of intestinal amino 
acid catabolism in response to high amino acid doses” (Baracos 2004).  
 
These recommendations also derive from the discussion in Part One, responses 10-12. 
 
INBI recommendations: 
R.62 The Authority should require a feeding study that meets the recommendations of 
Renwick (Renwick, 2004). 
R.63 The Authority should request that the Applicant use the promising pig intestinal model 
(Baracos, 2004) for assessing amino acid toxicity.  
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R.64 The Authority should make the 3-month rat feeding study available to the independent 
scientific community for evaluation before recommending to Council that the food 
code be amended to include LY038 corn. 
 
Equivalence of E. coli and in planta-produced cDHDPS 
 
Specific activities provided by the Applicant are not sufficient to establish equivalence (NZIGE 
submission section 5.3). In MSL-18585 “[t]he specific activity for the plant-produced and E. 
coli-produced cDHDPS protein was estimated to be 68±3 and 84±5 U/mg total protein, 
respectively.” Importantly, the authors use the same E. coli preparation for measuring specific 
activity in MSL-18365 (lot 20-100003) but find that the specific activity of the enzyme was 
107±6 U/mg of protein, or approximately 23 to 40 U/mg different from the E. coli- and in 
planta-produced cDHDPS, respectively, of MSL-18585. In published studies, differences in 
specific activity of comparable magnitudes to those in MSL-18365 and 18585 have been 
considered significant (e.g. Bessler et al., 2003). Measures of specific activity can suffer from a 
high variance. With this in mind, we suggest that the specific activity data is inappropriate for 
drawing conclusions of identity or functional similarity, other than to say that the isolated 
proteins perform the same conversion of substrate into product in this in vitro assay. Either the 
specific activity measures are significantly different and refute the suggestion of functional 
similarity, except by the most liberal of definitions of similarity, or they are unreliably variable 
and better measures, such as Km and Vmax, should be provided. 
 
INBI recommendations: 
R.65 The specific activity data is inappropriate for drawing conclusions of identity or 
functional similarity. Better measures for functional similarity, such as Km and Vmax, 
should be provided. 
 
Acute oral toxicity 
 
According to CAC/GL 45-2003 (paragraph 38), “[a]ppropriate oral toxicity studies may need to 
be carried out in cases where the protein present in the food is not similar to proteins that have 
previously been consumed safely in food, and taking into account its biological function in the 
plant where known.” We do not believe that a case has been made for assuming that prokaryotic 
DHDPS has been a normal component of human food (see section above, Potential dietary 
exposure). 
 
The applicant performed the acute oral toxicity in 2003 in general conformance to OECD 
reference 401. However, that guideline was deleted in December 2002. Why did the Authority 
not insist on the Applicant performing the test to the standard of the day? 
 
OECD Reference 401 has been replaced by 3 guidelines, 420, 423 and 425. Guideline 420 is 
the first alternative to the conventional acute toxicity test, described in Test Guideline 401 and 
seems to be the most appropriate for the application. The principle of the test is explained in the 
following text49: 
                                                 
49 Principle extracted from guideline 420 at http://www.oecd.org/dataoecd/17/49/1948362.pdf. Access date 29th 
May 2006. 
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“Groups of animals of a single sex are dosed in a stepwise procedure using the fixed doses of 5, 50, 
300 and 2000 mg/kg (exceptionally an additional fixed dose of 5000 mg/kg may be considered, see 
paragraph 19). The initial dose level is selected on the basis of a sighting study as the dose expected 
to produce some signs of toxicity without causing severe toxic effects or mortality. Clinical signs and 
conditions associated with pain, suffering, and impending death, are described in detail in a separate 
OECD Guidance Document (8). Further groups of animals may be dosed at higher or lower fixed 
doses, depending on the presence or absence of signs of toxicity or mortality. This procedure 
continues until the dose causing evident toxicity or no more than one death is identified, or when no 
effects are seen at the highest dose or when deaths occur at the lowest dose.” 
Thus, it is not clear why the Applicant chose to fix its value of toxicity at 800 mg/kg instead of 
2000 or 5000 mg/kg. 
 
Whole food feeding studies 
 
This subject is discussed in Part One, “response to recommendation 2” and “response to 
recommendation 12”. The protein should have been sourced from LY038 rather than E. coli. 
We remain unconvinced that the studies reviewed by Authority comprehensively demonstrate 
equivalence of all isoforms produced in planta with the form produced in E. coli. The 
Authority should supply results of a feeding study using in planta-produced protein and 
material that has been cooked and processed as would be normal for human food. 
 
INBI recommendations: 
R.66 The Authority should draw a recommendation based in part on feeding studies using 
the whole food (grain of transgenic plants and cooked products that would form a 
representation of how the food was to be consumed by people). 
R.67 The studies should be conducted using animal models that are most appropriate for 
identifying harms relevant to people. Long-term (lifetime) studies should be included 
because high lysine corn is also high free lysine, saccharopine, α-aminoadipic acid, 
cadaverine and pipecolic acid corn. The Authority should report on chronic effects, 
evidence of carcinogens and co-carcinogens (AGEs have been linked to cancer Heijst 
et al., 2005), and proteins that are capable of forming aggregates. No structural 
analysis alone will predict the effect of context on an enzyme or its potential to 
produce unanticipated products in a novel context. Therefore, structural analyses 
equating E. coli- and in planta-produced cDHDPS cannot substitute for the use of in 
planta-produced cDHDPS in all biochemical and feeding experiments (NZIGE 
Submission section 5.3.7.2).  
R.68 The Authority should report how both dietary and airborne allergens in LY038 were 
excluded by experimental tests conducted on animals previously fed the whole food 
derived from LY038. 
 
Bioinformatics studies 
 
Bioinformatics tools have never been validated as comprehensively predictive of potential 
allergens. So such approaches are useful when they return a match rather than when they return 
no matches. Therefore, we have consistently argued in other sections (above) for empirical data 
to make the risk of novel antigens known. 
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Where bioinformatics is used, the FAO/WHO (2001)50 suggests a procedure where: 
 a complete set of 80 amino-acids derived from the expressed protein is prepared and then 
compared to the allergen or toxin database; 
 a search for identity over 6 contiguous amino acids is performed. 
 
The Applicant used a search over 8 contiguous amino acids, saying that “the results 
demonstrated that searches with six or seven amino acid windows led to high rates of false 
positive matches” (MSL-18182 p. 16).  
 
INBI recommendation: 
R.69 For allergen identification, we are more concerned with false negatives than false 
positives. Thus we ask the Authority to review the bioinformatics data using the 
parameters set by FAO/WHO. 
 
The Applicant has provided three references in defence of this claim, all produced by the 
Applicant and Novartis, another GMO producer. However, 6 contiguous amino acids is the 
standard for the research on protein epitopes. If too many false positives are found, it is possible 
to apply “filters” (as explained in Kleter and Peijnenburg, 2002) that will distinguish between 
false and true positives. 
 
Moreover, it appears that the Applicant performed their bioinformatics using the Swissprot 
sequence with a leucine at position 268 (or 266, depending on start residue) of cDHDPS in 
MSL-18744 (p. 19). 
 
INBI recommendation: 
R.70 The Authority should report the results of a bioinformatic analysis using the actual 
sequence of in planta-produced recombinant cDHDPS. 
 
The wheat gamma gliadin protein is 34.3% identical to cDHDPS-frame 6 over a window of 99 
amino acids (MSL-19181). This is close enough for the Authority taking a precautionary 
approach to enforce the CAC recommendation (paragraph 9 of Annex) that “IgE cross-reactivity 
between the newly expressed protein and a known allergen should be considered a possibility 
when there is more than 35% identity in a segment of 80 or more amino acids (FAO/WHO 
2001) or other scientifically justified criteria. All the information resulting from the sequence 
homology comparison between the newly expressed protein and known allergens should be 
reported to allow a case-by-case scientifically based evaluation.”  
 
Moreover, several matches with allergens were made that had 35% sequence similarity, but in 
windows of less than 80 amino acids. For example, frame 3 shares a percentage of identity of 
41.3% with the bacterial protein AX005505. These matches should be the focus of more specific 
evaluations. 
 
Pepsin resistance 
 
                                                 
50 http://www.who.int/foodsafety/publications/biotech/en/ec_jan2001.pdf. Access date 15 May 2006. 
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The study submitted by the Applicant is not the international standard (see Part One “response 
to recommendation 8” of elaboration). The Applicant has used 2000 times the amount of pepsin 
by weight recommended in the FAO/WHO protocol (NZIGE submission section 7.1.11.1). 
 
The Authority has argued that “most food allergens tend to be stable to the peptic and acidic 
conditions of the digestive system if they are to reach and pass through the intestinal mucosa to 
elicit an allergic response”, citing dated literature on the topic (1996-1999). More recent studies 
have undermined the generality of the statement that allergens are more stable. “Food allergens 
were not necessarily more resistant to SGF and SIF digestion than nonallergenic proteins of 
similar cellular functions” (this reference and references within Fu, 2002). Fu (2002) goes on to 
say that “[c]hanges in pH or the relative amount of enzymes used could affect the digestibility 
measured and thus the estimated allergenic potential. We have found that the digestibility of 
proteins as determined by the SGF [simulated gastric fluid] assay could be greatly influenced 
by the relative amounts of pepsin and test protein present in the assay. For example, the 
stability of the major egg allergen ovalbumin changed from greater than 120 min to 0 min as 
the ratio of pepsin to test protein (by weight) increased from 0.1 to 100.” Such findings 
challenge the suggestion that using overwhelming quantities of pepsin at unrealistically low 
pHs is the best way to tease out information about the structural characteristics potential 
allergens. 
  
Clearly, it would be in the interests of the Applicant to use an assay that minimized the 
appearance of stability. While the FAO/WHO assay may overstate stability in some cases, the 
Authority should be less concerned about erring on the side of over-estimating potential 
allergenicity than under-estimating the potential for an allergen in a food crop, especially when 
human consumers gain no benefit from the recombinant cDHDPS protein in their food. The 
more subtle and biologically relevant FAO/WHO study, therefore, remains the undisputed 
standard in our view and that of the international food safety bodies. 
 
While the studies submitted have their merits and would augment studies performed to 
international standards, they do not substitute for the studies specified by FAO/WHO. What 
remains unclear to us is why it is in the interests of the people of Australia and New Zealand to 
compromise on the FAO/WHO standard for a product that the Authority expects to have no net 
benefit to consumers. 
 
INBI recommendations: 
R.71 Whereas there may be virtue in establishing a standard, as the industry-led groups in 
the Thomas et al. study did, it remains unclear why the FAO/WHO protocol is not the 
standard nor why reproducibility is a greater virtue than using a pH relevant to 
conditions in the stomach during a meal, such as pH4-5 (Schmidt et al., 1995, Thomas 
et al., 2004). The Authority should require results to the Thomas et al. industry-
preferred standard and the FAO/WHO standard. 
R.72 The Applicant should report digestibility measurements after processing/cooking of 
material from whole food. 
R.73 The Authority should require, at the very minimum, results of the digestion studies 
using a surrogate source of protein verified to represent all post-translationally 
modified forms of the protein in whole food, including after cooking and processing. 
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For this, the Authority will have to address our call for using 2D gel electrophoresis 
and MS to identify all isomers produced in plants. 
 
Nutritional impact 
 
Our recommendations are based on the evaluation of the study MSL-18883 “Sponsor Summary 
of Report for Study 02-01-72-16 Comparison of Broiler Performance When Fed Diets 
Containing LY038 x MON810, Negative Segregant Control, or Commercial Maize” written by 
Taylor, M.L., Hyun, Y., Hartnell, G.F., Nemeth, M.A., Karunanandaa, K., George, B., Glenna, 
K.C. and Heydens, W.F. (Monsanto Company 2003). 
 
Broiler study 
 
Two significant problems not addressed by the Authority in the DAR. 
(1) Young chicks grew significantly more slowly (NZIGE submission section 7.2.5). Broilers 
fed GM corn had significantly lower adjusted gain in the first 21 days relative to feed than 
groups fed conventional corn supplemented with similar amounts of lysine (p=0.008; t-test). 
This result suggests that there may be an unexpected and unexplained negative factor acting on 
broilers fed GM LY038 that prevented them from reaching the same growth rates as broilers 
fed conventional corn.  
 
(2) We also were troubled by the apparent contamination of LY038 seed stock by MON810, a 
different transgenic line, as reported in this study (NZIGE submission 7.2.7). Individual PCR 
analysis found that up to 20.5% of LY038 seed carried the MON810 event, or that up to 20.5% 
of the seed was MON810. This was also confirmed using an immunological detection method. 
The mixture of lines complicates analysis because it dilutes LY038. 
 
This subject is also addressed in FSANZ answer to recommendation 10. 
 
INBI recommendations: 
R.74 The Authority should provide the results of blood tests and data on organ weights and 
visual observations.  
R.75 The Authority should seek a satisfactory re-evaluation of the effects on chicks in the 
first 21 days. 
R.76 The Authority, at the very least, should seek a feeding trial using LY038 rather than a 
mix of transgenic strains that dilutes LY038. 
R.77 We agree with the Authority that high-lysine corn is a significantly changed product. 
We therefore recommend that properly conducted feeding trials be made available for 
review by the Authority and, if possible, the public. These trials will use animals 
suitable for gauging food safety in humans (i.e., not chickens), possibly pigs, and will 
use cooked and processed whole foods. 
Reasons for special restrictions on any approval of LY038 in human food 
 
Should the Authority come to recommend that the Code be amended to include event LY038, 
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then it is our opinion that a special condition be imposed upon event LY038. In Column 2 of 
the Table to Clause 2 of Standard 1.5.2, LY038 but not any other members of the LY038 line 
currently in existence or that may arise through breeding, hybridization or transformation in the 
future may benefit from a favorable assessment of LY038. In other words, approval of LY038 
does not extend to other lines of maize that share parentage or the I-DNA with LY038.  
 
Our reasons have been catalogued in great detail above. In summary, they are: 
1. Hybrids that have levels of total and free lysine significantly outside expected ranges 
reported in A549 have already been created by the Applicant. 
2. There is plausible reason to suspect that hybrids may have lysine catabolic activities that 
differ from LY038, leading to unpredictable levels of free lysine and potentially toxic 
lysine catabolites in human food. 
3. There remains doubt from the molecular analysis that all insertions have been found in 
LY038. 
4. The residual loxP site in LY038 may still be active and processing in inadvertent 
hybrids formed with cre expressing lines could lead to significant genomic instability. 
 
INBI recommendations: 
R.78 One, possibly several, genes in LY038 are likely have been affected by the 
transformation process to explain accumulation of lysine in the seed. As recommended 
in CAC/GL 45-2003(33-D), the Authority should be able to explain how LY038 
accumulates these levels of free lysine in grain and demonstrate that the mechanism 
would be exactly the same in all hybrids. 
R.79 Should the Authority recommend an amendment to the Food Code, then the Authority 
should impose a condition in Column 2 of the Table to Clause 2 of Standard 1.5.2 that 
limits this approval to LY038 without extension to hybrid lines derived from LY038. 
All hybrids, whether between LY038 and an unmodified line or another approved 
modified line, must in this case be treated as a new organism requiring a full safety 
evaluation. If it cannot do this, then it should not recommend amendment of the Food 
Code. 
 
Reasons for post-market monitoring 
 
Current work within Codex Alimentarius suggests that post-market monitoring, particularly of 
nutritionally enhanced plants, is an area of heightened concern. 
 
INBI recommendations: 
R.80 We ask the Authority to detail its position with reference to developments at the 
international level. 
R.81 If the Authority has requested details from the Applicant on its post-market 
surveillance plans, we ask for these to be released and for the Authority to publish its 
evaluation. If the Authority has not requested these details, we recommend that they 
are requested now. If the Authority does not feel obliged to do so, we ask for an 
explanation as to why. 
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Part Three: Evaluation of the Impact Analysis, DAR 
 
We have appraised the DAR Impact Analysis and wish to draw attention to the statements 
detailed below. We also seek an explanation of FSANZ’s decision-making process in assessing 
the Impact Analysis and identifying a preferred Option. 
 
Option 1 
1. FSANZ has correctly identified the following benefit for consumers in Option 1: 
Consumers: Benefit to consumers if there is a public health and safety concern. 
We would like to highlight the significance of this benefit in light of the fact that an 
amendment to the Food Code would automatically allow the human consumption of future 
hybrids of LY038 with potentially higher levels of lysine. The documentation of this point is 
provided in section “Reasons for special restrictions on any approval of LY038 in human 
food”, in Part Two above. 
 
Due to possible increases in lysine from the hybridization of LY038 with other GM crops, 
LY038 hybrids should undergo separate safety assessment. However, FSANZ allows hybrids to 
be approved alongside their parental lines, without specific evaluation. 
 
The benefit to consumers in Option 1, therefore, also applies to future public health and safety 
concerns that may arise from the hybridization of LY038. If the Food Code cannot be amended 
to exclude LY038 hybrids, Option 1 must be used to avoid any problems that may arise from 
their consumption. 
 
INBI recommendation: 
R.82 FSANZ should reconsider its statement, made in relation to this hypothetical benefit to 
consumers noted above, that: "As food from LY038 corn has been found to be as safe 
as food from other varieties of corn, option 1 is likely to be inconsistent with Australia 
and New Zealand's WTO obligations." We have demonstrated that this is an 
unreasonable conclusion to draw, given the scientific concerns we have listed as well 
as the fact that Codex Alimentarius and WHO recommended practices, which are 
acceptable under WTO, would require more stringent scientific scrutiny. 
 
2. In its DAR, FSANZ has retained the following impact statements for Option 1:  
Government: Potential impact if considered inconsistent with WTO obligations but impact would be 
in terms of trade policy rather than in government revenue. 
 
Industry: Potential longer-term impact - any successful WTO challenge has the potential to impact 
adversely on food industry. 
 
In line with FSANZ’s request for public comment “[t]o further develop the analysis of the costs 
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and benefits of the regulatory options proposed” (IAR p. 13), INBI questioned the 
appropriateness of the weight given by FSANZ to these hypothetical WTO challenges. FSANZ 
has not responded to this point. 
 
We restate, if the argument here is that any refusal to allow a product into the food supply 
should be considered a cost because someone might consider it inconsistent with WTO 
obligations, this should be made explicit and subjected to public scrutiny. We note that a 
significant proportion (two out of three) of the impacts considered in the analysis of Option 1 
relate to putative WTO concerns. 
 
INBI recommendations: 
R.83 The Authority states that “Government: Potential impact if considered inconsistent 
with WTO obligations but impact would be in terms of trade policy rather than in 
government revenue” and “Industry: Potential longer-term impact - any successful 
WTO challenge has the potential to impact adversely on food industry”. It should 
clarify the weighting given to WTO considerations and the relative cost attributed to 
this in the draft decision. 
Option 2 
1. FSANZ has retained the following impact statement for Option 2: 
Consumers: The amount of LY038 corn entering the food supply is likely to be low so the cost to 
consumers wishing to avoid GM food by a potential restriction of choice of products, or increased 
prices for non-GM food is likely to be low. 
In determining consumer impacts, FSANZ makes assumptions about the marketing of LY038 
that overlook some significant possibilities, both deliberate and inadvertent, for its entry into 
the food supply. 
 
This statement rests on the Applicant’s declared current intention to import LY038 only as 
animal feed. However, the proposed amendment to the Code will approve LY038 for human 
consumption. We reaffirm our position that any decision that is premised on a mere intention, 
which will not be secured by the regulation itself, is not appropriate or acceptable regulatory 
practice. 
 
We also note a number of reasons why the Authority’s unqualified assertion that approval will 
not impose significant costs on consumers wishing to avoid GM products does not adequately 
consider realistic post-approval scenarios:  
 
(i) It may be more profitable to permit commingling of LY038 with other food corn than to 
bear the costs of strict segregation. (The Applicant has already shown that contamination can 
occur even before commercial release, in the case of MON810 and LY038 [sections 7.2.7 and 
9.9.3 of our previous submission]). We maintain there will be little incentive to minimize food 
contamination if LY038 is approved in human food. 
 
(ii) FSANZ is confusing feed prices with food prices in its response to recommendation 18 (see 
Part One). It may well be profitable to sell LY038 as premium-priced stockfeed and as food. 
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(iii) The response also ignores the possibility that the Applicant in future will decide to market 
LY038 as (possibly “functional” or “fortified”) food, as lysine also plays an important role in 
human nutrition. We note that the introduction of the proposed new standard for health, 
nutrition and related claims would make this possible in principle. 
 
(iv) The fact that in some of these scenarios LY038 would be labeled as GM does not 
necessarily make it easy to avoid. This will depend on how prevalent LY038 and other GM 
corn varieties become in the food products that are available to consumers, and the proportions 
in which it occurs in food products. We note that in the DAR for P293 (on health, nutrition and 
related claims) FSANZ exempts gluten from some of its provisions in order that its regulatory 
action should not constrict access to suitable food products by consumers (such as coeliacs) 
needing to avoid ingredients (such as gluten), “because consumers who rely on these products 
should be able to choose from a full range of suitable products (based on the need to avoid 
undesirable reactions to chemical sensitivities)”; such impacts should also be taken into account 
when approving foods, particularly when there is no countervailing benefit to other consumers 
(see section 9.9.4, reproduced below). 
 
(v) The Authority’s argument that LY038 will be unattractive to the food industry does not take 
into account the parallel approval of LY038 hybrids that may have more appealing qualities to 
manufacturers. These hybrids may become more prevalent in the food supply than FSANZ has 
forecast for LY038 alone. FSANZ continues to base its analysis on the intention to sell LY038 
as animal feed without noting that a hybrid may be more suitable as a food ingredient, which 
will increase the cost to consumers who wish to avoid it. 
 
If, as FSANZ indicates, it is the impact of the approval (in this case, permitting the sale of 
LY038 as food) that is being assessed rather than the current, declared intention of the 
Applicant, it has not yet provided reasoning or evidence to support its views that little LY038 
corn will enter the food supply and that costs to consumers wishing to avoid LY038 corn in 
particular or GM corn in general will be low. We have shown that there are a number of 
plausible pathways, both deliberate and inadvertent, through which significant amounts of 
LY038 may enter the food supply. 
 
FSANZ has not addressed the contamination and consumer-impact concerns that INBI raised in 
its submission. Accordingly, we ask FSANZ to address our previous submission points 9.9.3. to 
9.9.4, which we reproduce here: 
 
9.9.3. In their discussion of the Broiler Growth Trial (MSL-18883), the Applicant revealed that their 
LY038 stocks were contaminated with MON810 (see section 7). This case demonstrates that 
even the seed producer has difficulty maintaining separate stocks and suggests that the 
measures used by the Applicant are less reliable than claimed, or that the cost of monitoring 
to achieve reliable segregation is prohibitively high. Given that the Applicant has not 
prevented the substantial contamination of its seed stock, FSANZ should scrutinize the 
claim that LY038 will only infrequently and at low quantities contaminate human food 
supplies.  
9.9.3.1 Should FSANZ recommend amending the Code for the event in LY038, then it is critical 
that threshold criteria be established in Column 2 of the Table to Clause 2 of Standard 
1.5.2 indicating below which levels and frequency of contamination, and range of 
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contaminated products, LY038 events would be seen as inadvertently contaminating 
the human food supply and what the consequences would be for contamination above 
these thresholds.  
9.9.4. The increasing incidence of coeliac disease among Australian and New Zealand consumers 
suggests a potentially serious impact of the introduction of LY038 into the food supply. 
Coeliacs are allergic to specific wheat, barley, rye and oat proteins; corn is one of the few 
remaining staple grains they are able to eat. Should coeliacs develop an allergic response to 
LY038, even its adventitious presence in the food supply will have serious consequences for 
them. Incidence of the disease is estimated at 1:300 (Kennedy and Feighery 2000). Studies 
in Australia and New Zealand have confirmed equal or greater rates in local populations 
(e.g. Hovell, et al. 2001, Cook 2004). A thirty-year study of diagnoses in the Canterbury 
region found rising rates of the disease among both adults and children over that period. 
Adult prevalence is noted as 1:83 in the Christchurch area (Cook 2004). The special dietary 
requirements of this large section of the population reaffirm the importance of carefully 
screening the introduction of new ingredients to the food supply. The range of products 
identified by the Applicant as vulnerable to contamination further argues against the 
estimation of a “low” impact on consumers wishing to avoid GM food. The possibility that 
the proposed amendment may result in the elimination of more foods from coeliacs’ already 
strict eating plan should be considered a significant cost.  
9.9.5. The statement implies that those wishing not to consume LY038 will bear the cost of avoiding 
LY038. There are three difficulties with this suggestion.  
9.9.5.1 First, only if the Code were amended to permit LY038 would it become the burden of the 
citizen to pay to avoid LY038. The status quo places the burden on those who benefit 
from the sale of the product. Thus, opting for Option 2 has a guaranteed impact on the 
citizen regardless of whether there is financial cost; Option 2 creates a new imbalance 
of power between consumer and producer.  
9.9.5.2 Second, the cost of demonstrating that a product is LY038-free will be just as high 
whether LY038 is a rare or a frequent contaminant of other corn-derived products. 
The testing is not simpler nor is it necessarily less rigorous or frequent. It will have to 
be conducted continually without certain knowledge of when or where the 
contamination will occur. Evidence should be provided for the assertion that the cost 
of avoiding LY038 will be low. Our internationally peer-reviewed work on 
monitoring does not lead us to this conclusion (Heinemann, et al. 2004).  
9.9.5.3 Third, since the Applicant’s case is that LY038 will only rarely contaminate corn intended 
for human consumption, the cost of that assurance ought to be borne by the Applicant 
and/or others who benefit financially from the production of LY038, as is the case 
under Option 1. Thus, we think FSANZ has inappropriately underestimated the 
impact on the consumer of opting for Option 2. 
 
INBI recommendations: 
R.84 FSANZ should reconsider its Impact Analysis and its decision from the perspective of 
the full range of eventualities its decision makes possible, in particular the various 
ways in which LY038 may inadvertently or deliberately be introduced into the food 
supply as well as the issues of prevalence, hybrids, dietary restrictions, and 
distribution of costs and benefits that we have noted.  
  
2. FSANZ has retained the following impact statements for Option 2:  
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Government: This decision may impact on monitoring resources as some foods derived from corn 
line LY038 will be required to be labelled as genetically modified and as having increased lysine 
levels. 
Industry: Possible cost to food industry as some foods derived from corn line LY038 will be required 
to be labelled as genetically modified and as having increased lysine levels. 
In the interests of achieving its objectives and guidelines, FSANZ should be concerned with the 
capacity of government monitoring resources to administer its food standards. If FSANZ is to 
support Option 2, it should provide evidence that monitoring cost to government will be low. 
 
The need for a careful appraisal of monitoring and labelling costs comes from the fact that they 
are immediate and certain, rather than speculative, impacts of the proposed amendment to the 
food code. The implications should therefore be carefully detailed, showing the extent to which 
the introduction of LY038 might impact already stressed resources with unique monitoring 
requirements to be applied to the full range of products that may be affected. The list is 
extensive, and it is reasonable to expect a significant impact on monitoring resources. 
Similarly, the costs of labelling will certainly impact upon the food industry.  
 
Monitoring costs, both to industry and to government, are more than just possibilities. In order 
for this issue to be carefully considered, it is reasonable to ask for supporting information from 
FSANZ. Without such information, it is difficult to see how the Impact Analysis can be 
properly assessed. 
 
INBI recommendations: 
R.85 We ask FSANZ to clarify: in its decision-making, is it considering potential cost to 
government, or not?  And if so,  
 how can it assign weight to monetary costs without attempting to quantify 
them? And 
 does it give equal consideration to costs of each option (approval and non-
approval), e.g., to the (certain) costs of monitoring as much as to the 
(speculative) costs of responding to illegal contamination? 
R.86 If FSANZ is not considering potential cost to government, we ask that it explain the 
reasoning behind including the Impact Statement relating to government monitoring 
resources. If FSANZ is considering potential cost to government (as indicated by a 
number of statements in the DAR), we ask again that it provide evidence that the cost 
to government of monitoring for the presence of LY038 in food will be low. 
R.87 In line with INBI’s previous submission, FSANZ should also provide evidence that 
the monitoring and labelling cost to industry will be low. 
R.88 Should FSANZ recommend amending the Code for the event in LY038, then we 
recommend that threshold criteria be established in Column 2 of the Table to Clause 2 
of Standard 1.5.2 indicating below which levels and frequency of contamination, and 
range of contaminated products, LY038 events would be seen as inadvertently 
contaminating the human food supply and what the consequences would be for 
contamination above these thresholds. 
R.89 Should FSANZ recommend amending the Code for the event in LY038, then we 
recommend that only certain existing varieties and hybrids be allowed (those that have 
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met stringent testing as described above and in our first submission) and not extend to 
other varieties with the same event. 
 
3. We note that in the DAR the only potential benefit listed for Option 2 is:  
Government: Benefit that if LY038 corn were to inadvertently enter the human food supply, this 
Application will ensure food imports containing LY038 corn comply with the Code. This would 
ensure that there is no potential for trade disruption on regulatory grounds. 
We note that this is identical to a statement in the IAR, except that the phrase “any corn imports 
from the United States” is replaced with the phrase “food imports containing LY038 corn”. 
This does not address a point raised in our submission (section 9.10), which we re-present in 
slightly abbreviated form here: 
9.10.1. We find this statement…inconsistent with the Authority's three primary objectives: to protect 
the public's health and safety; to provide adequate information relating to food to enable 
consumers to make informed choices; and to prevent misleading or deceptive conduct.  
9.10.1.1 To regard as a benefit the facilitation (through removal of disincentives) of adventitious 
contamination of the food supply with (GM) animal feed cannot be regarded as 
protective of the public's health and safety, either in itself or through the precedent it 
sets.  
9.10.1.2 “Ensur[ing] that there is no potential for trade disruption” requires measures that will 
simultaneously ensure that the public will not be provided with the information they 
need in order to make informed choices regarding LY038-contaminated food, as they 
will not be made aware of the presence of the contaminant (and at the same time, as 
we noted above, the proposed change to the Code makes such contamination more 
likely).  
9.10.1.3 Increasing the likelihood that the public remains unaware of instances of adventitious 
contamination of the food supply (i.e., by removing the regulatory and trade 
dimensions that might draw attention to it) could facilitate misleading and deceptive 
conduct by the food industry, particularly by those who export to us.  
 
The fact that this is the only benefit associated with the Authority's preferred Option suggests 
that FSANZ gives special weight to this consideration. This must be clarified, and weightings 
made explicit, so that the Impact Analysis is sufficiently transparent for public scrutiny. 
Transparency of the process used to derive a decision from the Impact 
Analysis 
 
INBI provided a comprehensive response to FSANZ’s Impact Analysis, in line with FSANZ’s 
request for public comment “[t]o further develop the analysis of the costs and benefits of the 
regulatory options proposed” (Initial Assessment Report p. 13). 
 
We note that while the content of the Impact Analysis has changed markedly since the IAR, 
specifically with the removal of most of the benefits of Option 2 and most of the costs of 
Option 1, the conclusion derived from that analysis has not.  We wonder how it was possible, 
based on the Impact Analysis, to conclude that the amendment to the Code is “of net benefit to 
both food producers and consumers” (p 7; also p 17). Of what do these benefits consist? No 
benefits are cited for industry or consumers. 
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We ask FSANZ to detail the process it used to weigh and evaluate potential impacts to form its 
decision. There has been no detail of a quantitative or qualitative comparison of the relative 
magnitude of the costs and benefits it has identified. There has also been no account of an 
analysis of the absolute magnitude of costs and benefits. The public cannot know how various 
costs and benefits, diverse in nature, have been integrated into FSANZ's decision. Without 
these details, one cannot conclude that the community has been properly consulted. We do not 
see its explanation in 7.2.3 of the DAR as sufficient. It does not mention several key impacts 
from the Analysis in its summary, so the public cannot know if they were considered.  
 
The explanation also does not appear to link to any of FSANZ’s three primary objectives. Are 
statements assigned more weight if they are related to FSANZ’s primary objectives, as opposed 
to those related to its secondary guidelines? Is a certain benefit/cost more significant than a 
possible benefit/cost? 
 
A proper explanation of FSANZ’s decision-making process, which explains both how different 
factors have been weighted and how public input has been taken into account, is a crucial 
element of public consultation, without which it is not possible to maintain public confidence in 
the food supply and its regulation. 
 
INBI recommendations: 
R.90 FSANZ should explain how it derived a conclusion of “net benefit to food producers 
and consumers” from the analysis presented. 
R.91 In light of the Authority’s commitment to “increased accountability and transparency 
in decision making” (Australia New Zealand Food Authority, 2001), FSANZ should 
explicate for the public the process it uses to move from impact analysis to preferred 
option, including an explanation of how various factors have been weighted and how 
public input has been taken into account. 
 
Summary of discussion on Impact 
 
We have challenged the reasoning behind the two potential costs cited under Option 1, and 
strongly question the benefit cited for Option 2. That impact statement—approving LY038 so 
that inadvertent contamination in the future will be legal (the only remaining benefit identified 
for Option 2)—is an extremely weak support for FSANZ’s preliminary decision. It is not a 
positive benefit, and may be at the expense of meeting FSANZ’s primary obligations. 
 
Moreover, it may be offset by the costs to government (also noted in the Impact Analysis) of 
increased monitoring to ensure that labeling requirements (FSANZ’s primary objective 2) are 
met. The two costs cited for Option 2 (related to government and industry monitoring and 
labelling resources) are not merely ‘potential’ costs but are immediate and certain, and should 
be weighed accordingly in FSANZ’s decision-making process. 
 
It is claimed that Option 2 will have no direct impact on consumers, as “[t]he amount of LY038 
corn entering the food supply is likely to be low so the cost to consumers wishing to avoid GM 
food by a potential restriction of choice of products, or increased prices for non-GM food is 
82 
likely to be low.”  
 
We have demonstrated the inappropriateness and invalidity of this claim. There is, in fact, no 
reason to assume that costs to consumers will be low. 
 
Thus, there are costs but no benefits for consumers; costs (labelling) but no benefits for 
industry; and real costs as well as questionable benefits to government. 
 
In contrast, the benefit to consumers cited for Option 1 is particularly significant, as an 
amendment to the Food Code will also approve LY038 hybrids with potentially higher levels of 
lysine that have not undergone separate safety assessment. 
 
Accordingly, we ask FSANZ for more evidence and information to explain its decision to 
support Option 2. 
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Part Four: The consultation process 
 
This section discusses significant issues raised in the consultation process that INBI would like 
to have addressed. 
 
The structure of this submission 
 
FSANZ addressed INBI’s previous submission (February 2005) by responding to each of the 
20 recommendations we made. We were not aware that only our recommendations would be 
addressed in the DAR. In composing our submission, we raised significant points without 
corresponding recommendations. Accordingly, some points that we feel were overlooked by 
FSANZ are repeated in this submission. 
 
Applying this submission to related cases 
 
FSANZ initial Impact Analysis included four statements that have since been withdrawn 
following public comment. These statements were questioned because they seemed to result 
from FSANZ misreading its own mandate. Several of these statements acknowledged potential 
price impacts for GM producers, without the corresponding impacts for non-GM farmers and 
food producers seeking to access non-GM feed or ingredients (see NZIGE submission 9.3.4; 
9.4.2 and 9.12.3). 
 
The fact that public submissions were required to raise these problems highlights the crucial 
role of public consultation in FSANZ assessment, and potential predispositions inherent in 
FSANZ and its sources in compiling Impact Analyses (which are “based on information 
supplied by the Applicant and experience FSANZ has gained from consideration of previous 
applications relating to GM foods”). 
 
The submission process is an accepted way for the public to review FSANZ’s assessments. 
However, because of the time and effort involved in putting together comprehensive and 
detailed submissions, it is not possible for individuals and groups to have input into the number 
of assessments that they might like. It is then up to FSANZ to apply public comments from 
previous assessments to related cases. 
 
In line with good public consultation practices, the points raised in this submission process 
should be considered by FSANZ in assessing current and future applications. 
 
Process of assessing applications and submissions 
 
FSANZ sent INBI’s submission (as NZIGE) on the IAR for A549 to an external reviewer and 
the Applicant itself for comment; however, INBI was not contacted to reply to these comments. 
As a result, we must use this submission to respond to issues raised in the evaluation process of 
our previous submission. 
 
We were never invited to respond or participate in the evaluation of our submission at any time, 
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yet we donated an enormous amount of time and expertise to preparing a document of use to 
FSANZ. When individuals and groups invest time and energy into participating in FSANZ 
decision-making processes, it is important to ensure that the evaluation of their submissions is 
transparent. We have several concerns about FSANZ’s selection of an external reviewer, Dr. 
Rudi Appels, for our submission, and the use of his comments. 
 
The selection of independent reviewers 
 
We have been assured by FSANZ that it has the expertise to evaluate the LY038 application. 
However, in that case, we wonder why an independent expert was contracted to review aspects 
of our submission. Surely the expertise required to evaluate those aspects of our submission 
was similar to that required to evaluate the original application. We would like to know if 
FSANZ similarly contracted an independent expert to review the application itself. 
 
We would like information on how FSANZ came to choose Dr. Appels to provide it with an 
opinion of our submission, and how, in general, it sets criteria for choosing scientific advice 
and identifying scientific advisors. How was the independent reviewer selected? What 
constitutes “independence” in these circumstances? 
 
INBI has no financial interest in the development or prohibition of biotechnologies, making it 
an ideal independent reviewer for the LY038 application, and FSANZ’s assessment. 
 
The use of the reviewer’s comments 
 
INBI’s submission to the IAR was composed with reference to FSANZ’s request that it 
“address the objectives of FSANZ as set out in section 10 of the FSANZ Act”, with 
“[c]laims…supported wherever possible by referencing or including relevant studies, research 
findings, trials, surveys etc.” (IAR, p. 3). 
 
The review of our submission was much less detailed and much less well substantiated. Logic 
and good judgement would seem to dictate that if the conclusions of the review of the 
submission are to be preferred to those of the submission itself, the review must be at least as 
well substantiated as the submission. 
 
INBI recommendations: 
R.92 The Authority should clarify whether it contracted external parties to review A549. 
R.93 FSANZ should explain the process it used to identify an independent reviewer for 
INBI’s IAR submission, including the criteria it used to determine the reviewer’s 
independence. 
R.94 In considering the comments of the independent reviewer, FSANZ should take into 
account the fact that the reviewer’s conclusions were based on differences of 
judgment, rather than findings of scientific error. 
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Final Remarks 
 
In the DAR (p. 7), the Authority says that “[a]n amendment to Standard 1.5.2 of the Code to 
give approval to the sale and use of food derived from corn line LY038 in Australia and New 
Zealand is recommended on the basis of the available scientific evidence for the following 
reasons: 
 the safety assessment did not identify any public health and safety concerns associated 
with the genetic modification used to produce corn line LY038.” 
 
(1) The “available scientific evidence” was however compromised as a result of FSANZ’s 
failure to require compositional and animal feeding studies using whole food derived from 
LY038 cooked and processed in ways relevant to human food. In our view, the Authority has 
not engaged in a level of risk characterization that is required for this crop. 
 
(2) The Codex Alimentarius Commission defines hazard identification and characterization as 
an integral part of a risk assessment51. Hazard identification is “[t]he identification of 
biological, chemical, and physical agents capable of causing adverse health effects and which 
may be present in a particular food or group of foods.” The Authority has not reviewed a 
scientific description that would serve to reveal unintended hazards because it has only 
reviewed studies that had flawed controls, notably: 
? key molecular analyses have internal contradictions, do not report their level of detection, 
and are not comprehensive for comparisons using the parental non-GMO control. 
? the compositional analysis does not use the proper parental non-GMO control. 
? only one of the two novel protein species produced in-planta were characterized. 
? the bioinformatics analysis for allergens used the wrong amino acid sequence. 
 
(3) CAC defines hazard characterization as “[t]he qualitative and/or quantitative evaluation of 
the nature of the adverse health effects associated with biological, chemical and physical agents 
which may be present in food…For biological or physical agents, a dose-response assessment 
should be performed if the data are obtainable.” 
 
(4) The Authority has not indicated that it has reviewed compositional, toxicological or anti-
nutritional studies using LY038 whole food prepared as people would consume it. In the case of 
high-lysine corn, key hazards would only become apparent after cooking and processing. Thus, 
the Authority has not completed a proper hazard characterization because there was no: 
? compositional analysis of processed and cooked food 
? quantification of AGEs, which are anticipated products. 
? explanation for the growth inhibition of young broilers. 
? animal feeding studies using cooked and processed whole food. 
? pepsin resistance study at FAO/WHO standard. 
 
                                                 
51 Joint FAO/WHO Food Standards Programme. Codex Alimentarius Commission. Procedural Manual. 12th ed. 
Rome: Food and Agriculture Organization of the United Nations : World Health Organization, 2001. Available 
online http://www.fao.org/DOCREP/005/Y2200E/y2200e00.htm. Access date 31 May 2006. 
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(5) A final and robust risk characterization—“[t]he qualitative and/or quantitative estimation, 
including attendant uncertainties, of the probability of occurrence and severity of known or 
potential adverse health effects in a given population based on hazard identification, hazard 
characterization and exposure assessment”—thus cannot be arrived at until the problems in 
hazard identification and characterization are corrected. 
 
The Authority says that: 
 “in terms of its safety for human consumption and nutritional adequacy, food derived 
from corn line LY038 is equivalent to food from other commercially available corn 
varieties. The only difference is the increase in lysine.” 
 
This is clearly incorrect. Lysine, free lysine, saccharopine, α-aminoadipic acid, pipecolic acid, 
and possibly cadaverine were all increased well beyond the control. The Authority has not 
presented total pipecolic acid levels, only L-pipecolic acid. Free lysine and saccharopine were 
well outside all historical and literature ranges for conventional corn. 
 
The Authority says that: 
 “a regulation impact assessment process has been undertaken that also fulfils the 
requirement in New Zealand for an assessment of compliance costs. The assessment 
concluded that the amendment to the Code is of net benefit to both food producers and 
consumers.” 
 
No benefits are cited for industry or consumers. The only benefit cited by FSANZ is for 
government, in that an approval for LY038 will ensure that inadvertent contamination in the 
future is legal. This is an extremely weak support for FSANZ’s preliminary decision. It is not a 
positive benefit, and may be at the expense of meeting FSANZ’s primary obligations. 
 
The Authority says that: 
 “the proposed draft variation to Standard 1.5.2 of the Code is consistent with the section 
10 objectives of the FSANZ Act and the regulatory impact assessment.” 
 
 (1) Section 10.1 of the FSANZ Act lists the Authority’s objectives as: 
(1) The objectives (in descending priority order) of the Authority in developing or reviewing food 
regulatory measures and variations of food regulatory measures are: 
(a) the protection of public health and safety; and 
(b) the provision of adequate information relating to food to enable consumers to make 
informed choices; and 
(c) the prevention of misleading or deceptive conduct. 
In our view, the risk assessment conducted by the Authority fails to achieve a high standard of 
confidence in the protection of public health and safety because the Authority did not— 
? require all scientific studies to be at the highest legitimate CAC standard; 
? enforce the use of parental conventional varieties as controls in the molecular, 
compositional and feeding studies; and 
? has provided no evidence of evaluating LY038 as a human food. 
 
(2) The last point in particular may be reason to consider that the Authority has not met the 
second objective of providing adequate information to consumers. Without reporting the actual 
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AGE content in cooked and processed food derived from LY038, consumers could not make 
informed decisions. 
 
In ANZFA’s Standards Decision Making Framework, A Report to ANZFSC (p. 7)52, the 
Authority says that:  
 “The basis for permitting substances with no prior history of safe use is that: the relevant 
and appropriate scientific data indicate that the foods are as safe as their conventional 
counterparts when present in food.” It also states that it compares conventional crops of 
the same type grown under the same conditions.  
 
However, in this case the Applicant used a genetically modified variety LY038(-) as the control 
in the compositional studies and in some key molecular studies, and the Authority used lentils, 
red meat, eggs, fish, broccoli and mushrooms as comparators for lysine and lysine catabolites. 
 
Finally, under section 10.2.a of the Act, the Authority has a statutory obligation to: 
 “have regard to…the need for standards to be based on the risk analysis using the best 
available scientific evidence”.   
 
This submission has demonstrated that in a number of instances, the Authority has not made 
use of the best available scientific evidence in undertaking its risk assessment and has thus 
failed to meet a key requirement of the Act. 
                                                 
52 http://www.foodstandards.gov.au/_srcfiles/Report_to_ANZFSC.pdf. Access date 31 May 2006. 
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Appendix: Summary of Recommendations 
 
R.1 The Authority should report the DNA sequence of the Glb1 promoter in event LY038. 
Since the Applicant claims that it is the endogenous corn promoter, the actual 
sequence should not be a commercial secret. 
R.2 The Authority should report the true breeding history for both LY038 and LY038(-) 
that includes the precise point at which the two lines segregate. From this history, the 
Authority should evaluate whether there is certain evidence that LY038 is more 
closely related to LY038(-) than to H99. 
R.3 The Authority is requested to have the anomalous result in figure 6 of MSL-19871 
explained, or have the analysis re-done, before accepting this as evidence of either a 
single insertion in LY038 or the absence of insertions in LY038(-). 
R.4 Consistent with CAC/GL 45-2003, “the sensitivity of all analytical methods should be 
documented.” Therefore, the Authority should report the minimum size of target DNA 
that all probes could detect at a minimum stringency of 0.5 copies per genome. 
R.5 We recommend that the Authority require a range of analytical methods that includes 
a combination of FISH, fiber-FISH and Southern analysis. 
R.6 The issue of background hybridization could be fully proved by sequencing the light 
bands visible in the Southern blots. The Authority should therefore base their final 
conclusion on the results of sequencing. 
R.7 The Authority should clarify whether additional insertions are present in LY038 by 
requiring additional studies on the high molecular weight fragments in MSL-19871. 
R.8 The Authority should explain how it has confidence that the experimental procedures 
used by the Applicant would have detected an insert the size of the loxP site in an 
unknown location at 0.5 copies per genome. 
R.9 The Authority should verify that the residual loxP site in LY038 is not processed by 
the cre recombinase.  
R.10 The Authority should provide evidence that all novel RNA species have been 
identified, characterized and tested for food safety. 
R.11 We recommend that the Authority require a complete microarray description of the 
LY038 transcriptome, compared to the unmodified control, for proper hazard 
identification.  
R.12 The Authority should require the Applicant to report on results of microarray analyses 
using the mouse genome and RNA extracts from the intestinal cells of mice fed 
LY038. 
R.13 While the Applicant continues to rely upon unvalidated methods (e.g. bioinformatics 
as described above) for hazard identification, the Authority should make the insertion 
and flanking sequences publicly available for evaluation by those who may then bring 
more relevant analyses to bear. 
R.14 The Authority should report not just total lysine content of foods, but free lysine 
content of foods and provide comparisons with conventional corn, especially H99. The 
Authority should also consider the ratio of carbohydrate to free lysine. 
R.15 The Authority should provide the people of Australia and New Zealand with reliable 
data demonstrating that processing and cooking temperatures normal to products that 
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could contain this corn are as safe as products derived from conventional corn, 
particularly the parental varieties of LY038. 
R.16 The Authority should request an analysis of all novel AGE content or AGE 
concentrations, including Maillard reaction products and glycotoxins, that could arise 
from cooking, storage or processing of LY038 corn compared to parental varieties. 
R.17 The Authority should justify its conclusion that lysine levels in a genetically modified 
variety of corn can be considered safe by comparison to lysine levels in unrelated food 
sources, such as red meat, chicken, eggs, cheese, broccoli, lentils and fish. 
R.18 The Authority should require that the Applicant supplement application A549 with a 
complete set of long-term, chronic, sub-chronic and acute toxicity feeding studies and 
allergenicity studies using cooked products derived from LY038, and compared to the 
parental varieties. 
R.19 The Applicant should conduct dietary AGE mouse feeding studies equivalent to those 
reported by Peppa et al. (Peppa et al., 2003b). 
R.20 The Authority should justify its claim with reference to recommendations of 
international food safety agencies that for LY038, with its significantly different 
nutritional profile, additional feeding studies are not required. 
R.21 The Authority should explain why it has accepted comparisons between LY038 and 
another product of gene technology with no history of safe use, LY038(-), rather than 
the CAC recommended standard of a comparison to conventional parental varieties. 
R.22 The Authority should explain why LY038(-) was used as a control instead of the more 
closely related conventional variety, and parent, H99. 
R.23 If the Authority accepts LY038(-) as a control, then it should explain how it verified 
the absence of small inserts in LY038(-) with experiments that would detect the 34 bp 
loxP sequence at 0.5 copies per genome. 
R.24 The Authority should provide a statistical analysis of the reference ranges per site. 
R.25 The Authority should base its recommendation to amend the Food Code based on a 
proper comparison between LY038 and its parental varieties H99, Inbred A, B, and C 
grown under identical conditions in at least five test sites repeated in at least two 
growing seasons. 
R.26 If the Authority is satisfied with the existing compositional data, we then ask it to 
indicate how it determined the values provided by the Applicant were as scientifically 
sound as those used in international guidelines. 
R.27 The Authority should evaluate the use of other novel foods as comparators in safety 
assessments and determine how long a novel food must be used safely before it is 
considered having a “history of safe use.” 
R.28 The Authority should require the proximate analysis of maize starch, grits and flour 
derived from LY038. 
R.29 The Authority should justify its conclusion that lysine catabolite levels in a genetically 
modified variety of corn can be considered safe by comparison to lysine levels in 
unrelated food sources. 
R.30 The Authority should provide quantitative evidence of cadaverine levels in LY038, 
perhaps by requiring NMR combined with chemometrics and univariant statistics to 
achieve more sensitive detection. If it does not, then the Authority should require 
feeding studies using LY038 cooked and processed as normal for human food to 
assess the potential for cadaverine at elevated levels in corn to produce food hazards. 
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R.31 The Authority should assess the sensitivity of those on monoamine oxidase inhibitors 
to measured levels of cadaverine in a diet composed of LY038 corn. 
R.32 The Authority should report total pipecolic acid levels in LY038 and not just L-
pipecolic acid levels. 
R.33 The Authority should assess the contribution the intestinal flora will make to pipecolic 
acid levels in consumers who eat corn with high levels of lysine, free lysine and 
pipecolic acid. 
R.34 The Authority should explain how it has considered the impact of pipecolic acid in 
high lysine corn on those suffering from chronic hepatic encephalopathy. 
R.35 The Applicant has reported absolute amounts (by weight) of the amino acids in its 
most recent study (MSL-18881) but the Authority has accepted the statistical analysis 
based on %AA. The Authority should present the statistical analysis based on absolute 
amounts by weight. 
R.36 The Authority should provide evidence that hybrids with the LY038 event have the 
same absolute amounts of glutamate, free lysine, saccharopine and α-aminoadipic acid 
as LY038 to assure the Authority that LY038 has no physiological behaviours that are 
unique to its genetic background with regard to lysine catabolism in seed. 
R.37 The Authority should address the difference in expected ranges of total and free lysine 
(as reported in A549) and the higher values already known to exist in hybrids created 
by the Applicant by explaining how it has determined what absolute levels of these 
compounds in corn could be a cause for concern. 
R.38 The Authority should provide evidence that LY038 and any hybrids with the LY038 
event have the same absolute amounts of SAM and spermidine, and report on feeding 
studies using LY038 corn prepared as per normal for human consumption to assure the 
Authority that LY038 has no physiological behaviours that are unique to its genetic 
background with regard to lysine catabolism in seed. 
R.39 The Authority should report on the characterization of the 35kDa bands found in 
preparations of cDHDPS produced in-planta. 
R.40 The 34 and 35kDa forms should be demonstrated to be free of all post translational 
modifications, not just the addition of sugars. 
R.41 The 34 and 35kDa forms should be used in allergenicity and toxicity studies. 
R.42 The Authority should be able to confirm the existence of molecular data to 
demonstrate that the modification made to the amino acid sequence, in this case amino 
acid 266, does not affect its post-translational modification or range of biochemical 
functions. 
R.43    We recommend that the Authority require a complete proteomic analysis of LY038 
grain using 2D gel electrophoresis and MS and an account of all changes between 
LY038 and its non-modified parent. The Applicant has demonstrated in a recent series 
of publications that it has the technology to do such profiling (e.g. Monsanto studies 
Ruebelt et al., 2006a, Ruebelt et al., 2006b). Each change should be identified as 
either a variant of cDHDPS or an unintended change in the modified plant. All variant 
forms of cDHDPS should be characterized for glycosylation or other post-
translational modifications (5.3.17). 
R.44 The Authority should know and report the detection level of the Western blots, and 
justify those detection levels if they are above the fmol range (Küster et al., 2001). 
R.45 The Authority should indicate how it has eliminated the possibility of post-
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translational modifications with molecules other than sugar. 
R.46 All previously un-notified changes in the protein profile of the plant compared to its 
non-modified parent should then be analysed for potential harmful affects on 
consumers. 
R.47 The Authority should verify and then report whether the antiserum used for protein 
isolation was raised against E. coli-produced cDHDPS, C. glutamicum DHDPS, or in 
planta-produced cDHDPS (5.3.6.9). If the antiserum was not raised against the latter, 
then the Authority must confirm that the antisera will detect all in planta-produced 
isoforms detected by 2D gel electrophoresis and MS. 
R.48 The Authority should confirm whether the antiserum was affinity purified and 
comment on how the purification might bias the reported results. 
R.49 The Authority should report how many exposures and how frequently goats were 
exposed to the antigen(s) and the antibody classes of the serum. 
R.50 The Authority should report whether the antiserum affinity purified. If yes, the 
Applicant may have lost any antibodies that would bind to antigens unique to in 
planta-produced cDHDPS.  
R.51 The Authority should address the possibility that other classes of antibodies could 
have masked epitopes from those classes used in the detection assay. 
R.52 The Authority should confirm that the antiserum was raised to in planta-produced 
protein(s) rather than raised against E. coli-produced cDHDPS or C. glutamicum-
produced cDHDPS. 
R.53 The Authority should confirm that the goat anti-cDHDPS antiserum used is not 
affected by post-translational modification of cDHDPS, for example glycosylation, by 
demonstrating that the antisera will detect all in planta-produced isoforms detected by 
2D gel electrophoresis and MS. 
R.54 The Authority should provide evidence that cDHDPS has no more propensity to form 
toxic aggregates when produced in planta than mDHDPS produced in planta. 
R.55 The Authority should provide evidence that proteins in the chloroplast of corn cells do 
not survive through digestion in humans, or cannot be taken up by gut cells. 
R.56 The Authority should provide evidence that all recombinant forms of cDHDPS are 
exclusively located in the chloroplast and not found in the ER, golgi or cytoplasm of 
plant cells at some concentration. If they are, then the Authority should provide 
reliable evidence that these forms do not survive through digestion in humans, or 
cannot be taken up by gut cells. 
R.57 The Authority should provide evidence that transgenic cDHDPS aggregates do not 
form in the plant chloroplast or during cooking/processing of the whole food derived 
from the modified plant. 
R.58 If aggregates are detected, they Authority should provide evidence for their safety 
using established tissue culture assays for cytotoxicity and animal feeding studies. 
R.59 The Authority should justify how it can assume the history of safe use of cDHDPS 
based on an extrapolation from the mDHDPS structure when there are profound 
differences in structure. 
R.60 The Authority should justify how it can assume the history of safe use of cDHDPS 
based on historical human consumption of natural cDHDPS. 
R.61 Should the Authority recommend amendment of the Food Code to allow LY038, then 
it should impose quantitative restrictions on the levels of LY038 that may enter the 
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human food supply to ensure that Applicant intentions are translated into responsible 
achievements should this material be approved for human food. 
R.62 The Authority should require a feeding study that meets the recommendations of 
Renwick (Renwick, 2004). 
R.63 The Authority should request that the Applicant use the promising pig intestinal model 
(Baracos, 2004) for assessing amino acid toxicity.  
R.64 The Authority should make the 3-month rat feeding study available to the independent 
scientific community for evaluation before recommending to Council that the food 
code be amended to include LY038 corn. 
R.65 The specific activity data is inappropriate for drawing conclusions of identity or 
functional similarity. Better measures for functional similarity, such as Km and Vmax, 
should be provided. 
R.66 The Authority should draw a recommendation based in part on feeding studies using 
the whole food (grain of transgenic plants and cooked products that would form a 
representation of how the food was to be consumed by people). 
R.67 The studies should be conducted using animal models that are most appropriate for 
identifying harms relevant to people. Long-term (lifetime) studies should be included 
because high lysine corn is also high free lysine, saccharopine, α-aminoadipic acid, 
cadaverine and pipecolic acid corn. The Authority should report on chronic effects, 
evidence of carcinogens and co-carcinogens (AGEs have been linked to cancer Heijst 
et al., 2005), and proteins that are capable of forming aggregates. No structural 
analysis alone will predict the effect of context on an enzyme or its potential to 
produce unanticipated products in a novel context. Therefore, structural analyses 
equating E. coli- and in planta-produced cDHDPS cannot substitute for the use of in 
planta-produced cDHDPS in all biochemical and feeding experiments (NZIGE 
Submission section 5.3.7.2).  
R.68 The Authority should report how both dietary and airborne allergens in LY038 were 
excluded by experimental tests conducted on animals previously fed the whole food 
derived from LY038. 
R.69 For allergen identification, we are more concerned with false negatives than false 
positives. Thus we ask the Authority to review the bioinformatics data using the 
parameters set by FAO/WHO. 
R.70 The Authority should report the results of a bioinformatic analysis using the actual 
sequence of in planta-produced recombinant cDHDPS. 
R.71 Whereas there may be virtue in establishing a standard, as the industry-led groups in 
the Thomas et al. study did, it remains unclear why the FAO/WHO protocol is not the 
standard nor why reproducibility is a greater virtue than using a pH relevant to 
conditions in the stomach during a meal, such as pH4-5 (Schmidt et al., 1995, Thomas 
et al., 2004). The Authority should require results to the Thomas et al. industry-
preferred standard and the FAO/WHO standard. 
R.72 The Applicant should report digestibility measurements after processing/cooking of 
material from whole food. 
R.73 The Authority should require, at the very minimum, results of the digestion studies 
using a surrogate source of protein verified to represent all post-translationally 
modified forms of the protein in whole food, including after cooking and processing. 
For this, the Authority will have to address our call for using 2D gel electrophoresis 
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and MS to identify all isomers produced in plants. 
R.74 The Authority should provide the results of blood tests and data on organ weights and 
visual observations.  
R.75 The Authority should seek a satisfactory re-evaluation of the effects on chicks in the 
first 21 days. 
R.76 The Authority, at the very least, should seek a feeding trial using LY038 rather than a 
mix of transgenic strains that dilutes LY038. 
R.77 We agree with the Authority that high-lysine corn is a significantly changed product. 
We therefore recommend that properly conducted feeding trials be made available for 
review by the Authority and, if possible, the public. These trials will use animals 
suitable for gauging food safety in humans (i.e., not chickens), possibly pigs, and will 
use cooked and processed whole foods. 
R.78 One, possibly several, genes in LY038 are likely have been affected by the 
transformation process to explain accumulation of lysine in the seed. As recommended 
in CAC/GL 45-2003(33-D), the Authority should be able to explain how LY038 
accumulates these levels of free lysine in grain and demonstrate that the mechanism 
would be exactly the same in all hybrids. 
R.79 Should the Authority recommend an amendment to the Food Code, then the Authority 
should impose a condition in Column 2 of the Table to Clause 2 of Standard 1.5.2 that 
limits this approval to LY038 without extension to hybrid lines derived from LY038. 
All hybrids, whether between LY038 and an unmodified line or another approved 
modified line, must in this case be treated as a new organism requiring a full safety 
evaluation. If it cannot do this, then it should not recommend amendment of the Food 
Code. 
R.80 We ask the Authority to detail its position with reference to developments at the 
international level. 
R.81 If the Authority has requested details from the Applicant on its post-market 
surveillance plans, we ask for these to be released and for the Authority to publish its 
evaluation. If the Authority has not requested these details, we recommend that they 
are requested now. If the Authority does not feel obliged to do so, we ask for an 
explanation as to why. 
R.82 FSANZ should reconsider its statement, made in relation to this hypothetical benefit to 
consumers noted above, that: "As food from LY038 corn has been found to be as safe 
as food from other varieties of corn, option 1 is likely to be inconsistent with Australia 
and New Zealand's WTO obligations." We have demonstrated that this is an 
unreasonable conclusion to draw, given the scientific concerns we have listed as well 
as the fact that Codex Alimentarius and WHO recommended practices, which are 
acceptable under WTO, would require more stringent scientific scrutiny. 
R.83 The Authority states that “Government: Potential impact if considered inconsistent 
with WTO obligations but impact would be in terms of trade policy rather than in 
government revenue” and “Industry: Potential longer-term impact - any successful 
WTO challenge has the potential to impact adversely on food industry”. It should 
clarify the weighting given to WTO considerations and the relative cost attributed to 
this in the draft decision. 
R.84 FSANZ should reconsider its Impact Analysis and its decision from the perspective of 
the full range of eventualities its decision makes possible, in particular the various 
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ways in which LY038 may inadvertently or deliberately be introduced into the food 
supply as well as the issues of prevalence, hybrids, dietary restrictions, and 
distribution of costs and benefits that we have noted.  
R.85 We ask FSANZ to clarify: in its decision-making, is it considering potential cost to 
government, or not?  And if so,  
 how can it assign weight to monetary costs without attempting to quantify 
them? And 
 does it give equal consideration to costs of each option (approval and non-
approval), e.g., to the (certain) costs of monitoring as much as to the 
(speculative) costs of responding to illegal contamination? 
R.86 If FSANZ is not considering potential cost to government, we ask that it explain the 
reasoning behind including the Impact Statement relating to government monitoring 
resources. If FSANZ is considering potential cost to government (as indicated by a 
number of statements in the DAR), we ask again that it provide evidence that the cost 
to government of monitoring for the presence of LY038 in food will be low. 
R.87 In line with INBI’s previous submission, FSANZ should also provide evidence that 
the monitoring and labelling cost to industry will be low. 
R.88 Should FSANZ recommend amending the Code for the event in LY038, then we 
recommend that threshold criteria be established in Column 2 of the Table to Clause 2 
of Standard 1.5.2 indicating below which levels and frequency of contamination, and 
range of contaminated products, LY038 events would be seen as inadvertently 
contaminating the human food supply and what the consequences would be for 
contamination above these thresholds. 
R.89 Should FSANZ recommend amending the Code for the event in LY038, then we 
recommend that only certain existing varieties and hybrids be allowed (those that have 
met stringent testing as described above and in our first submission) and not extend to 
other varieties with the same event. 
R.90 FSANZ should explain how it derived a conclusion of “net benefit to food producers 
and consumers” from the analysis presented. 
R.91 In light of the Authority’s commitment to “increased accountability and transparency 
in decision making” (Australia New Zealand Food Authority, 2001), FSANZ should 
explicate for the public the process it uses to move from impact analysis to preferred 
option, including an explanation of how various factors have been weighted and how 
public input has been taken into account. 
R.92 The Authority should clarify whether it contracted external parties to review A549. 
R.93 FSANZ should explain the process it used to identify an independent reviewer for 
INBI’s IAR submission, including the criteria it used to determine the reviewer’s 
independence. 
R.94 In considering the comments of the independent reviewer, FSANZ should take into 
account the fact that the reviewer’s conclusions were based on differences of 
judgment, rather than findings of scientific error. 
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